

# Combined Pharmacotherapies and Behavioral Intervention

JAMA - Journal of the American Medical Association  
295, 2003

DOI: [10.1001/jama.295.17.2003](https://doi.org/10.1001/jama.295.17.2003)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Alcoholism in primary care. , 0, , 125-132.		0
2	The new pharmacotherapies for alcohol dependence. , 0, , 188-206.		0
3	Psychotic Spectrum Disorders and Alcohol Abuse: A Review of Pharmacotherapeutic Strategies and a Report on the Effectiveness of Naltrexone and Disulfiram. Schizophrenia Bulletin, 2005, 32, 644-654.	4.3	69
6	Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence. Future Neurology, 2006, 1, 389-398.	0.5	10
7	A Rational Approach to the Pharmacotherapy of Alcohol Dependence. Journal of Clinical Psychopharmacology, 2006, 26, S3-S12.	1.4	23
8	Neurobiology and Evidence-Based Biological Treatments for Substance Abuse Disorders. CNS Spectrums, 2006, 11, 864-877.	1.2	6
9	Current and Future Drug Therapies for Alcohol Dependence. Journal of Clinical Psychopharmacology, 2006, 26, S20-S29.	1.4	16
10	The Status of Naltrexone in the Treatment of Alcohol Dependence. Journal of Clinical Psychopharmacology, 2006, 26, 610-625.	1.4	148
11	Combining Psychosocial Treatment with Pharmacotherapy for Alcohol Dependence. Journal of Clinical Psychopharmacology, 2006, 26, S37-S42.	1.4	30
12	Prevalence, risk factors and treatment for substance abuse in older adults. Current Opinion in Psychiatry, 2006, 19, 587-592.	6.3	14
13	Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addiction Biology, 2006, 11, 397-403.	2.6	62
14	Hippocampus Volume Loss Due to Chronic Heavy Drinking. Alcoholism: Clinical and Experimental Research, 2006, 30, 1866-1870.	2.4	141
15	Factors Affecting %CDT Status at Entry Into a Multisite Clinical Treatment Trial: Experience from the COMBINE Study. Alcoholism: Clinical and Experimental Research, 2006, 30, 1878-1883.	2.4	18
16	Concurrent validity of the Alcohol Use Disorders Identification Test (AUDIT) and AUDIT zones in defining levels of severity among out-patients with alcohol dependence in the COMBINE study. Addiction, 2006, 101, 1696-1704.	3.3	134
17	Choosing the right medication for the treatment of alcoholism. Current Psychiatry Reports, 2006, 8, 383-388.	4.5	31
18	Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?. Expert Opinion on Pharmacotherapy, 2006, 7, 2169-2173.	1.8	6
19	Pharmacotherapy and Behavioral Intervention for Alcohol Dependence. JAMA - Journal of the American Medical Association, 2006, 296, 1727.	7.4	24
20	Evidence-Based Treatments for Alcohol Dependence. JAMA - Journal of the American Medical Association, 2006, 295, 2075.	7.4	18

#	ARTICLE	IF	CITATIONS
21	New pharmacological approaches for the treatment of alcoholism. Expert Opinion on Pharmacotherapy, 2006, 7, 2341-2353.	1.8	32
22	Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Review of Neurotherapeutics, 2007, 7, 1265-1277.	2.8	180
23	Varenicline, an $\alpha 4\beta 2$ nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12518-12523.	7.1	343
24	Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Review of Neurotherapeutics, 2007, 7, 1465-1477.	2.8	20
25	Naltrexone increased abstinence and reduced heavy drinking during treatment. Evidence-Based Medicine, 2007, 12, 20-20.	0.6	0
26	Improving adherence in patients with alcohol dependence: A new role for pharmacists. American Journal of Health-System Pharmacy, 2007, 64, S23-S29.	1.0	8
27	Opioid Antagonism of Cannabinoid Effects: Differences between Marijuana Smokers and Nonmarijuana Smokers. Neuropsychopharmacology, 2007, 32, 1391-1403.	5.4	103
28	Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland. Alcohol and Alcoholism, 2007, 42, 333-339.	1.6	11
29	Alcohol use and misuse. Cmaj, 2007, 176, 621-622.	2.0	8
30	Prevalence, Correlates, Disability, and Comorbidity of DSM-IV Alcohol Abuse and Dependence in the United States. Archives of General Psychiatry, 2007, 64, 830.	12.3	2,236
31	Emerging approaches to managing alcohol dependence. American Journal of Health-System Pharmacy, 2007, 64, S12-S22.	1.0	32
32	Pharmacotherapy of Dual Substance Abuse and Dependence. CNS Drugs, 2007, 21, 213-237.	5.9	60
33	Are Special Treatments Needed for Special Populations?. Alcoholism Treatment Quarterly, 2007, 25, 63-78.	0.8	25
34	Alcoholics in Acute Medical Settings Have Increased Risk for other Drug, Mood, and Personality Disorders. International Journal of Psychiatry in Medicine, 2007, 37, 59-67.	1.8	13
35	Medications to Treat Alcohol Dependence. JAMA - Journal of the American Medical Association, 2007, 298, 1691.	7.4	21
36	Dopamine in Drug Abuse and Addiction. Archives of Neurology, 2007, 64, 1575.	4.5	550
37	Further Validation of the Alcohol Dependence Scale as an Index of Severity*. Journal of Studies on Alcohol and Drugs, 2007, 68, 149-156.	1.0	12
38	Smoking Status as a Clinical Indicator for Alcohol Misuse in US Adults. Archives of Internal Medicine, 2007, 167, 716.	3.8	162

#	ARTICLE	IF	CITATIONS
39	Preclinical Development and Clinical Implementation of Treatments for Substance Abuse Disorders. Focus (American Psychiatric Publishing), 2007, 5, 151-162.	0.8	1
40	Guideline Watch (April 2007): Practice Guideline for the Treatment of Patients With Substance Use Disorders, 2nd Edition. Focus (American Psychiatric Publishing), 2007, 5, 163-166.	0.8	7
41	Clinical Advances in Pharmacological and Integrated Treatment Approaches for Alcohol and Drug Use Disorders. Focus (American Psychiatric Publishing), 2007, 5, 141-150.	0.8	2
42	Adverse reactions to drugs used to treat alcoholism. Adverse Drug Reaction Bulletin, 2007, &NA;; 947-250.	0.5	0
43	Efficacy of Extended-Release Naltrexone in Alcohol-Dependent Patients Who Are Abstinent Before Treatment. Journal of Clinical Psychopharmacology, 2007, 27, 507-512.	1.4	108
44	The evidence for drug treatment of alcohol dependence in liver transplant patients. Current Opinion in Organ Transplantation, 2007, 12, 176-181.	1.6	3
45	The treatment of alcohol dependence. Current Opinion in Psychiatry, 2007, 20, 222-227.	6.3	37
46	Two-year Experience with Buprenorphine-naloxone (Suboxone) for Maintenance Treatment of Opioid Dependence Within a Private Practice Setting. Journal of Addiction Medicine, 2007, 1, 104-110.	2.6	33
47	Acamprosate in Alcohol Dependence: Implications of a Unique Mechanism of Action. Journal of Addiction Medicine, 2007, 1, 115-125.	2.6	57
48	Detecting Alcohol Use Disorders in Recently Hospitalized Persons: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Addiction Medicine, 2007, 1, 40-43.	2.6	3
49	Alcohol Use and Anxiety: Diagnostic and Management Issues. American Journal of Psychiatry, 2007, 164, 217-221.	7.2	17
50	Effects of Naltrexone on Alcohol Sensitivity and Genetic Moderators of Medication Response. Archives of General Psychiatry, 2007, 64, 1069.	12.3	244
51	How should the effectiveness of treatment for alcohol problems be evaluated?. Drugs and Alcohol Today, 2007, 7, 22-32.	0.7	2
52	Topiramate Found Effective Therapy for Alcoholism, But Will It Work with Comorbid Neurological Conditions?. Neurology Today: an Official Publication of the American Academy of Neurology, 2007, 7, 4.	0.0	0
53	Endogenous opiates and behavior: 2006. Peptides, 2007, 28, 2435-2513.	2.4	67
54	Management of relapse in naltrexone maintenance for heroin dependence. Drug and Alcohol Dependence, 2007, 91, 289-292.	3.2	49
55	Outcomes, performance, and qualityâ€”What's the difference?. Journal of Substance Abuse Treatment, 2007, 32, 331-340.	2.8	104
56	Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: An open randomised comparative study. European Neuropsychopharmacology, 2007, 17, 781-789.	0.7	53

#	ARTICLE	IF	CITATIONS
57	Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. <i>Lancet</i> , The, 2007, 370, 1915-1922.	13.7	611
58	Screening, Brief Intervention, and Referral to Treatment (SBIRT). <i>Substance Abuse</i> , 2007, 28, 7-30.	2.3	804
59	Clinical Care of the HIV-Infected Drug User. <i>Infectious Disease Clinics of North America</i> , 2007, 21, 149-179.	5.1	74
60	New Insights into the Efficacy of Naltrexone Based on Trajectory-Based Reanalyses of Two Negative Clinical Trials. <i>Biological Psychiatry</i> , 2007, 61, 1290-1295.	1.3	43
61	Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking. <i>Biological Psychiatry</i> , 2007, 62, 694-697.	1.3	105
62	High-Risk Situations. , 2007, , 19-33.		6
63	Guidelines and Evidence-Based Practice. <i>NAD Nordic Studies on Alcohol and Drugs</i> , 2007, 24, 588-599.	1.3	2
65	What is addiction, what is alcoholism?. <i>Liver Transplantation</i> , 2007, 13, S55-S58.	2.4	4
66	Treatment of alcohol and other drug dependence. <i>Liver Transplantation</i> , 2007, 13, S59-S64.	2.4	8
67	Circuit breakers for addiction. <i>Internal Medicine Journal</i> , 2007, 37, 320-325.	0.8	1
68	Does matching matter? Examining matches and mismatches between patient attributes and therapy techniques in alcoholism treatment. <i>Addiction</i> , 2007, 102, 587-596.	3.3	29
69	A vision of the next generation of behavioral therapies research in the addictions. <i>Addiction</i> , 2007, 102, 850-862.	3.3	155
70	Advancing the analysis of treatment process. <i>Addiction</i> , 2007, 102, 1539-1545.	3.3	17
71	A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. <i>Addiction</i> , 2007, 102, 1292-1302.	3.3	50
72	IMAGEN: IMPLICATIONS FOR ADDICTION SCIENCE AND SCIENCE POLICY. <i>Addiction</i> , 2007, 102, 1699-1700.	3.3	0
73	Development of Naltrexone Supersensitivity During Food-Maintained Responding Enhances Naltrexone's Ability to Reduce Ethanol-Maintained Responding. <i>Alcoholism: Clinical and Experimental Research</i> , 2007, 31, 39-47.	2.4	7
74	Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2007, 31, 070212174136005-???	2.4	178
75	What Role Does Measuring Medication Compliance Play in Evaluating the Efficacy of Naltrexone?. <i>Alcoholism: Clinical and Experimental Research</i> , 2007, 31, 070212174136003-???	2.4	50

#	ARTICLE	IF	CITATIONS
76	Naltrexone and Cognitive Behavioral Coping Skills Therapy for the Treatment of Alcohol Drinking and Eating Disorder Features in Alcohol-Dependent Women: A Randomized Controlled Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2007, 31, 070227012339006-???	2.4	65
77	Simplifying Alcohol Assessment: Two Questions to Identify Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2007, 31, 1392-1398.	2.4	44
78	Absence of Significant Interactive Effects of High-Dose Cycloserine and Ethanol in Healthy Human Subjects: Preliminary Insights Into Ethanol Actions at the Glycine <sub>B</sub> Site of NMDA Glutamate Receptors. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 36-42.	2.4	10
79	Naltrexone Is Associated With Reduced Drinking by Alcohol Dependent Patients Receiving Antidepressants for Mood and Anxiety Symptoms: Results From VA Cooperative Study No. 425, "Naltrexone in the Treatment of Alcoholism". <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 85-91.	2.4	20
80	Role of State Policies in the Adoption of Naltrexone for Substance Abuse Treatment. <i>Health Services Research</i> , 2008, 43, 951-970.	2.0	36
81	Preclinical and clinical pharmacology of alcohol dependence. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 9-28.	1.9	39
82	Pharmacotherapeutic interventions in alcohol and illicit drug dependence. <i>Psychiatry (Abingdon, England)</i> , 2007, 70, 10-20.	0.2	10
83	Monitored Naltrexone without Counseling for Alcohol Abuse/Dependence in Schizophrenia-Spectrum Disorders. <i>American Journal on Addictions</i> , 2007, 16, 253-259.	1.4	29
84	The psychiatric management of patients with alcohol dependence. <i>Current Treatment Options in Neurology</i> , 2007, 9, 381-392.	1.8	0
86	Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. <i>Psychopharmacology</i> , 2007, 193, 449-456.	3.1	40
87	Naltrexone's suppressant effects on drinking are limited to the first 3 months of treatment. <i>Psychopharmacology</i> , 2007, 194, 1-10.	3.1	10
89	Alcoholism in women: is it different in onset and outcome compared to men?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 344-351.	3.2	97
90	The psychiatric management of patients with alcohol dependence. <i>Current Treatment Options in Neurology</i> , 2007, 9, 381-392.	1.8	10
91	Update in Addiction Medicine for the Generalist. <i>Journal of General Internal Medicine</i> , 2007, 22, 1190-1194.	2.6	8
92	Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. <i>Psychopharmacology</i> , 2008, 200, 521-527.	3.1	153
93	Preserved DNA from past clinical trials yields new information about a subtype of alcoholism. <i>Current Psychiatry Reports</i> , 2008, 10, 375-376.	4.5	0
94	Association between single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) and self-reported responses to alcohol in American Indians. <i>BMC Medical Genetics</i> , 2008, 9, 35.	2.1	47
95	Why people change? The role of cognitive-control processes in the onset and cessation of substance abuse disorders. <i>International Journal of Methods in Psychiatric Research</i> , 2008, 17, S4-S15.	2.1	49

#	ARTICLE	IF	CITATIONS
96	Finding the ideal place for a psychotherapeutic intervention in a stepped care approach – a brief overview of the literature and preliminary results from the Project PREDICT. <i>International Journal of Methods in Psychiatric Research</i> , 2008, 17, S60-S64.	2.1	14
97	$\gamma$ -Hydroxybutyric acid (GHB) suppresses alcohol's motivational properties in alcohol-preferring rats. <i>Alcohol</i> , 2008, 42, 107-113.	1.7	15
98	Effect of naltrexone during extinction of alcohol-reinforced responding and during repeated cue-conditioned reinstatement sessions in a cue exposure style treatment. <i>Alcohol</i> , 2008, 42, 553-563.	1.7	19
99	How large must a treatment effect be before it matters to practitioners? An estimation method and demonstration. <i>Drug and Alcohol Review</i> , 2008, 27, 524-528.	2.1	38
100	Are Medications that Reduce Risk of Drinking or Heavy Drinking, or that Promote Abstinence, of Value in the Treatment of Alcohol Dependence?. <i>American Journal on Addictions</i> , 2008, 17, 1-5.	1.4	1
101	Acamprosate Efficacy in Alcohol-Dependent Patients: Summary of Results from Three Pivotal Trials. <i>American Journal on Addictions</i> , 2008, 17, 70-76.	1.4	209
102	Effects of Naltrexone During the Descending Limb of the Blood Alcohol Curve. <i>American Journal on Addictions</i> , 2008, 17, 257-264.	1.4	28
103	Gender Differences in Predictors of Treatment Attrition with High Dose Naltrexone in Cocaine and Alcohol Dependence. <i>American Journal on Addictions</i> , 2008, 17, 463-468.	1.4	26
104	Topiramate for Alcohol Dependence. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1475-1480.	1.9	44
105	Addiction: the clinical interface. <i>British Journal of Pharmacology</i> , 2008, 154, 397-405.	5.4	39
106	Effects of Acamprosate on Neuronal Receptors and Ion Channels Expressed in <i>Xenopus</i> Oocytes. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 188-196.	2.4	30
107	Hepatic Safety of Once-Monthly Injectable Extended-Release Naltrexone Administered to Actively Drinking Alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 498-504.	2.4	41
108	Naltrexone and Cognitive Behavioral Therapy for the Treatment of Alcohol Dependence: Do Sex Differences Exist?. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 771-776.	2.4	35
109	Using Topiramate or Naltrexone for the Treatment of Alcohol-Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 1251-1259.	2.4	64
110	Naltrexone Alone and With Sertraline for the Treatment of Alcohol Dependence in Alaska Natives and Non-Natives Residing in Rural Settings: A Randomized Controlled Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 1271-1283.	2.4	86
111	Acamprosate: Recent Findings and Future Research Directions. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 1105-1110.	2.4	154
112	A Placebo-Controlled Randomized Clinical Trial of Naltrexone in the Context of Different Levels of Psychosocial Intervention. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 1299-1308.	2.4	51
113	Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 1159-1166.	2.4	68

#	ARTICLE	IF	CITATIONS
114	Relationship Between Medication Adherence and Treatment Outcomes: The COMBINE Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 1661-1669.	2.4	38
115	Practitioner Review: Adolescent alcohol use disorders: assessment and treatment issues. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2008, 49, 1131-1154.	5.2	34
116	Regression to the mean in substance use disorder treatment research. <i>Addiction</i> , 2008, 103, 42-52.	3.3	64
117	On treatment mechanismsâ€”what can we learn from the COMBINE study?. <i>Addiction</i> , 2008, 103, 703-705.	3.3	36
118	[Commentary] JOINING THE QUEUE OF DISSENTERS. <i>Addiction</i> , 2008, 103, 706-707.	3.3	15
119	[Commentary] DRUG TREATMENTâ€”NOT AS USELESS AS IT SEEMS. <i>Addiction</i> , 2008, 103, 707-708.	3.3	4
120	[Commentary] COMBINE AND MATCH: THE FINAL BLOW FOR LARGEâ€”SCALE BLACK BOX RANDOMIZED CONTROLLED TRIALS. <i>Addiction</i> , 2008, 103, 708-710.	3.3	11
121	[Commentary] INTERPRETATION OF THE OUTCOME OF THE COMBINE STUDY: A RESPONSE TO THE COMMENTARIES. <i>Addiction</i> , 2008, 103, 710-710.	3.3	0
122	Do acamprostate or naltrexone have an effect on daily drinking by reducing craving for alcohol?. <i>Addiction</i> , 2008, 103, 953-959.	3.3	57
123	Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. <i>Addiction</i> , 2008, 103, 1622-1628.	3.3	43
124	Comparing topiramate with naltrexone in the treatment of alcohol dependence*. <i>Addiction</i> , 2008, 103, 2035-2044.	3.3	131
125	Glutamatergic substrates of drug addiction and alcoholism. <i>Biochemical Pharmacology</i> , 2008, 75, 218-265.	4.4	439
126	Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. <i>Biochemical Pharmacology</i> , 2008, 75, 34-56.	4.4	246
128	En el futuro, Â¿utilizaremos topiramato en el tratamiento de la dependencia alcohÃ³lica?. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2008, 15, 469.	0.0	0
129	Pharmacogenetic Treatments for Drug Addiction: Alcohol and Opiates. <i>American Journal of Drug and Alcohol Abuse</i> , 2008, 34, 355-381.	2.1	58
130	Naltrexone for the Management of Alcohol Dependence. <i>New England Journal of Medicine</i> , 2008, 359, 715-721.	27.0	140
131	A Novel Delta Opioid Receptor Antagonist, SoRI-9409, Produces a Selective and Long-Lasting Decrease in Ethanol Consumption in Heavy-Drinking Rats. <i>Biological Psychiatry</i> , 2008, 64, 974-981.	1.3	41
132	Financing Mental Health and Substance Use Disorder Care Within Physical Health: A Look to the Future. <i>Psychiatric Clinics of North America</i> , 2008, 31, 11-25.	1.3	11



#	ARTICLE	IF	CITATIONS
133	Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. <i>Journal of Substance Abuse Treatment</i> , 2008, 34, 378-390.	2.8	86
134	Longitudinal trends in hospital admissions with co-occurring alcohol/drug diagnoses, 1994-2002. <i>Journal of Substance Abuse Treatment</i> , 2008, 35, 1-12.	2.8	37
135	A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. <i>Addictive Behaviors</i> , 2008, 33, 651-667.	3.0	89
136	Empirically supported substance abuse treatment approaches: A survey of treatment providers' perspectives and practices. <i>Addictive Behaviors</i> , 2008, 33, 699-712.	3.0	76
137	A pilot study of naltrexone and BASICS for heavy drinking young adults. <i>Addictive Behaviors</i> , 2008, 33, 1048-1054.	3.0	17
138	Modifications of the Obsessive Compulsive Drinking Scale (OCDS-G) for use in longitudinal studies. <i>Addictive Behaviors</i> , 2008, 33, 1276-1281.	3.0	21
139	A brief 7-day estimate of alcohol consumption for use in smoking cessation clinical trials. <i>Addictive Behaviors</i> , 2008, 33, 1606-1609.	3.0	8
141	Drugs for relapse prevention of alcoholism: ten years of progress. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 109-115.	8.7	147
142	Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. <i>Drug and Alcohol Dependence</i> , 2008, 96, 145-154.	3.2	151
143	Manejo extrahospitalario del paciente con consumo alcohólico de riesgo. <i>Medicine</i> , 2008, 10, 643-650.	0.0	0
144	Brain science and addiction. <i>Lancet, The</i> , 2008, 372, 1280-1281.	13.7	0
145	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 6-23.	2.6	67
146	New indications for topiramate: alcohol dependency and binge-eating disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 869-873.	1.8	4
147	Medical Students'™ Experiences with Addicted Patients. <i>Substance Abuse</i> , 2008, 29, 25-32.	2.3	3
148	Pharmacotherapeutic Treatment of Alcohol Dependence: An Overview. <i>Journal of Teaching in the Addictions</i> , 2008, 7, 75-95.	0.3	2
149	Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 317-324.	1.4	114
150	Topiramate as Treatment for Alcohol Dependence—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, .	7.4	0
151	A Blocker of N- and T-type Voltage-Gated Calcium Channels Attenuates Ethanol-Induced Intoxication, Place Preference, Self-Administration, and Reinstatement. <i>Journal of Neuroscience</i> , 2008, 28, 11712-11719.	3.6	35

#	ARTICLE	IF	CITATIONS
152	Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. <i>Journal of Psychopharmacology</i> , 2008, 22, 11-23.	4.0	288
153	Alcohol abuse in adolescents. <i>Archives of Disease in Childhood</i> , 2008, 93, 524-527.	1.9	15
154	Microneedles permit transdermal delivery of a skin-impermeant medication to humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 2058-2063.	7.1	248
155	Self-Efficacy as a Factor in Abstinence from Alcohol/Other Drug Abuse: A Meta-Analysis. <i>Alcoholism Treatment Quarterly</i> , 2008, 26, 480-489.	0.8	37
156	Alcohol consumption, %CDT, GGT and blood pressure change during alcohol treatment. <i>Alcohol and Alcoholism</i> , 2008, 43, 192-197.	1.6	21
157	Computer-Assisted Delivery of Cognitive-Behavioral Therapy for Addiction: A Randomized Trial of CBT4CBT. <i>American Journal of Psychiatry</i> , 2008, 165, 881-888.	7.2	359
158	Association Between the Stin2 VNTR Polymorphism of the Serotonin Transporter Gene and Treatment Outcome in Alcohol-Dependent Patients. <i>Alcohol and Alcoholism</i> , 2008, 43, 516-522.	1.6	26
159	An Intervention for Treating Alcohol Dependence: Relating Elements of Medical Management to Patient Outcomes With Implications for Primary Care. <i>Annals of Family Medicine</i> , 2008, 6, 435-440.	1.9	24
160	An Evaluation of $\mu$ -Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence. <i>Archives of General Psychiatry</i> , 2008, 65, 135.	12.3	428
161	Cellular and Behavioral Interactions of Gabapentin with Alcohol Dependence. <i>Journal of Neuroscience</i> , 2008, 28, 5762-5771.	3.6	116
164	Effect of Naltrexone and Ondansetron on Alcohol Cue-Induced Activation of the Ventral Striatum in Alcohol-Dependent People. <i>Archives of General Psychiatry</i> , 2008, 65, 466.	12.3	237
165	Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. <i>Pharmacogenomics</i> , 2008, 9, 655-658.	1.3	14
166	Does Smoking Intervention Influence Adolescent Substance Use Disorder Treatment Outcomes?. <i>Substance Abuse</i> , 2008, 29, 81-88.	2.3	29
167	The validity of the desired effects of drinking scale with a late adolescent sample.. <i>Psychology of Addictive Behaviors</i> , 2008, 22, 587-591.	2.1	4
168	The test-retest reliability of the Form 90-DWI: An instrument for assessing intoxicated driving.. <i>Psychology of Addictive Behaviors</i> , 2008, 22, 117-121.	2.1	6
169	Cost and Cost-effectiveness of the COMBINE Study in Alcohol-Dependent Patients. <i>Archives of General Psychiatry</i> , 2008, 65, 1214.	12.3	59
170	Achieving Remission and Favorable Outcomes in Patients with Depression/Anxiety and Substance use Disorders. <i>CNS Spectrums</i> , 2008, 13, 10-12.	1.2	3
171	Specialised alcohol treatment services are a luxury the NHS cannot afford. <i>British Journal of Psychiatry</i> , 2008, 192, 245-247.	2.8	6

#	ARTICLE	IF	CITATIONS
172	Pilot Study of Interpersonal Psychotherapy Versus Supportive Psychotherapy for Dysthymic Patients With Secondary Alcohol Abuse or Dependence. <i>Journal of Nervous and Mental Disease</i> , 2008, 196, 468-474.	1.0	47
173	The Relationship Between Substance Use Patterns and Economic and Health Outcomes Among Low-Income Caregivers and Children. <i>Psychiatric Services</i> , 2008, 59, 974-981.	2.0	3
174	Complex interventions for alcohol use disorders. , 0, , 320-339.		0
175	Pharmacotherapy of alcohol misuse, dependence and withdrawal. , 0, , 289-313.		0
176	Acamprosate: Safety and Tolerability in the Treatment of Alcohol Dependence. <i>Journal of Addiction Medicine</i> , 2008, 2, 40-50.	2.6	21
177	Mindfulness Meditation for Alcohol Relapse Prevention: A Feasibility Pilot Study. <i>Journal of Addiction Medicine</i> , 2008, 2, 165-173.	2.6	155
178	A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Aripiprazole for the Treatment of Alcohol Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 5-12.	1.4	93
179	Pharmacotherapy for Alcohol Dependence, Medical Management and the Role of Nursing. <i>Journal of Addictions Nursing</i> , 2008, 19, 170-171.	0.4	0
180	Quetiapine Versus Trazodone in Reducing Rehospitalization for Alcohol Dependence: A Large Data-Base Study. <i>Journal of Addiction Medicine</i> , 2008, 2, 128-134.	2.6	8
181	Characteristics of First-Time Alcohol Treatment Seekers: The COMBINE Study. <i>Journal of Studies on Alcohol and Drugs</i> , 2008, 69, 885-895.	1.0	17
182	From the Neurobiologic Basis of Alcohol Dependency to Pharmacologic Treatment Strategies: Bridging the Knowledge Gap. <i>Southern Medical Journal</i> , 2008, 101, 179-185.	0.7	3
183	Do Patients With Alcohol Dependence Respond to Placebo? Results From the COMBINE Study. <i>Journal of Studies on Alcohol and Drugs</i> , 2008, 69, 878-884.	1.0	50
185	Alcohol Treatment Effects on Secondary Nondrinking Outcomes and Quality of Life: The COMBINE Study. <i>Journal of Studies on Alcohol and Drugs</i> , 2009, 70, 186-197.	1.0	46
186	Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence. <i>Current Drug Abuse Reviews</i> , 2009, 2, 135-142.	3.4	66
187	What Is Evidence-Based Treatment?. , 2009, , 1-20.		2
188	Pharmacological Research on Addictions: A Framework for Ethical and Policy Considerations. <i>Journal of Psychoactive Drugs</i> , 2009, 41, 49-60.	1.7	5
189	Effective Strategies for Maintaining Research Participation in Clinical Trials. <i>Drug Information Journal</i> , 2009, 43, 459-467.	0.5	62
191	College Student Receptiveness to Various Alcohol Treatment Options. <i>Journal of American College Health</i> , 2009, 58, 26-32.	1.5	25

#	ARTICLE	IF	CITATIONS
192	Questionable Efficacy for Naltrexone in Patients With Asp40. Archives of General Psychiatry, 2009, 66, 796.	12.3	1
193	The potential of pharmacogenomics to treat drug addiction. Pharmacogenomics, 2009, 10, 1883-1886.	1.3	4
194	Impaired inhibition of proactive interference in abstinent individuals with alcoholism. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 57-64.	1.3	17
195	Understanding and Treating Alcohol Craving and Dependence: Recent Pharmacological and Neuroendocrinological Findings. Alcohol and Alcoholism, 2009, 44, 341-352.	1.6	30
196	Packages of Care for Alcohol Use Disorders in Low- And Middle-Income Countries. PLoS Medicine, 2009, 6, e1000170.	8.4	89
197	What Was Useful about That Session? Clients' and Therapists' Comments after Sessions in the UK Alcohol Treatment Trial (UKATT). Alcohol and Alcoholism, 2009, 44, 306-313.	1.6	15
198	Sex-Specific Dissociations in Autonomic and HPA Responses to Stress and Cues in Alcohol-Dependent Patients with Cocaine Abuse. Alcohol and Alcoholism, 2009, 44, 575-585.	1.6	55
199	Beer and Other Alcoholic Beverages: Implications for Dependence, Craving and Relapse. , 2009, , 201-209.		0
200	The Cure for Alcoholism. Drink Your Way Sober without Willpower, Abstinence or Discomfort. Alcohol and Alcoholism, 2009, 44, 635-635.	1.6	0
201	Adjunctive Pharmacotherapy in the Treatment of Alcohol and Drug Dependence. , 2009, , 287-310.		5
202	COMT Genotype Influences the Effect of Alcohol on Blood Pressure: Results From the COMBINE Study. American Journal of Hypertension, 2009, 22, 87-91.	2.0	19
203	Smoking and alcohol intervention before surgery: evidence for best practice. British Journal of Anaesthesia, 2009, 102, 297-306.	3.4	216
204	Effects of naltrexone on cortisol levels in heavy drinkers. Pharmacology Biochemistry and Behavior, 2009, 91, 489-494.	2.9	19
205	Anti-relapse medications: Preclinical models for drug addiction treatment. , 2009, 124, 235-247.		65
206	Improvements in readiness to change and drinking in primary care patients with unhealthy alcohol use: a prospective study. BMC Public Health, 2009, 9, 101.	2.9	15
207	Psychosocial interventions in breast cancer. Cancer, 2009, 115, 5617-5619.	4.1	4
208	Genetics of alcohol dependence. Human Genetics, 2009, 126, 91-99.	3.8	109
209	Typologies of Alcohol Dependence. From Jellinek to Genetics and Beyond. Neuropsychology Review, 2009, 19, 115-129.	4.9	173

#	ARTICLE	IF	CITATIONS
210	Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats. <i>Psychopharmacology</i> , 2009, 204, 335-348.	3.1	45
211	Extended naltrexone and broad spectrum treatment or motivational enhancement therapy. <i>Psychopharmacology</i> , 2009, 206, 367-376.	3.1	18
212	Outpatient alcoholism treatment – 24-month outcome and predictors of outcome. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2009, 4, 15.	2.2	26
213	Conversation with William R. Miller. <i>Addiction</i> , 2009, 104, 883-893.	3.3	2
214	Review article: the diagnosis and management of alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 3-13.	3.7	36
215	Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence. <i>Drug and Alcohol Review</i> , 2009, 28, 222-229.	2.1	9
216	Effects of Alcoholism Typology on Response to Naltrexone in the COMBINE Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 10-18.	2.4	30
217	A Pilot Trial of the Alpha-1 Adrenergic Antagonist, Prazosin, for Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 255-263.	2.4	147
218	Effect of Extended-Release Naltrexone (XR-NTX) on Quality of Life in Alcohol-Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 350-356.	2.4	46
219	<i>OPRM1</i> Asn40Asp Predicts Response to Naltrexone Treatment: A Haplotype-Based Approach. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 383-393.	2.4	82
220	Searching for Responders to Acamprosate and Naltrexone in Alcoholism Treatment: Rationale and Design of the <i>Predict Study</i> . <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 674-683.	2.4	86
221	Influence of a Drinking Quantity and Frequency Measure on the Prevalence and Demographic Correlates of DSM-IV Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 761-771.	2.4	36
222	Predicting Treatment Seekers' Readiness to Change Their Drinking Behavior in the COMBINE Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 879-892.	2.4	58
223	Blood Glucose Level, Alcohol Heavy Drinking, and Alcohol Craving During Treatment for Alcohol Dependence: Results From the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 1539-1544.	2.4	31
224	A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Naltrexone in Outpatients With Bipolar Disorder and Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 1863-1869.	2.4	83
225	Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. <i>HIV Medicine</i> , 2009, 10, 133-142.	2.2	54
226	Potency of naltrexone to reduce ethanol self-administration in rats is greater for subcutaneous versus intraperitoneal injection. <i>Alcohol</i> , 2009, 43, 119-126.	1.7	36
227	A Randomized, Double-Blind, Placebo-Controlled Trial of Naltrexone in the Treatment of Concurrent Alcohol Use Disorder and Pathological Gambling. <i>American Journal on Addictions</i> , 2009, 18, 219-225.	1.4	53

#	ARTICLE	IF	CITATIONS
228	Intermittent Marijuana Use Is Associated with Improved Retention in Naltrexone Treatment for Opiate Dependence. <i>American Journal on Addictions</i> , 2009, 18, 301-308.	1.4	50
229	Controversies in the Management of Alcoholic Liver Disease. <i>Mount Sinai Journal of Medicine</i> , 2009, 76, 484-498.	1.9	28
230	Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior. <i>Physiological Reviews</i> , 2009, 89, 649-705.	28.8	620
231	Sociological, Social Psychological, and Psychopathological Correlates of Substance Use Disorders in the U.S. Jail Population. <i>International Journal of Offender Therapy and Comparative Criminology</i> , 2009, 53, 168-190.	1.2	10
232	A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. <i>Drug and Alcohol Dependence</i> , 2009, 99, 317-321.	3.2	26
233	A "community-friendly" version of integrated group therapy for patients with bipolar disorder and substance dependence: A randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2009, 104, 212-219.	3.2	87
234	Naltrexone for the treatment of alcohol dependence among African Americans: Results from the COMBINE Study. <i>Drug and Alcohol Dependence</i> , 2009, 105, 256-258.	3.2	30
235	Psychometric properties of the German version of the Motivational Interviewing Treatment Integrity Code. <i>Journal of Substance Abuse Treatment</i> , 2009, 36, 44-48.	2.8	35
236	Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. <i>Journal of Substance Abuse Treatment</i> , 2009, 37, 247-255.	2.8	47
237	How do people recover from alcohol dependence? A systematic review of the research on mechanisms of behavior change in Alcoholics Anonymous. <i>Addiction Research and Theory</i> , 2009, 17, 236-259.	1.9	219
238	A Double-Blind, Placebo-Controlled Study of the Opiate Antagonist, Naltrexone, in the Treatment of Kleptomania. <i>Biological Psychiatry</i> , 2009, 65, 600-606.	1.3	145
239	Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers. <i>Biological Psychiatry</i> , 2009, 66, 185-190.	1.3	275
240	The $\mu$ 1 Opioid Receptor Is a Heterodimer That Opposes the Actions of the $\mu$ 2 Receptor on Alcohol Intake. <i>Biological Psychiatry</i> , 2009, 66, 777-784.	1.3	86
241	Mindfulness Meditation for Substance Use Disorders: A Systematic Review. <i>Substance Abuse</i> , 2009, 30, 266-294.	2.3	296
242	What is Relapse? A Contemporary Exploration of Treatment of Alcoholism. <i>Journal of Social Work Practice in the Addictions</i> , 2009, 9, 245-262.	0.7	4
243	Management of Alcoholic Liver Disease. <i>Clinics in Liver Disease</i> , 2009, 13, 267-275.	2.1	24
244	Meta-Analyses of Placebo-Controlled Trials of Acamprosate for the Treatment of Alcohol Dependence. <i>Journal of Addiction Medicine</i> , 2009, 3, 74-82.	2.6	16
245	Targeted Naltrexone for Problem Drinkers. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 350-357.	1.4	66

#	ARTICLE	IF	CITATIONS
246	Pharmacotherapy of Addictive Disorders. <i>Clinical Neuropharmacology</i> , 2009, 32, 277-289.	0.7	44
247	Effects of Nicotine and Illicit Substance Use on Alcoholism Treatment Outcomes and Acamprosate Efficacy. <i>Journal of Addiction Medicine</i> , 2009, 3, 164-171.	2.6	12
248	Pharmacologic Treatment for Substance Use Disorders in Children and Adolescents. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2009, 44, 65-72.	0.1	0
249	Cognitive-Behavioral Treatment With Adult Alcohol and Illicit Drug Users: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Studies on Alcohol and Drugs</i> , 2009, 70, 516-527.	1.0	572
250	Management of alcohol use disorders. <i>Irish Journal of Psychological Medicine</i> , 2009, 26, i-vii.	1.0	1
251	Betting on change: Modeling transitional probabilities to guide therapy development for opioid dependence.. <i>Psychology of Addictive Behaviors</i> , 2009, 23, 47-55.	2.1	16
252	Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 589.	2.1	41
253	The implications of medication development in the treatment of substance use disorders in developing countries. <i>Current Opinion in Psychiatry</i> , 2009, 22, 274-280.	6.3	23
254	Perioperative management of patients with alcohol, tobacco and drug dependency. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 384-390.	2.0	49
255	Acamprosate Determinations in Plasma and Cerebrospinal Fluid After Multiple Dosing Measured by Liquid Chromatography-Mass Spectroscopy: A Pharmacokinetic Study in Healthy Volunteers. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 489-496.	2.0	14
256	Pharmacogenetics of Alcohol and Alcohol Dependence Treatment. <i>Current Pharmaceutical Design</i> , 2010, 16, 2141-2148.	1.9	61
257	Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users. <i>Aids</i> , 2010, 24, 331-340.	2.2	38
258	Revisiting the Cost-Effectiveness of the COMBINE Study for Alcohol Dependent Patients. <i>Medical Care</i> , 2010, 48, 306-313.	2.4	18
259	The Effect of Aripiprazole on Cue-Induced Brain Activation and Drinking Parameters in Alcoholics. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 365-372.	1.4	67
260	The Effect of Alcohol Treatment on Social Costs of Alcohol Dependence. <i>Medical Care</i> , 2010, 48, 396-401.	2.4	37
261	Impact of Treatment With Intramuscular, Injectable, Extended-Release Naltrexone on Counseling and Support Group Participation in Patients With Alcohol Dependence. <i>Journal of Addiction Medicine</i> , 2010, 4, 181-185.	2.6	7
262	Combining Motivational Interviewing With Compliance Enhancement Therapy (MI-CET): Development and Preliminary Evaluation of a New, Manual-Guided Psychosocial Adjunct to Alcohol-Dependence Pharmacotherapy. <i>Journal of Studies on Alcohol and Drugs</i> , 2010, 71, 61-70.	1.0	18
263	Network Support as a Prognostic Indicator of Drinking Outcomes: The COMBINE Study. <i>Journal of Studies on Alcohol and Drugs</i> , 2010, 71, 837-846.	1.0	137



#	ARTICLE	IF	CITATIONS
265	Motivational interviewing in relational context.. American Psychologist, 2010, 65, 298-299.	4.2	25
266	Effect of Acamprosate on Magnetic Resonance Spectroscopy Measures of Central Glutamate in Detoxified Alcohol-Dependent Individuals. Archives of General Psychiatry, 2010, 67, 1069.	12.3	136
267	Hidden Markov models for alcoholism treatment trial data. Annals of Applied Statistics, 2010, 4, .	1.1	52
268	Acamprosate: A Prototypic Neuromodulator in the Treatment of Alcohol Dependence. CNS and Neurological Disorders - Drug Targets, 2010, 9, 23-32.	1.4	61
269	Individualised treatment in alcohol-dependent patients. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 116-120.	3.2	62
270	Factors Associated with Favorable Drinking Outcome 12 Months After Hospitalization in a Prospective Cohort Study of Inpatients with Unhealthy Alcohol Use. Journal of General Internal Medicine, 2010, 25, 1024-1029.	2.6	16
271	What Can General Medical Providers Do for Hospitalized Patients with Alcohol Dependence After Discharge?. Journal of General Internal Medicine, 2010, 25, 1000-1002.	2.6	3
272	New horizons for therapeutics in drug and alcohol abuse. , 2010, 125, 138-168.		64
273	Alcoholic liver disease. Hepatology, 2010, 51, 307-328.	7.3	981
274	Assessment of benefits of a universal screen for maternal alcohol use during pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology, 2010, 88, 838-846.	1.6	19
275	Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients: Design and Implementation. Alcoholism: Clinical and Experimental Research, 2010, 34, 317-330.	2.4	24
276	Naltrexone Selectively Elevates GABAergic Neuroactive Steroid Levels in Heavy Drinkers With the ASP40 Allele of the OPRM1 Gene: A Pilot Investigation. Alcoholism: Clinical and Experimental Research, 2010, 34, 1479-1487.	2.4	15
277	Gender Differences in Alcohol Treatment: An Analysis of Outcome From the COMBINE Study. Alcoholism: Clinical and Experimental Research, 2010, 34, 1803-1812.	2.4	85
278	Efficacy and Safety of Baclofen for Alcohol Dependence: A Randomized, Double-blind, Placebo-controlled Trial. Alcoholism: Clinical and Experimental Research, 2010, 34, 1849-1857.	2.4	258
279	Percentage of Subjects With No Heavy Drinking Days: Evaluation as an Efficacy Endpoint for Alcohol Clinical Trials. Alcoholism: Clinical and Experimental Research, 2010, 34, 2022-2034.	2.4	156
280	A Comparison of Methods for Estimating Change in Drinking following Alcohol Treatment. Alcoholism: Clinical and Experimental Research, 2010, 34, 2116-2125.	2.4	33
281	OCDS Craving Scores Predict 24-Month Outcome in Alcoholic Outpatients. American Journal on Addictions, 2010, 19, 264-269.	1.4	10
282	The 10 most important things known about addiction. Addiction, 2010, 105, 6-13.	3.3	84



#	ARTICLE	IF	CITATIONS
283	What neurobiology cannot tell us about addiction. <i>Addiction</i> , 2010, 105, 780-789.	3.3	104
284	CULTURE, TREATMENT AND THE CULTURE OF TREATMENT. <i>Addiction</i> , 2010, 105, 16-17.	3.3	2
285	Alcohol: No Ordinary Commodity â€“ a summary of the second edition. <i>Addiction</i> , 2010, 105, 769-779.	3.3	138
286	WHAT DO MARSHMALLOWS AND GOLF TELL US ABOUT NATURAL RECOVERY RESEARCH?. <i>Addiction</i> , 2010, 105, 1521-1522.	3.3	3
287	Mechanisms of change in control group drinking in clinical trials of brief alcohol intervention: Implications for bias toward the null. <i>Drug and Alcohol Review</i> , 2010, 29, 498-507.	2.1	62
288	Quetiapine for the treatment of alcoholism: Scientific rationale and review of the literature. <i>Drug and Alcohol Review</i> , 2010, 29, 568-575.	2.1	22
289	Artikel. <i>NAD Nordic Studies on Alcohol and Drugs</i> , 2010, 27, 107-126.	1.3	0
290	The effects of Naltrexone among alcohol non-abstainers: results from the COMBINE Study. <i>Frontiers in Psychiatry</i> , 2010, 1, 26.	2.6	18
291	Molecular Basis and Current Treatment for Alcoholic Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , 2010, 7, 1872-1888.	2.6	34
292	Disruption of Long-Term Alcohol-Related Memory Reconsolidation: Role of $\beta^2$ -Adrenoceptors and NMDA Receptors. <i>Frontiers in Behavioral Neuroscience</i> , 2010, 4, 179.	2.0	49
293	Neuronal Nicotinic Acetylcholine Receptors as Pharmacotherapeutic Targets for the Treatment of Alcohol Use Disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 60-76.	1.4	91
294	Alcohol use among older adults. <i>Reviews in Clinical Gerontology</i> , 2010, 20, 56-68.	0.5	12
295	Medication Treatment of Different Types of Alcoholism. <i>American Journal of Psychiatry</i> , 2010, 167, 630-639.	7.2	135
296	A Double-Blind, Placebo-Controlled Trial Combining Sertraline and Naltrexone for Treating Co-Occurring Depression and Alcohol Dependence. <i>American Journal of Psychiatry</i> , 2010, 167, 668-675.	7.2	221
297	Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. <i>Journal of Psychopharmacology</i> , 2010, 24, 1367-1374.	4.0	54
298	Improving Healthcare for Incarcerated Women. <i>Journal of Women's Health</i> , 2010, 19, 13-15.	3.3	14
299	Alcoholic Liver Disease. <i>American Journal of Gastroenterology</i> , 2010, 105, 14-32.	0.4	220
300	Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management and intervention. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 1136-1145.	1.2	26

#	ARTICLE	IF	CITATIONS
301	Addiction Medicine and Addiction Psychiatry in America: Commonalities in the Medical Treatment of Addiction. <i>Contemporary Drug Problems</i> , 2010, 37, 139-163.	1.6	6
302	Dual Efficacy of Delta Opioid Receptor-Selective Ligands for Ethanol Drinking and Anxiety. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 133-139.	2.5	55
303	Effectiveness of a nurse-led alcohol liaison service in a secondary care medical unit. <i>Clinical Medicine</i> , 2010, 10, 435-440.	1.9	24
304	Subjective Responses to Alcohol Consumption as Endophenotypes: Advancing Behavioral Genetics in Etiological and Treatment Models of Alcoholism. <i>Substance Use and Misuse</i> , 2010, 45, 1742-1765.	1.4	114
305	Acetyl-L-Carnitine for Alcohol Craving and Relapse Prevention in Anhedonic Alcoholics: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial. <i>Alcohol and Alcoholism</i> , 2010, 45, 449-455.	1.6	20
306	Clinical Predictors of Outcome from an Australian Pharmacological Relapse Prevention Trial. <i>Alcohol and Alcoholism</i> , 2010, 45, 520-526.	1.6	9
307	Supervised Disulfiram in Relapse Prevention in Alcohol-Dependent Patients Suffering From Comorbid Borderline Personality Disorder--A Case Series. <i>Alcohol and Alcoholism</i> , 2010, 45, 146-150.	1.6	16
308	Why is Disulfiram Superior to Acamprosate in the Routine Clinical Setting? A Retrospective Long-Term Study in 353 Alcohol-Dependent Patients. <i>Alcohol and Alcoholism</i> , 2010, 45, 271-277.	1.6	44
309	Safety and Efficacy of Baclofen in the Treatment of Alcohol-Dependent Patients. <i>Current Pharmaceutical Design</i> , 2010, 16, 2113-2117.	1.9	86
310	Treatments for Alcohol Dependence: Rethinking the Role of Comorbidity and Clinical Subtypes. <i>American Journal of Psychiatry</i> , 2010, 167, 620-622.	7.2	7
311	Evolving therapeutic indications for N-type calcium channel blockers: from chronic pain to alcohol abuse. <i>Future Medicinal Chemistry</i> , 2010, 2, 791-802.	2.3	6
312	Neurologic Aspects of Drug Abuse. <i>Neurologic Clinics</i> , 2010, 28, 199-215.	1.8	19
313	Screening and Brief Intervention for Underage Drinkers. <i>Mayo Clinic Proceedings</i> , 2010, 85, 380-391.	3.0	29
314	Emerging drugs to treat alcoholism. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 695-711.	2.4	28
315	Cognitive Behavioral Therapy for Substance Use Disorders. <i>Psychiatric Clinics of North America</i> , 2010, 33, 511-525.	1.3	330
316	Opioid antagonists for alcohol dependence. <i>The Cochrane Library</i> , 0, , .	2.8	101
317	Relapse Prevention and Recycling in Addiction. , 2010, , 765-782.		5
318	Stigma and Treatment for Alcohol Disorders in the United States. <i>American Journal of Epidemiology</i> , 2010, 172, 1364-1372.	3.4	320

#	ARTICLE	IF	CITATIONS
319	Predictors of motivation for abstinence at the end of outpatient substance abuse treatment. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, 317-327.	2.8	77
320	Extended-release naltrexone for treatment of alcohol dependence in primary care. <i>Journal of Substance Abuse Treatment</i> , 2010, 39, 14-21.	2.8	42
321	Effect of early and late compliance on the effectiveness of acamprosate in the treatment of alcohol dependence. <i>Journal of Substance Abuse Treatment</i> , 2010, 39, 218-226.	2.8	17
322	When should clinicians switch treatments? An application of signal detection theory to two treatments for women with alcohol use disorders. <i>Behaviour Research and Therapy</i> , 2010, 48, 524-530.	3.1	16
323	Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. <i>Drug and Alcohol Dependence</i> , 2010, 107, 221-229.	3.2	44
324	Estimating risk of alcohol dependence using alcohol screening scores. <i>Drug and Alcohol Dependence</i> , 2010, 108, 29-36.	3.2	120
325	Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. <i>Drug and Alcohol Dependence</i> , 2010, 109, 20-29.	3.2	91
326	Cost-effectiveness of computer-assisted training in cognitive-behavioral therapy as an adjunct to standard care for addiction. <i>Drug and Alcohol Dependence</i> , 2010, 110, 200-207.	3.2	59
327	A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. <i>Drug and Alcohol Dependence</i> , 2010, 112, 178-193.	3.2	325
328	Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA. <i>Drug and Alcohol Dependence</i> , 2010, 114, 201-6.	3.2	10
329	Opioid receptors in the basolateral amygdala but not dorsal hippocampus mediate context-induced alcohol seeking. <i>Behavioural Brain Research</i> , 2010, 211, 58-63.	2.2	39
330	Biological and psychological interventions: Trends in substance use disorders intervention research. <i>Addictive Behaviors</i> , 2010, 35, 1083-1088.	3.0	6
331	Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. <i>Lancet, The</i> , 2010, 376, 367-387.	18.7	431
333	Novel Pharmacological Approaches to Drug Abuse Treatment. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 3, 343-386.	1.7	14
334	Acamprosate for alcohol dependence. <i>The Cochrane Library</i> , 2010, , CD004332.	2.8	232
335	Acamprosate. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 363-380.	3.3	15
336	The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 177-188.	2.4	40
337	Substance Use Disorders: Realizing the Promise of Pharmacogenomics and Personalized Medicine. <i>Annual Review of Clinical Psychology</i> , 2010, 6, 577-589.	12.3	63

#	ARTICLE	IF	CITATIONS
338	Tanning addiction: current trends and future treatment. <i>Expert Review of Dermatology</i> , 2010, 5, 123-125.	0.3	44
339	Co-morbid Bipolar and Alcohol Use Disorders: A Treatment-Focused Review. <i>Journal of Dual Diagnosis</i> , 2010, 6, 171-188.	1.2	2
340	Opioid modulators for alcohol dependence. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1073-1086.	4.1	26
341	Ten Take Home Lessons from the First 10 Years of the CTN and 10 Recommendations for the Future. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 275-282.	2.1	21
342	Pharmacotherapy for Substance Abuse Disorders in Adolescence. <i>Pediatric Clinics of North America</i> , 2011, 58, 243-258.	1.8	8
343	Baclofen-induced acute hepatitis in alcohol-dependent patient. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 420-421.	1.5	13
344	Molecular Targets of Alcohol Action. <i>Progress in Molecular Biology and Translational Science</i> , 2011, 98, 293-347.	1.7	15
347	Validation of a nine-dimensional measure of drinking motives for use in clinical applications: The desired effects of drinking scale. <i>Addictive Behaviors</i> , 2011, 36, 1052-1060.	3.0	23
348	The Obsessive Compulsive Cocaine Scale: Assessment of factor structure, reliability, and validity. <i>Addictive Behaviors</i> , 2011, 36, 1223-1227.	3.0	6
349	A systematic review of Internet-based therapy for the treatment of addictions. <i>Clinical Psychology Review</i> , 2011, 31, 490-498.	11.4	155
350	Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. <i>Drug and Alcohol Dependence</i> , 2011, 116, 142-150.	3.2	184
351	Alcohol consumption and depressive symptoms over time: A longitudinal study of patients with and without HIV infection. <i>Drug and Alcohol Dependence</i> , 2011, 117, 158-163.	3.2	74
352	The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: A randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2011, 118, 417-422.	3.2	23
353	How cognitive assessment through clinical neurophysiology may help optimize chronic alcoholism treatment. <i>Neurophysiologie Clinique</i> , 2011, 41, 115-123.	2.2	7
354	Baseline functioning among individuals with posttraumatic stress disorder and alcohol dependence. <i>Journal of Substance Abuse Treatment</i> , 2011, 41, 186-192.	2.8	49
355	A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients. <i>Addictive Behaviors</i> , 2011, 36, 265-269.	3.0	17
357	Case Report of Severe Injection Site Reaction Associated with Intramuscular Naltrexone. <i>American Journal of Pharmacology and Toxicology</i> , 2011, 6, 1-4.	0.7	4
358	Beyond the Ubiquitous Relapse Curve: A Data-Informed Approach. <i>Frontiers in Psychiatry</i> , 2011, 2, 12.	2.6	4

#	ARTICLE	IF	CITATIONS
359	A Literature Review of Cost-Benefit Analyses for the Treatment of Alcohol Dependence. <i>International Journal of Environmental Research and Public Health</i> , 2011, 8, 3351-3364.	2.6	17
360	Does Family History of Alcoholism Moderate Naltrexone's Effects on Alcohol Use?. <i>Journal of Studies on Alcohol and Drugs</i> , 2011, 72, 135-140.	1.0	15
361	Adherence Monitoring in Naltrexone Pharmacotherapy Trials: A Systematic Review. <i>Journal of Studies on Alcohol and Drugs</i> , 2011, 72, 1012-1018.	1.0	56
362	Proposed Model of the Neurobiological Mechanisms Underlying Psychosocial Alcohol Interventions: The Example of Motivational Interviewing. <i>Journal of Studies on Alcohol and Drugs</i> , 2011, 72, 903-916.	1.0	52
363	Safety and Efficacy of Long-Term Disulfiram Aftercare. <i>Clinical Neuropharmacology</i> , 2011, 34, 195-198.	0.7	15
364	Current and Promising Pharmacotherapies, and Novel Research Target Areas in the Treatment of Alcohol Dependence: A Review. <i>Current Pharmaceutical Design</i> , 2011, 17, 1323-1332.	1.9	74
365	Drinking outcomes following drink refusal skills training: Differential effects for African American and non-Hispanic White clients.. <i>Psychology of Addictive Behaviors</i> , 2011, 25, 162-167.	2.1	18
366	Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.. <i>Journal of Consulting and Clinical Psychology</i> , 2011, 79, 54-63.	2.0	78
367	Self-efficacy change as a mediator of associations between therapeutic bond and one-year outcomes in treatments for alcohol dependence.. <i>Psychology of Addictive Behaviors</i> , 2011, 25, 269-278.	2.1	80
368	Reframing the Placebo Concept. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 703-704.	1.9	1
369	Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal. <i>British Journal of Pharmacology</i> , 2011, 164, 1335-1356.	5.4	27
370	Baseline Trajectories of Drinking Moderate Acamprosate and Naltrexone Effects in the COMBINE Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 523-531.	2.4	19
371	How Psychosocial Alcohol Interventions Work: A Preliminary Look at What fMRI Can Tell Us. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 643-651.	2.4	71
372	Commentary on Falk. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 191-193.	2.4	0
373	Supervised Disulfiram in the Treatment of Alcohol Use Disorder: A Commentary. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 1732-1736.	2.4	15
374	The Efficacy of Disulfiram for the Treatment of Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 1749-1758.	2.4	305
375	Efficacy of Extended-Release Naltrexone in Patients with Relatively Higher Severity of Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 1804-1811.	2.4	18
376	Alcohol research: past, present, and future. <i>Annals of the New York Academy of Sciences</i> , 2011, 1216, 1-23.	3.8	38

#	ARTICLE	IF	CITATIONS
377	Intramuscular extended-release naltrexone: current evidence. <i>Annals of the New York Academy of Sciences</i> , 2011, 1216, 144-166.	3.8	65
378	Factor Structure Validation of the Alcohol Dependence Scale in a Heavy Drinking College Sample. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2011, 33, 523-530.	1.2	5
379	Reducing Sexual HIV/STI Risk and Harmful Alcohol Use Among Female Sex Workers in Mongolia: A Randomized Clinical Trial. <i>AIDS and Behavior</i> , 2011, 15, 1785-1794.	2.7	44
380	Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. <i>Psychopharmacology</i> , 2011, 216, 267-277.	3.1	102
382	Update in Addiction Medicine for the Generalist. <i>Journal of General Internal Medicine</i> , 2011, 26, 77-82.	2.6	7
383	Quality Concerns with Routine Alcohol Screening in VA Clinical Settings. <i>Journal of General Internal Medicine</i> , 2011, 26, 299-306.	2.6	114
384	Recent Advances in Behavioral Addiction Treatments: Focusing on Mechanisms of Change. <i>Current Psychiatry Reports</i> , 2011, 13, 382-389.	4.5	55
385	Barriers to Use of Pharmacotherapy for Addiction Disorders and How to Overcome Them. <i>Current Psychiatry Reports</i> , 2011, 13, 374-381.	4.5	125
386	Chronic disease and recent addiction treatment utilization among alcohol and drug dependent adults. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2011, 6, 28.	2.2	8
387	Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study. <i>Human Psychopharmacology</i> , 2011, 26, 125-132.	1.5	16
388	Prediction of the Risk of Comorbid Alcoholism in Schizophrenia by Interaction of Common Genetic Variants in the Corticotropin-Releasing Factor System. <i>Archives of General Psychiatry</i> , 2011, 68, 1247.	12.3	33
389	Association of Frontal and Posterior Cortical Gray Matter Volume With Time to Alcohol Relapse: A Prospective Study. <i>American Journal of Psychiatry</i> , 2011, 168, 183-192.	7.2	168
390	Effects of Adrenal Sensitivity, Stress- and Cue-Induced Craving, and Anxiety on Subsequent Alcohol Relapse and Treatment Outcomes. <i>Archives of General Psychiatry</i> , 2011, 68, 942.	12.3	318
391	Gabapentin Combined With Naltrexone for the Treatment of Alcohol Dependence. <i>American Journal of Psychiatry</i> , 2011, 168, 709-717.	7.2	127
392	After Inclusion, Information and Inference: Reporting on Clinical Trials Results After 15 Years of Monitoring Inclusion of Women. <i>Journal of Women's Health</i> , 2011, 20, 829-836.	3.3	28
393	Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. <i>Current Medical Research and Opinion</i> , 2011, 27, 2309-2320.	1.9	46
394	Clients' Self-efficacy and Outcome Expectations. <i>Addictive Disorders and Their Treatment</i> , 2011, 10, 157-168.	0.5	5
395	Pre-Treatment Expectations in Clients: Impact on Retention and Effectiveness in Outpatient Substance Abuse Treatment. <i>Behavioural and Cognitive Psychotherapy</i> , 2011, 39, 257-271.	1.2	22

#	ARTICLE	IF	CITATIONS
396	Topiramate for the Treatment of Alcohol Dependence: Comparison with Naltrexone. <i>European Addiction Research</i> , 2011, 17, 29-36.	2.4	49
397	Personality Disorders and the 3-Year Course of Alcohol, Drug, and Nicotine Use Disorders. <i>Archives of General Psychiatry</i> , 2011, 68, 1158.	12.3	184
398	Applying Motivational Interviewing Principles in a Modified Interpersonal Group for Comorbid Addiction. <i>International Journal of Group Psychotherapy</i> , 2011, 61, 556-575.	0.6	1
399	Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. <i>Pharmacogenomics Journal</i> , 2011, 11, 368-374.	2.0	93
400	Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. <i>Journal of Dual Diagnosis</i> , 2011, 7, 64-73.	1.2	17
401	Using a Lifecourse Context for Exploring Alcohol Change Attempts and Treatment Efforts Among Individuals With Alcohol Dependency. <i>Journal of Social Work Practice in the Addictions</i> , 2011, 11, 101-123.	0.7	2
402	Substance Use Prevalence and Screening Instrument Comparisons in Urban Primary Care. <i>Substance Abuse</i> , 2011, 32, 128-134.	2.3	16
403	Medical Treatment of Alcohol Dependence: A Systematic Review. <i>International Journal of Psychiatry in Medicine</i> , 2011, 42, 227-266.	1.8	90
404	A Randomized Trial of Two Behavioral Interventions to Improve Outcomes Following Inpatient Detoxification for Alcohol Dependence. <i>Journal of Addictive Diseases</i> , 2011, 30, 136-148.	1.3	30
405	Assessment Reactivity: Can Assessment of Alcohol Use During Research be an Active Treatment?. <i>Alcoholism Treatment Quarterly</i> , 2011, 29, 108-115.	0.8	26
406	Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence. <i>Archives of General Psychiatry</i> , 2011, 68, 1238.	12.3	463
407	What Works for Patients in Outpatient Treatment for Alcohol Addiction? An Explorative Study into Clients'™ Evaluation of Subjective Factors and Therapy Satisfaction. <i>Substance Abuse: Research and Treatment</i> , 2011, 5, SART.S6796.	0.9	1
408	Alcohol, Tobacco, and Prescription Drugs: The Relationship With Illicit Drugs in the Treatment of Substance Users. <i>Substance Use and Misuse</i> , 2012, 47, 963-971.	1.4	15
409	The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders. <i>Neuropsychopharmacology</i> , 2012, 37, 402-411.	5.4	25
410	Pharmacogenetics of Naltrexone in Asian Americans: A Randomized Placebo-Controlled Laboratory Study. <i>Neuropsychopharmacology</i> , 2012, 37, 445-455.	5.4	69
411	Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence. <i>Neuropsychopharmacology</i> , 2012, 37, 996-1004.	5.4	104
412	The Impact of Significant Others in Motivational Enhancement Therapy: Findings from Project MATCH. <i>Behavioural and Cognitive Psychotherapy</i> , 2012, 40, 297-312.	1.2	17
413	The Impact of Acamprosate on Cue Reactivity in Alcohol Dependent Individuals. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 661-665.	1.4	21



#	ARTICLE	IF	CITATIONS
414	Implementing Evidence-Based Alcohol Interventions in a Resource-Limited Setting: Novel Delivery Strategies in Tomsk, Russia. <i>Harvard Review of Psychiatry</i> , 2012, 20, 58-67.	2.1	6
415	Alcohol Consumption Induces Endogenous Opioid Release in the Human Orbitofrontal Cortex and Nucleus Accumbens. <i>Science Translational Medicine</i> , 2012, 4, 116ra6.	12.4	190
416	Multiple-Dose Safety, Pharmacokinetics, and Pharmacodynamics of the $\mu$ -Opioid Receptor Inverse Agonist GSK1521498. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1456-1467.	2.0	15
417	The Role of Genomics in Health Behavior Change: Challenges and Opportunities. <i>Public Health Genomics</i> , 2012, 15, 139-145.	1.0	14
418	Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence. <i>Journal of Human Genetics</i> , 2012, 57, 670-675.	2.3	57
419	Alcohol treatment research assessment exposure: A critical review of the literature.. <i>Psychology of Addictive Behaviors</i> , 2012, 26, 773-781.	2.1	32
420	Role of Two Clusters of Male Alcoholics in Treatment Retention. <i>European Addiction Research</i> , 2012, 18, 201-211.	2.4	8
421	$\mu$ -Opioid Receptor Function in the Dorsal Striatum Plays a Role in High Levels of Ethanol Consumption in Rats. <i>Journal of Neuroscience</i> , 2012, 32, 4540-4552.	3.6	37
423	Drink refusal training as part of a combined behavioral intervention: Effectiveness and mechanisms of change.. <i>Journal of Consulting and Clinical Psychology</i> , 2012, 80, 440-449.	2.0	52
424	Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: A preliminary study.. <i>Experimental and Clinical Psychopharmacology</i> , 2012, 20, 181-190.	1.8	62
425	A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men.. <i>Journal of Consulting and Clinical Psychology</i> , 2012, 80, 863-875.	2.0	41
426	Do Manualized Psychosocial Interventions Help Reduce Relapse among Alcohol-Dependent Adults Treated with Naltrexone or Placebo? A Meta-Analysis. <i>American Journal on Addictions</i> , 2012, 21, 501-507.	1.4	13
427	Trajectory Analyses in Alcohol Treatment Research. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 1442-1448.	2.4	6
428	EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. <i>Journal of Hepatology</i> , 2012, 57, 399-420.	3.7	602
429	Current progress in pharmacologic treatment strategies for alcohol dependence. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 427-435.	3.1	17
430	The Relationship of Appetitive, Reproductive and Posterior Pituitary Hormones to Alcoholism and Craving in Humans. <i>Neuropsychology Review</i> , 2012, 22, 211-228.	4.9	33
431	Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 458-462.	2.8	27
432	The contribution of executive functions deficits to impaired episodic memory in individuals with alcoholism. <i>Psychiatry Research</i> , 2012, 198, 116-122.	3.3	60



#	ARTICLE	IF	CITATIONS
433	Management of Alcohol Abuse. <i>Clinics in Liver Disease</i> , 2012, 16, 737-762.	2.1	7
434	PL02-01 - Individualised therapy of alcoholism. <i>European Psychiatry</i> , 2012, 27, 1.	0.2	0
435	Tratamiento de la dependencia del alcohol. <i>Medicine</i> , 2012, 11, 1412-1420.	0.0	1
436	A new look at the difference between the GEE and the GLMM when modeling longitudinal count responses. <i>Journal of Applied Statistics</i> , 2012, 39, 2067-2079.	1.3	29
437	Defining the Role of Baclofen for the Treatment of Alcohol Dependence. <i>CNS Drugs</i> , 2012, 26, 69-78.	5.9	42
438	BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. <i>Journal of Psychopharmacology</i> , 2012, 26, 899-952.	4.0	268
439	Relapse prevention: From radical idea to common practice. <i>Addiction Research and Theory</i> , 2012, 20, 204-217.	1.9	23
440	Review of biological mechanisms and pharmacological treatments of comorbid PTSD and substance use disorder. <i>Neuropharmacology</i> , 2012, 62, 542-551.	4.1	80
441	Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1. <i>Neuropharmacology</i> , 2012, 62, 2480-2488.	4.1	25
442	Comparing alternative specifications of quality measures: Access to pharmacotherapy for alcohol use disorders. <i>Journal of Substance Abuse Treatment</i> , 2012, 42, 102-107.	2.8	7
443	Reduction of Ethanol Consumption in Alcohol-Preferring Rats by Dual Expression Gene Transfer. <i>Alcohol and Alcoholism</i> , 2012, 47, 102-108.	1.6	17
444	Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum with high-performance liquid chromatography. <i>BMC Research Notes</i> , 2012, 5, 439.	1.4	2
445	A randomized trial evaluating an mHealth system to monitor and enhance adherence to pharmacotherapy for alcohol use disorders. <i>Addiction Science &amp; Clinical Practice</i> , 2012, 7, 9.	2.6	25
446	Medications development to treat alcohol dependence: a vision for the next decade. <i>Addiction Biology</i> , 2012, 17, 513-527.	2.6	176
447	Simultaneous Modeling of the Impact of Treatments on Alcohol Consumption and Quality of Life in the COMBINE Study: A Coupled Hidden Markov Analysis. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 2141-2149.	2.4	6
448	Emergence of Functional Spinal Delta Opioid Receptors After Chronic Ethanol Exposure. <i>Biological Psychiatry</i> , 2012, 71, 232-238.	1.3	51
449	Cigarette Smoking Predicts Differential Benefit from Naltrexone for Alcohol Dependence. <i>Biological Psychiatry</i> , 2012, 72, 832-838.	1.3	56
450	Extended-Release Mixed Amphetamine Salts and Topiramate for Cocaine Dependence: A Randomized Controlled Trial. <i>Biological Psychiatry</i> , 2012, 72, 950-956.	1.3	69

#	ARTICLE	IF	CITATIONS
451	The Monoamine Stabilizer (-)-OSU6162 Attenuates Voluntary Ethanol Intake and Ethanol-Induced Dopamine Output in Nucleus Accumbens. <i>Biological Psychiatry</i> , 2012, 72, 823-831.	1.3	56
452	The cost-effectiveness of tailored, postal feedback on general practitioners' prescribing of pharmacotherapies for alcohol dependence. <i>Drug and Alcohol Dependence</i> , 2012, 124, 207-215.	3.2	7
453	Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 103, 253-259.	2.9	53
454	Psychosocial and Clinical Predictors of Retention in Outpatient Alcoholism Treatment. <i>Revista Brasileira De Psiquiatria</i> , 2012, 34, 413-421.	1.7	11
455	Foreword: The Neuroethics of Drug Addiction. , 2012, , xi-xiv.		1
456	Pharmacogenetically Driven Treatments for Alcoholism. <i>CNS Drugs</i> , 2012, 26, 461-476.	5.9	17
457	Bipolar Disorder and Alcohol Use Disorder: A Review. <i>Current Psychiatry Reports</i> , 2012, 14, 659-666.	4.5	70
458	HIV disease among substance users. , 2012, , 537-549.		1
459	Influence of the <i>OPRM1</i> A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. <i>Pharmacogenomics</i> , 2012, 13, 1161-1172.	1.3	20
460	Personalized Treatment of Alcohol Dependence. <i>Current Psychiatry Reports</i> , 2012, 14, 486-493.	4.5	61
461	Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals. <i>Psychopharmacology</i> , 2012, 224, 501-509.	3.1	24
462	Effects of naltrexone on alcohol drinking patterns and extinction of alcohol seeking in baboons. <i>Psychopharmacology</i> , 2012, 223, 55-66.	3.1	17
463	Cost-Effectiveness of Peer-Delivered Interventions for Cocaine and Alcohol Abuse among Women: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2012, 7, e33594.	2.5	12
464	Electroacupuncture Decreases Excessive Alcohol Consumption Involving Reduction of FosB <sup>Δ</sup> FosB Levels in Reward-Related Brain Regions. <i>PLoS ONE</i> , 2012, 7, e40347.	2.5	20
465	Obtaining the Optimal Dose in Alcohol Dependence Studies. <i>Frontiers in Psychiatry</i> , 2012, 3, 100.	2.6	2
466	Mu opioid receptor ( <i>OPRM1</i> ) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 99.	0.7	20
467	Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 45.	2.0	43
469	Cost-Effectiveness of Peer-Delivered Interventions For Cocaine and Alcohol Abuse Among Women: A Randomized Controlled Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
470	Evidence-based pharmacotherapy of nicotine and alcohol dependence. , 0, , 214-234.		0
471	The public health implications of genetic research on addiction. , 0, , 155-173.		0
472	The implications of genetic research on alcohol dependence for prevention and treatment. , 0, , 16-30.		1
473	Next Steps in Addressing the Prevention, Screening, and Treatment of Substance Use Disorder in Active Duty and Veteran Operation Enduring Freedom and Operation Iraqi Freedom Populations. <i>Military Medicine</i> , 2012, 177, 39-46.	0.8	2
474	Evidence-Based Pharmacological Treatment of Substance Use Disorders and Pathological Gambling. <i>Current Drug Abuse Reviews</i> , 2012, 5, 3-31.	3.4	94
475	Evidence-Based Screening, Diagnosis, and Treatment of Substance Use Disorders Among Veterans and Military Service Personnel. <i>Military Medicine</i> , 2012, 177, 29-38.	0.8	23
476	The Role of Delta Opioid Receptors in Ethanol Consumption and Seeking: Implications for New Treatments for Alcohol Use Disorders. , 2012, , .		0
477	Hepatic Safety and Antiretroviral Effectiveness in HIV-Infected Patients Receiving Naltrexone. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 318-324.	2.4	39
478	Acamprosate for Alcohol Dependence: A Sex-Specific Meta-Analysis Based on Individual Patient Data. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 497-508.	2.4	73
479	Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. <i>Addiction</i> , 2012, 107, 709-718.	3.3	172
480	The clinical significance of drug craving. <i>Annals of the New York Academy of Sciences</i> , 2012, 1248, 1-17.	3.8	396
481	Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment. <i>Alcohol</i> , 2012, 46, 121-131.	1.7	20
482	Phosphatidylethanol (PEth) as a Biomarker of Alcohol Consumption in HIV-Positive Patients in Sub-Saharan Africa. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 854-862.	2.4	105
483	Does Session Attendance by a Supportive Significant Other Predict Outcomes in Individual Treatment for Alcohol Use Disorders?. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 1237-1243.	2.4	14
484	Glutamatergic medications for the treatment of drug and behavioral addictions. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 801-810.	2.9	187
485	The long-lasting effects of JDTic, a kappa opioid receptor antagonist, on the expression of ethanol-seeking behavior and the relapse drinking of female alcohol-preferring (P) rats. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 101, 581-587.	2.9	40
486	Direct-to-consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value. <i>Addiction</i> , 2012, 107, 2069-2074.	3.3	23
487	Association of $\mu$ -opioid receptor ( <i>OPRM1</i> ) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. <i>Addiction Biology</i> , 2012, 17, 505-512.	2.6	132

#	ARTICLE	IF	CITATIONS
488	A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. <i>Bipolar Disorders</i> , 2012, 14, 54-63.	1.9	60
489	Care for hospitalized patients with unhealthy alcohol use: a narrative review. <i>Addiction Science &amp; Clinical Practice</i> , 2013, 8, 11.	2.6	24
490	2012 Update in addiction medicine for the generalist. <i>Addiction Science &amp; Clinical Practice</i> , 2013, 8, 6.	2.6	4
491	The relationship between impulsivity and craving in alcohol dependent patients. <i>Psychopharmacology</i> , 2013, 226, 273-283.	3.1	46
492	Management of Alcohol Dependence in Patients with Liver Disease. <i>CNS Drugs</i> , 2013, 27, 287-299.	5.9	87
493	Random forest methodology for model-based recursive partitioning: the mobForest package for R. <i>BMC Bioinformatics</i> , 2013, 14, 125.	2.6	73
496	A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. <i>American Journal on Addictions</i> , 2013, 22, 443-452.	1.4	126
497	Alcohol use disorders and mortality: a systematic review and meta-analysis. <i>Addiction</i> , 2013, 108, 1562-1578.	3.3	232
498	Identification of trajectories of social network composition change and the relationship to alcohol consumption and norms. <i>Drug and Alcohol Dependence</i> , 2013, 132, 309-315.	3.2	25
499	Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis. <i>Drug and Alcohol Dependence</i> , 2013, 130, 45-51.	3.2	30
500	Self-perceived problem with alcohol use among opioid substitution treatment clients. <i>Addictive Behaviors</i> , 2013, 38, 2018-2021.	3.0	11
501	Ethical implications of research on craving. <i>Addictive Behaviors</i> , 2013, 38, 1593-1599.	3.0	7
502	Effect of modafinil on impulsivity and relapse in alcohol dependent patients: A randomized, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2013, 23, 948-955.	0.7	45
503	Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. <i>Addictive Behaviors</i> , 2013, 38, 2119-2127.	3.0	22
504	Attributions of Change and Self-Efficacy in a Randomized Controlled Trial of Medication and Psychotherapy for Problem Drinking. <i>Behavior Therapy</i> , 2013, 44, 88-99.	2.4	8
505	Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed Nalmefene. <i>Biological Psychiatry</i> , 2013, 73, 706-713.	1.3	457
506	Levetiracetam Has Opposite Effects on Alcohol- and Cocaine-Related Behaviors in C57BL/6J Mice. <i>Neuropsychopharmacology</i> , 2013, 38, 1322-1333.	5.4	12
507	Naltrexone and Nalmefene: Any Meaningful Difference?. <i>Biological Psychiatry</i> , 2013, 73, 700-701.	1.3	31

#	ARTICLE	IF	CITATIONS
508	Glutamatergic targets for new alcohol medications. <i>Psychopharmacology</i> , 2013, 229, 539-554.	3.1	167
509	Nalmefene: A Review of Its Use in the Treatment of Alcohol Dependence. <i>CNS Drugs</i> , 2013, 27, 761-772.	5.9	203
510	An investigator-blinded, randomized study to compare the efficacy of combined CBT for alcohol use disorders and social anxiety disorder versus CBT focused on alcohol alone in adults with comorbid disorders: the Combined Alcohol Social Phobia (CASP) trial protocol. <i>BMC Psychiatry</i> , 2013, 13, 199.	2.6	19
511	2013 Update in addiction medicine for the generalist. <i>Addiction Science &amp; Clinical Practice</i> , 2013, 8, 18.	2.6	3
512	Targeted Opioid Receptor Antagonists in the Treatment of Alcohol Use Disorders. <i>CNS Drugs</i> , 2013, 27, 777-787.	5.9	51
513	Peter Riederer – 70th birthday – Neurobiological foundations of modern addiction treatment. <i>Journal of Neural Transmission</i> , 2013, 120, 55-64.	2.8	0
514	Pharmacotherapy for alcohol dependence: status of current treatments. <i>Current Opinion in Neurobiology</i> , 2013, 23, 692-699.	4.2	91
515	Common and distinct neural targets of treatment: Changing brain function in substance addiction. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2806-2817.	6.1	64
516	Modeling longitudinal drinking data in clinical trials: An application to the COMBINE study. <i>Drug and Alcohol Dependence</i> , 2013, 132, 244-250.	3.2	8
517	Craving Typology Questionnaire (CTQ): A scale for alcohol craving in normal controls and alcoholics. <i>Comprehensive Psychiatry</i> , 2013, 54, 925-932.	3.1	42
518	Novelty-Seeking Behaviors and the Escalation of Alcohol Drinking After Abstinence in Mice Are Controlled by Metabotropic Glutamate Receptor 5 on Neurons Expressing Dopamine D1 Receptors. <i>Biological Psychiatry</i> , 2013, 73, 263-270.	1.3	54
519	Emerging pharmacotherapies for alcohol dependence: A systematic review focusing on reduction in consumption. <i>Drug and Alcohol Dependence</i> , 2013, 133, 15-29.	3.2	46
520	Motivation and Problem Solving (MAPS): Motivationally Based Skills Training for Treating Substance Use. <i>Cognitive and Behavioral Practice</i> , 2013, 20, 501-516.	1.5	47
521	A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. <i>European Neuropsychopharmacology</i> , 2013, 23, 1432-1442.	0.7	359
522	– Success – Following Alcohol Treatment: Moving Beyond Abstinence. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, E9-13.	2.4	40
523	Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence. <i>Addiction</i> , 2013, 108, 115-123.	3.3	77
524	Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?. <i>Addiction</i> , 2013, 108, 275-293.	3.3	337
525	Posttreatment Low-Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, E373-80.	2.4	44

#	ARTICLE	IF	CITATIONS
526	Alcohol Use in Adults. <i>New England Journal of Medicine</i> , 2013, 368, 365-373.	27.0	119
527	Does substance abuse affect outcomes for trauma-focused treatment of combat-related PTSD?. <i>Addiction Research and Theory</i> , 2013, 21, 357-364.	1.9	7
528	How Can We Use Our Knowledge of Alcohol-Tobacco Interactions to Reduce Alcohol Use?. <i>Annual Review of Clinical Psychology</i> , 2013, 9, 649-674.	12.3	131
529	Lesion Procedures in Psychiatric Neurosurgery. <i>World Neurosurgery</i> , 2013, 80, S31.e9-S31.e16.	1.3	41
530	Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. <i>Addiction Biology</i> , 2013, 18, 937-946.	2.6	98
531	Improving clinical outcomes for naltrexone as a management of problem alcohol use. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 632-641.	2.4	12
532	Motivational Interviewing in the Health Care Setting. <i>American Journal of Lifestyle Medicine</i> , 2013, 7, 246-249.	1.9	2
533	Medications for Substance Use Disorders. <i>Social Work in Public Health</i> , 2013, 28, 264-278.	1.4	52
534	Randomized Trial of Web-Based Training to Promote Counselor Use of Cognitive Behavioral Therapy Skills in Client Sessions. <i>Substance Abuse</i> , 2013, 34, 179-187.	2.3	14
535	Severity of alcohol dependence in the Swedish adult population: Association with consumption and social factors. <i>Alcohol</i> , 2013, 47, 21-25.	1.7	38
536	Naltrexone (50 mg) Plus Psychotherapy in Alcohol-Dependent Patients: A Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Drug and Alcohol Abuse</i> , 2013, 39, 144-160.	2.1	24
537	Chronic Care Management for Dependence on Alcohol and Other Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1156.	7.4	116
538	Concurrent Naltrexone and Prolonged Exposure Therapy for Patients With Comorbid Alcohol Dependence and PTSD. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 488.	7.4	205
539	Why Not Add Consumption Measures to Current Definitions of Substance Use Disorders? Commentary on Rehm et al. "Defining Substance Use Disorders: Do We Really Need More Than Heavy Use?". <i>Alcohol and Alcoholism</i> , 2013, 48, 642-643.	1.6	4
540	Improved Drinking Behaviour Improves Quality of Life: A Follow-Up in Alcohol-Dependent Subjects 7 Years After Treatment. <i>Alcohol and Alcoholism</i> , 2013, 48, 579-584.	1.6	21
541	Combining Naltrexone and Prazosin in a Single Oral Medication Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1763-1770.	2.4	33
542	Ghrelin Receptor (GHS-R1A) Antagonism Suppresses Both Alcohol Consumption and the Alcohol Deprivation Effect in Rats following Long-Term Voluntary Alcohol Consumption. <i>PLoS ONE</i> , 2013, 8, e71284.	2.5	75
543	Varenicline Treatment of Concurrent Alcohol and Nicotine Dependence in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 243-247.	1.4	194

#	ARTICLE	IF	CITATIONS
544	Placebo Group Improvement in Trials of Pharmacotherapies for Alcohol Use Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 649-657.	1.4	14
545	Activation of $\text{PPAR}\gamma^3$ by Pioglitazone Potentiates the Effects of Naltrexone on Alcohol Drinking and Relapse in <i>msP</i> Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1351-1360.	2.4	77
546	Prazosin Reduces Alcohol Drinking Throughout Prolonged Treatment and Blocks the Initiation of Drinking in Rats Selectively Bred for High Alcohol Intake. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1552-1560.	2.4	39
547	Pretreatment Alcohol Drinking Goals are Associated with Treatment Outcomes. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1745-1752.	2.4	68
548	Missing Data in Alcohol Clinical Trials: A Comparison of Methods. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 2152-2160.	2.4	127
549	The Challenges of Improving Statistical Practice in Alcohol Treatment Research. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1999-2001.	2.4	2
550	Cravings as a mediator and moderator of drinking outcomes in the <i>COMBINE</i> study. <i>Addiction</i> , 2013, 108, 1737-1744.	3.3	35
551	Commentary on Subbaraman <i>et al</i> . (2013): Cravings as a mediator and moderator of drinking outcomes in the <i>COMBINE</i> Study. <i>Addiction</i> , 2013, 108, 1745-1746.	3.3	3
552	NMDA Receptor Modulators in the Treatment of Drug Addiction. <i>Pharmaceuticals</i> , 2013, 6, 251-268.	3.8	47
553	Efficacy of Acamprosate for Alcohol Dependence in a Family Medicine Setting in the <i>UNITED STATES</i> : A Randomized, Double-blind, Placebo-controlled Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 668-674.	2.4	21
554	Safety and Efficacy of Acamprosate for the Treatment of Alcohol Dependence. <i>Substance Abuse: Research and Treatment</i> , 2013, 7, SART.S9345.	0.9	20
555	The Grog Mob: lessons from an evaluation of a multi-disciplinary alcohol intervention for Aboriginal clients. <i>Australian and New Zealand Journal of Public Health</i> , 2013, 37, 450-456.	1.8	13
556	Transdisciplinary collaboration and endorsement of pharmacological and psychosocial evidence-based practices by medical and psychosocial substance abuse treatment providers in the United States. <i>Drugs: Education, Prevention and Policy</i> , 2013, 20, 408-416.	1.3	5
557	Management of patients with moderate alcoholic liver disease. <i>Clinical Liver Disease</i> , 2013, 2, 76-79.	2.1	3
558	The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective $\mu$ -opioid receptor antagonist GSK1521498 in healthy subjects. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1078-1090.	2.0	10
559	Randomized controlled trial of cognitive behaviour therapy for comorbid post-traumatic stress disorder and alcohol use disorders. <i>Addiction</i> , 2013, 108, 1397-1410.	3.3	102
560	Identification and Efficient Estimation of the Natural Direct Effect among the Untreated. <i>Biometrics</i> , 2013, 69, 310-317.	1.4	10
561	Evidence from regression-discontinuity analyses for beneficial effects of a criterion-based increase in alcohol treatment. <i>International Journal of Methods in Psychiatric Research</i> , 2013, 22, 59-70.	2.1	17



#	ARTICLE	IF	CITATIONS
562	Sodium oxybate to treat alcohol dependence: 20 years of clinical experience. <i>Addiction Biology</i> , 2013, 18, 901-903.	2.6	4
563	The Placebo Effect in Clinical Trials for Alcohol Dependence: An Exploratory Analysis of 51 Naltrexone and Acamprosate Studies. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 2128-2137.	2.4	44
564	Acamprosate Suppresses Ethanol-Induced Place Preference in Mice With Ethanol Physical Dependence. <i>Journal of Pharmacological Sciences</i> , 2013, 122, 289-298.	2.5	12
565	Pharmacotherapy for alcohol dependence: Perceived treatment barriers and action strategies among Veterans Health Administration service providers.. <i>Psychological Services</i> , 2013, 10, 410-419.	1.5	66
566	Neuroimaging mechanisms of change in psychotherapy for addictive behaviors: Emerging translational approaches that bridge biology and behavior.. <i>Psychology of Addictive Behaviors</i> , 2013, 27, 329-335.	2.1	38
567	Development of an in-home telehealth program for outpatient veterans with substance use disorders.. <i>Psychological Services</i> , 2013, 10, 304-314.	1.5	15
568	Neuroimaging in clinical studies of craving: Importance of reward and control networks.. <i>Psychology of Addictive Behaviors</i> , 2013, 27, 543-546.	2.1	4
569	The effects of drinking goal on treatment outcome for alcoholism.. <i>Journal of Consulting and Clinical Psychology</i> , 2013, 81, 13-22.	2.0	60
570	The contributions of cognitive neuroscience and neuroimaging to understanding mechanisms of behavior change in addiction.. <i>Psychology of Addictive Behaviors</i> , 2013, 27, 336-350.	2.1	53
571	Drinking Patterns and Their Predictive Factors in CONTROL: a 12-Month Prospective Study in a Sample of Alcohol-Dependent Patients Initiating Treatment. <i>Alcohol and Alcoholism</i> , 2013, 48, 189-195.	1.6	7
572	Positive Affect and Stress Reactivity in Alcohol-Dependent Outpatients. <i>Journal of Studies on Alcohol and Drugs</i> , 2013, 74, 152-157.	1.0	18
574	Integración e interacciones entre los tratamientos farmacológicos y psicológicos de las adicciones: una revisión.. <i>Anales De Psicología</i> , 2013, 29, .	0.7	2
575	Environmental and behavioral interventions. , 0, , 604-626.		0
576	Variation in Mu-Opioid Receptor Gene (OPRM1) as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort. <i>Journal of Alcoholism and Drug Dependence</i> , 2013, 01, 101.	0.2	15
577	KASL Clinical Practice Guidelines: Management of Alcoholic Liver Disease. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 216.	8.9	31
578	Identification of subpopulations of prairie voles differentially susceptible to peer influence to decrease high alcohol intake. <i>Frontiers in Pharmacology</i> , 2013, 4, 84.	3.5	14
580	Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 99.	1.2	24
583	Naltrexone and Opioid Antagonists for Alcohol Dependence. , 2013, , 375-384.		0



#	ARTICLE	IF	CITATIONS
585	Comparison of Self-Reported Alcohol Consumption to Phosphatidylethanol Measurement among HIV-Infected Patients Initiating Antiretroviral Treatment in Southwestern Uganda. PLoS ONE, 2014, 9, e113152.	2.5	89
586	Nalmefene: a new approach to the treatment of alcohol dependence. Substance Abuse and Rehabilitation, 2014, 5, 87.	4.8	33
587	Targeting central melanocortin receptors: a promising novel approach for treating alcohol abuse disorders. Frontiers in Neuroscience, 2014, 8, 128.	2.8	25
588	PTSD and comorbid AUD: a review of pharmacological and alternative treatment options. Substance Abuse and Rehabilitation, 2014, 5, 25.	4.8	40
589	Patient preferences and perspectives regarding reducing alcohol consumption: role of nalmefene. Patient Preference and Adherence, 2014, 8, 1347.	1.8	14
590	Cumulative Proportion of Responders Analysis (CPRA) as a Tool to Assess Treatment Outcome in Alcohol Clinical Trials. Journal of Studies on Alcohol and Drugs, 2014, 75, 335-346.	1.0	11
591	Subjective Responses to Alcohol in the Lab Predict Neural Responses to Alcohol Cues. Journal of Studies on Alcohol and Drugs, 2014, 75, 124-135.	1.0	20
592	Dissemination, Adoption, and Implementation of Acamprosate for Treating Alcohol Use Disorders. Journal of Studies on Alcohol and Drugs, 2014, 75, 467-475.	1.0	17
594	The development of acamprosate as a treatment against alcohol relapse. Expert Opinion on Drug Discovery, 2014, 9, 1355-1369.	5.0	14
595	Predicting Naltrexone Response in Alcohol-Dependent Patients: The Contribution of Functional Magnetic Resonance Imaging. Alcoholism: Clinical and Experimental Research, 2014, 38, 2754-2762.	2.4	79
596	Medications for Alcohol Use Disorders in a Primary Care Practice-Based Research Network Implementation Study. Alcoholism Treatment Quarterly, 2014, 32, 58-66.	0.8	1
597	Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds. Addiction Science & Clinical Practice, 2014, 9, 20.	2.6	6
598	Lost in translation? Moving contingency management and cognitive behavioral therapy into clinical practice. Annals of the New York Academy of Sciences, 2014, 1327, 94-111.	3.8	49
599	Posttreatment Effects of Topiramate Treatment for Heavy Drinking. Alcoholism: Clinical and Experimental Research, 2014, 38, 3017-3023.	2.4	22
600	Current pharmacological treatment approaches for alcohol dependence. Expert Opinion on Pharmacotherapy, 2014, 15, 471-481.	1.8	57
601	A Double-Blind Placebo-Controlled Randomized Trial of Varenicline for Smokeless Tobacco Dependence in India. Nicotine and Tobacco Research, 2014, 16, 50-57.	2.6	26
602	Ethyl Glucuronide (EtG): Better than Breathalyser or Self-Reports to Detect Covert Short-Term Relapses into Drinking. Alcohol and Alcoholism, 2014, 49, 51-54.	1.6	15
603	Proteomic Approaches and Identification of Novel Therapeutic Targets for Alcoholism. Neuropsychopharmacology, 2014, 39, 104-130.	5.4	40

#	ARTICLE	IF	CITATIONS
604	Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. <i>Contemporary Clinical Trials</i> , 2014, 39, 256-268.	1.8	32
605	Commentary on the Adding Individual Psychotherapy After Relapse in a Pharmacotherapy Trial: Commentary on the PREDICT Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 2164-2166.	2.4	0
606	Do Brief Alcohol Motivational Interventions Work Like We Think They Do?. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 853-859.	2.4	41
607	Predictors of Abstinence from Heavy Drinking During Treatment in <scp>COMBINE</scp> and External Validation in <scp>PREDICT</scp>. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 2647-2656.	2.4	18
608	A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. <i>American Journal on Addictions</i> , 2014, 23, 68-75.	1.4	22
609	Medications for Alcohol Use Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1350.	7.4	1
610	Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. <i>Journal of Psychopharmacology</i> , 2014, 28, 733-744.	4.0	109
611	Current treatment options for alcohol-related liver disease. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 238-244.	2.3	5
612	Generalised partial linear single-index mixed models for repeated measures data. <i>Journal of Nonparametric Statistics</i> , 2014, 26, 291-303.	0.9	6
613	Effects of Naltrexone on Neural and Subjective Response to Alcohol in Treatment-Seeking Alcohol-Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 3024-3032.	2.4	26
614	Gabapentin. <i>JAMA Internal Medicine</i> , 2014, 174, 78.	5.1	10
615	A Bayesian Mixed-Treatment Comparison Meta-analysis of Treatments for Alcohol Dependence and Implications for Planning Future Trials. <i>Medical Decision Making</i> , 2014, 34, 899-910.	2.4	9
616	Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1889.	7.4	690
617	Disturbi da abuso di sostanze. , 2014, , 125-142.		0
618	Evidence Based Psychosocial Interventions in Substance Use. <i>Indian Journal of Psychological Medicine</i> , 2014, 36, 112-118.	1.5	96
619	Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment. <i>Substance Abuse and Rehabilitation</i> , 2014, 5, 1.	4.8	31
620	Methods to Analyze Treatment Effects in the Presence of Missing Data for a Continuous Heavy Drinking Outcome Measure When Participants Drop Out from Treatment in Alcohol Clinical Trials. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 2826-2834.	2.4	48
621	Joint Modeling and Clustering Paired Generalized Longitudinal Trajectories With Application to Cocaine Abuse Treatment Data. <i>Journal of the American Statistical Association</i> , 2014, 109, 1412-1424.	3.1	17

#	ARTICLE	IF	CITATIONS
622	The Effects of Varenicline on Alcohol Seeking and Self-Administration in Baboons. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 376-383.	2.4	31
623	A Phase 2, Placebo-Controlled Study of the Opioid Receptor Antagonist LY2196044 for the Treatment of Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 511-520.	2.4	12
624	Bioinformatics Analyses Reveal Age-Specific Neuroimmune Modulation as a Target for Treatment of High Ethanol Drinking. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 428-437.	2.4	36
625	The clinical pharmacology of acamprosate. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 315-323.	2.4	77
626	Reasons for opioid use among patients with dependence on prescription opioids: The role of chronic pain. <i>Journal of Substance Abuse Treatment</i> , 2014, 47, 140-145.	2.8	123
627	Toward empirical identification of a clinically meaningful indicator of treatment outcome: Features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes. <i>Drug and Alcohol Dependence</i> , 2014, 137, 3-19.	3.2	85
628	Screening and Brief Intervention for Risky Alcohol Use. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2014, 44, 82-87.	1.7	6
629	Pharmacological management of alcohol dependence: From mono-therapy to pharmacogenetics and beyond. <i>European Neuropsychopharmacology</i> , 2014, 24, 181-191.	0.7	30
630	No Detectable Association Between Frequency of Marijuana Use and Health or Healthcare Utilization Among Primary Care Patients Who Screen Positive for Drug Use. <i>Journal of General Internal Medicine</i> , 2014, 29, 133-139.	2.6	22
631	Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice. <i>Psychopharmacology</i> , 2014, 231, 333-343.	3.1	40
632	Pharmacological Approaches to Reducing Craving in Patients with Alcohol Use Disorders. <i>CNS Drugs</i> , 2014, 28, 343-360.	5.9	65
633	Combined Pharmacotherapies for the Management of Alcoholism: Rationale and Evidence to Date. <i>CNS Drugs</i> , 2014, 28, 107-119.	5.9	15
634	Repeated Detoxification of Alcohol-Dependent Patients Impairs Brain Mechanisms of Behavioural Control Important in Resisting Relapse. <i>Current Addiction Reports</i> , 2014, 1, 1-9.	3.4	12
635	Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users. <i>Psychopharmacology</i> , 2014, 231, 2741-2750.	3.1	15
636	Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. <i>Addiction</i> , 2014, 109, 1274-1284.	3.3	69
637	Viral Suppression and Antiretroviral Medication Adherence Among Alcohol Using HIV-Positive Adults. <i>International Journal of Behavioral Medicine</i> , 2014, 21, 811-820.	1.7	57
638	Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 245-257.	1.8	42
639	The Place of Additional Individual Psychotherapy in the Treatment of Alcoholism: A Randomized Controlled Study in Nonresponders to Anticraving Medication—Results of the <sc>PREDICT</sc> Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 1118-1125.	2.4	13

#	ARTICLE	IF	CITATIONS
640	Efficacy and Safety of the Glycine Transporterâ€1 Inhibitor Org 25935 for the Prevention of Relapse in Alcoholâ€Dependent Patients: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 2427-2435.	2.4	30
641	Predictive Factors for Relapse in Patients on Buprenorphine Maintenance. <i>American Journal on Addictions</i> , 2014, 23, 62-67.	1.4	51
642	Is the Alcohol Deprivation Effect Genetically Mediated? Studies with HXB/BXH Recombinant Inbred Rat Strains. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 2148-2157.	2.4	11
643	Antagonist Models for Treating Persons With Substance use Disorders. <i>Current Psychiatry Reports</i> , 2014, 16, 489.	4.5	11
644	Posttraumatic stress disorder and alcohol dependence: Does order of onset make a difference?. <i>Journal of Anxiety Disorders</i> , 2014, 28, 894-901.	3.2	11
645	Addiction Disorders. <i>Medical Clinics of North America</i> , 2014, 98, 1097-1122.	2.5	11
646	What happens when people discontinue taking medications? Lessons from COMBINE. <i>Addiction</i> , 2014, 109, 2044-2052.	3.3	4
647	Alcohol use disorders and current pharmacological therapies: the role of GABAA receptors. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 981-993.	6.1	100
648	Reduced ethanol consumption by alcohol-preferring (P) rats following pharmacological silencing and deep brain stimulation of the nucleus accumbens shell. <i>Journal of Neurosurgery</i> , 2014, 120, 997-1005.	1.6	41
649	Molecular basis of alcoholism. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 125, 89-111.	1.8	52
650	Pharmacologic treatment of alcoholism. <i>Handbook of Clinical Neurology</i> / Edited By PJ Vinken and G W Bruyn, 2014, 125, 527-542.	1.8	9
651	Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. <i>Psychopharmacology</i> , 2014, 231, 3843-3853.	3.1	44
652	Low dose naltrexone for induction of remission in Crohn's disease. <i>The Cochrane Library</i> , 2014, , CD010410.	2.8	20
653	Alcohol. <i>Progress in Brain Research</i> , 2014, 211, 201-233.	1.4	37
654	Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. <i>Contemporary Clinical Trials</i> , 2014, 37, 209-218.	1.8	22
655	Prevalence of clinically recognized alcohol and other substance use disorders among VA outpatients with unhealthy alcohol use identified by routine alcohol screening. <i>Drug and Alcohol Dependence</i> , 2014, 135, 95-103.	3.2	36
656	Alcoholic hepatitis: Prognosis and treatment. <i>GastroenterologÃa Y HepatologÃa</i> , 2014, 37, 262-268.	0.5	23
657	The effectiveness and ineffectiveness of complex behavioral interventions: Impact of treatment fidelity. <i>Contemporary Clinical Trials</i> , 2014, 37, 234-241.	1.8	215

#	ARTICLE	IF	CITATIONS
658	The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 116, 107-115.	2.9	9
659	Alcoholic Hepatitis: Current Management. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2357-2366.	2.3	20
660	Substance Abuse Among Older Adults. <i>Clinics in Geriatric Medicine</i> , 2014, 30, 629-654.	2.6	298
661	Harm reduction with pharmacotherapy for homeless people with alcohol dependence: Protocol for a randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2014, 38, 221-234.	1.8	8
662	Referral for substance abuse treatment and depression improvement among patients with co-occurring disorders seeking behavioral health services in primary care. <i>Journal of Substance Abuse Treatment</i> , 2014, 46, 106-112.	2.8	22
663	An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. <i>Journal of Substance Abuse Treatment</i> , 2014, 47, 35-40.	2.8	25
664	Being Unaware of Being HIV-Infected is Associated with Alcohol Use Disorders and High-Risk Sexual Behaviors Among Men Who have Sex with Men in Peru. <i>AIDS and Behavior</i> , 2014, 18, 120-127.	2.7	35
665	Association of smoking with $\mu$ -opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects. <i>Addiction Biology</i> , 2014, 19, 733-742.	2.6	27
666	Pharmacotherapy of Alcohol Use Disorders: Seventy-Five Years of Progress. <i>Journal of Studies on Alcohol and Drugs Supplement</i> , 2014, , 79-88.	3.7	81
667	Predictors of Pretreatment Commitment to Abstinence: Results from the COMBINE Study. <i>Journal of Studies on Alcohol and Drugs</i> , 2014, 75, 438-446.	1.0	33
668	Elements That Define Recovery: The Experiential Perspective. <i>Journal of Studies on Alcohol and Drugs</i> , 2014, 75, 999-1010.	1.0	156
669	The relationship in motivational interviewing.. <i>Psychotherapy</i> , 2014, 51, 358-363.	1.2	63
670	Anticonvulsants for alcohol dependence. <i>The Cochrane Library</i> , 2014, , CD008544.	2.8	40
671	Computerised cognitive behavioural therapy for alcohol use disorder: a pilot randomised control trial. <i>Irish Journal of Psychological Medicine</i> , 2015, 32, 237-246.	1.0	9
672	Treatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatment. <i>Addiction Research and Theory</i> , 2015, 23, 391-403.	1.9	5
676	Social network influences on initiation and maintenance of reduced drinking among college students.. <i>Journal of Consulting and Clinical Psychology</i> , 2015, 83, 36-44.	2.0	28
677	Association between physical pain and alcohol treatment outcomes: The mediating role of negative affect.. <i>Journal of Consulting and Clinical Psychology</i> , 2015, 83, 1044-1057.	2.0	41
678	Predictors of Abstinence From Heavy Drinking During Follow-Up in COMBINE. <i>Journal of Studies on Alcohol and Drugs</i> , 2015, 76, 935-941.	1.0	15

#	ARTICLE	IF	CITATIONS
679	Outpatient treatment of alcohol use disorders among subjects 60+ years: design of a randomized clinical trial conducted in three countries (Elderly Study). <i>BMC Psychiatry</i> , 2015, 15, 280.	2.6	34
680	Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC. <i>Implementation Science</i> , 2015, 11, 64.	6.9	28
681	Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 305-312.	1.5	15
682	From Translational Neuroscience to Personalized Medicine. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 585-586.	2.4	1
683	Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial. <i>Addiction</i> , 2015, 110, 1262-1271.	3.3	69
684	Subgroup Identification in Personalized Treatment of Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 1253-1259.	2.4	17
685	Guidelines for the Reporting of Treatment Trials for Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 1571-1581.	2.4	28
686	Prazosin+Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 1832-1841.	2.4	17
687	Predicting the future relapse of alcohol-dependent patients from structural and functional brain images. <i>Addiction Biology</i> , 2015, 20, 1042-1055.	2.6	40
688	Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 1557-1570.	2.4	61
689	Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence. <i>World Journal of Gastroenterology</i> , 2015, 21, 8516.	3.3	10
690	Treatment of Adolescent Substance Use Disorders and Co-Occurring Internalizing Disorders: A Critical Review and Proposed Model. <i>Current Drug Abuse Reviews</i> , 2015, 8, 41-49.	3.4	22
691	Naltrexone and liver disease. <i>Australian Prescriber</i> , 2015, 38, 150-151.	1.0	10
692	The Evaluation of Substance User Treatmentâ€”A Jubilee Proposal for the 21st Century. <i>Substance Use and Misuse</i> , 2015, 50, 1055-1057.	1.4	0
693	â€œEvidenceâ€•and the Treatment of Alcohol Use Disorder. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2015, 53, 11-14.	0.6	2
694	Pharmacological interventions for alcohol relapse prevention. <i>Internet Journal of Medical Update</i> , 2015, 10, 41.	0.2	2
695	Rational Polypharmacy in Psychiatry. , 0, , .		0
696	The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. <i>Neuropsychopharmacology</i> , 2015, 40, 2347-2356.	5.4	58

#	ARTICLE	IF	CITATIONS
697	Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. <i>American Journal of Drug and Alcohol Abuse</i> , 2015, 41, 35-44.	2.1	32
698	The Early-Career Consultation Psychiatrist: Leading the Integration of Substance Use Treatment Into the Primary Care Setting. <i>Psychosomatics</i> , 2015, 56, 706-707.	2.5	0
699	Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial. <i>Contemporary Clinical Trials</i> , 2015, 41, 110-117.	1.8	26
700	Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 495-504.	2.4	18
701	The forest and the trees: relational and specific factors in addiction treatment. <i>Addiction</i> , 2015, 110, 401-413.	3.3	118
702	Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 93-104.	1.2	51
703	Patients with Substance Use Disorders and Addiction: Perioperative Issues. , 2015, , 1831-1859.		0
704	Pharmacological Long-Term Treatment of Alcohol Use Disorders. , 2015, , 319-331.		0
705	Drug and alcohol addiction: new pharmacotherapies. <i>BJ Psych Advances</i> , 2015, 21, 33-41.	0.7	4
706	The Pharmacogenetics of Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 391-402.	2.4	71
707	Alcohol preferring (P) rats as a model for examining sex differences in alcohol use disorder and its treatment. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 132, 1-9.	2.9	43
708	An Inpatient Treatment and Discharge Planning Protocol for Alcohol Dependence: Efficacy in Reducing 30-Day Readmissions and Emergency Department Visits. <i>Journal of General Internal Medicine</i> , 2015, 30, 365-370.	2.6	82
709	A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV. <i>AIDS and Behavior</i> , 2015, 19, 156-162.	2.7	20
710	On having and eating cake. <i>Addiction</i> , 2015, 110, 418-419.	3.3	1
711	An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. <i>European Neuropsychopharmacology</i> , 2015, 25, 1586-1599.	0.7	11
712	Acamprosate: A Review of Its Use in Alcohol Dependence. <i>Drugs</i> , 2015, 75, 1255-1268.	10.9	52
713	Breaking the addictive cycle of the system: improving US criminal justice practices to address substance use disorders. <i>International Journal of Prisoner Health</i> , 2015, 11, 4-16.	0.9	6
714	Single- and Multiple-dose Pharmacokinetics of Samidorphan, A Novel Opioid Antagonist, in Healthy Volunteers. <i>Clinical Therapeutics</i> , 2015, 37, 338-348.	2.5	33



#	ARTICLE	IF	CITATIONS
715	Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C. <i>Addiction Science &amp; Clinical Practice</i> , 2015, 10, 6.	2.6	1
716	Low-dose prazosin alone and in combination with propranolol or naltrexone: effects on ethanol and sucrose seeking and self-administration in the P rat. <i>Psychopharmacology</i> , 2015, 232, 2647-2657.	3.1	14
717	Pharmacotherapy of Alcohol and Drug Dependence. <i>Current Behavioral Neuroscience Reports</i> , 2015, 2, 30-39.	1.3	1
718	Comparing the effectiveness of an enhanced MOtiVational intErviewing InTervention (MOVE IT) with usual care for reducing cardiovascular risk in high risk subjects: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 112.	1.6	15
719	Pharmacotherapy for alcohol dependence: A stratified approach. , 2015, 153, 10-24.		7
720	Targeting glutamate uptake to treat alcohol use disorders. <i>Frontiers in Neuroscience</i> , 2015, 9, 144.	2.8	118
721	Naltrexone vs Placebo for the Treatment of Alcohol Dependence. <i>JAMA Psychiatry</i> , 2015, 72, 430.	11.0	101
722	Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. <i>Neuropsychopharmacology</i> , 2015, 40, 2489-2498.	5.4	55
726	A Randomized Trial of Combined Citalopram and Naltrexone for Nonabstinent Outpatients With Co-Occurring Alcohol Dependence and Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 143-149.	1.4	36
727	Distribution-free inference of zero-inflated binomial data for longitudinal studies. <i>Journal of Applied Statistics</i> , 2015, 42, 2203-2219.	1.3	8
728	Pharmacotherapy for Alcohol Use Disorder. <i>Harvard Review of Psychiatry</i> , 2015, 23, 122-133.	2.1	74
729	A systemic failure to address at-risk drinking and alcohol use disorders: the Canadian story. <i>Cmaj</i> , 2015, 187, 479-480.	2.0	3
730	High-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2015, 25, 1167-1177.	0.7	148
731	Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers. <i>CNS Drugs</i> , 2015, 29, 833-845.	5.9	12
732	Social Network Moderators of Naltrexone and Behavioral Treatment Effects on Heavy Drinking in the <sc>COMBINE</sc> Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 93-100.	2.4	17
733	A Pilot Trial of Prazosin, an Alpha $\alpha$ 1 Adrenergic Antagonist, for Comorbid Alcohol Dependence and Posttraumatic Stress Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 808-817.	2.4	73
734	The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta $\alpha$ analysis. <i>Addiction</i> , 2015, 110, 920-930.	3.3	99
736	The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review. <i>Current HIV/AIDS Reports</i> , 2015, 12, 421-436.	3.1	155



#	ARTICLE	IF	CITATIONS
737	Noninvasive brain stimulation to suppress craving in substance use disorders: Review of human evidence and methodological considerations for future work. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 59, 184-200.	6.1	42
738	Alcohol Interventions: Disease Models vs. Harm Reduction. , 2015, , 501-506.		0
739	Primary Care Management of Alcohol Misuse. <i>Medical Clinics of North America</i> , 2015, 99, 989-1016.	2.5	8
740	Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. <i>Psychiatry Research</i> , 2015, 230, 121-129.	3.3	16
741	Baclofen as Add-On to Standard Psychosocial Treatment for Alcohol Dependence: a Randomized, Double-Blind, Placebo-Controlled Trial With 1Year Follow-Up. <i>Journal of Substance Abuse Treatment</i> , 2015, 52, 24-30.	2.8	69
742	A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. <i>Psychopharmacology</i> , 2015, 232, 233-243.	3.1	36
743	Addiction, 12-Step Programs, and Evidentiary Standards for Ethically and Clinically Sound Treatment Recommendations: What Should Clinicians Do?. <i>AMA Journal of Ethics</i> , 2016, 18, 646-655.	0.7	32
744	Two-year prognosis after residential treatment for patients with alcohol dependence: three chief guidelines for sobriety in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 1983-1991.	2.2	1
746	Contribution of Noradrenaline, Serotonin, and the Basolateral Amygdala to Alcohol Addiction: Implications for Novel Pharmacotherapies for AUDs. , 0, , .		2
748	Specialist treatment of drinking problems. , 0, , 190-214.		0
749	Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 21-30.	2.1	25
750	Missing Data in Alcohol Clinical Trials with Binary Outcomes. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1548-1557.	2.4	25
751	Ambivalence: Prerequisite for success in motivational interviewing with adolescents?. <i>Addiction</i> , 2016, 111, 1900-1907.	3.3	29
752	Association between a brief alcohol craving measure and drinking in the following week. <i>Addiction</i> , 2016, 111, 1004-1010.	3.3	46
753	The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 434-441.	2.8	14
754	Role of the $\alpha_1$ blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. <i>Addiction Biology</i> , 2016, 21, 904-914.	2.6	58
755	Simultaneous Inference on Treatment Effects in Survival Studies with Factorial Designs. <i>Biometrics</i> , 2016, 72, 1078-1085.	1.4	4
756	Pharmacotherapy for alcohol addiction in a patient with alcoholic cirrhosis and massive upper gastrointestinal bleed: A case study. <i>Drug and Alcohol Review</i> , 2016, 35, 236-239.	2.1	3

#	ARTICLE	IF	CITATIONS
757	Commentary on Wilson <i>et al</i> . (2016): The meaning of success in failure. <i>Addiction</i> , 2016, 111, 2155-2156.	3.3	0
758	Aggregating and Analyzing Daily Drinking Data in Clinical Trials: A Comparison of Type I Errors, Power, and Bias. <i>Journal of Studies on Alcohol and Drugs</i> , 2016, 77, 986-991.	1.0	8
759	Alcohol Use. <i>Annals of Internal Medicine</i> , 2016, 164, ITC1.	3.9	33
760	Substance Use Disorders. <i>Annals of Internal Medicine</i> , 2016, 164, ITC49.	3.9	17
761	Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence. <i>Drug Safety</i> , 2016, 39, 627-645.	3.2	43
762	Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research. <i>Behaviour Research and Therapy</i> , 2016, 86, 11-22.	3.1	23
763	Pilot outcome results of culturally adapted evidence-based substance use disorder treatment with a Southwest Tribe. <i>Addictive Behaviors Reports</i> , 2016, 3, 21-27.	1.9	48
764	Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use. <i>Journal of Substance Abuse Treatment</i> , 2016, 62, 68-73.	2.8	52
765	Pharmacotherapy for Substance Use Disorders. <i>Medical Clinics of North America</i> , 2016, 100, 891-910.	2.5	40
766	Treatment of alcohol use disorders in patients with alcoholic liver disease. <i>Journal of Hepatology</i> , 2016, 65, 618-630.	3.7	156
767	Do Alcohol Relapse Episodes During Treatment Predict Long-Term Outcomes? Investigating the Validity of Existing Definitions of Alcohol Use Disorder Relapse. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 2180-2189.	2.4	20
768	The Zebrafish, a Novel Model Organism for Screening Compounds Affecting Acute and Chronic Ethanol-Induced Effects. <i>International Review of Neurobiology</i> , 2016, 126, 467-484.	2.0	19
769	National trends in alcohol pharmacotherapy: Findings from an Australian claims database. <i>Drug and Alcohol Dependence</i> , 2016, 166, 254-257.	3.2	34
770	NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. <i>Contemporary Clinical Trials</i> , 2016, 50, 253-264.	1.8	49
771	The Alcohol Intervention Mechanisms Scale (AIMS): Preliminary Reliability and Validity of a Common Factor Observational Rating Measure. <i>Journal of Substance Abuse Treatment</i> , 2016, 70, 28-34.	2.8	4
772	Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment. <i>Journal of Substance Abuse Treatment</i> , 2016, 70, 14-20.	2.8	7
773	Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?. <i>Neurotoxicity Research</i> , 2016, 30, 698-714.	2.7	2
774	Randomized Trial of Computerized Cognitive Behavioral Therapy for Alcohol Use Disorders: Efficacy as a Virtual Stand-Alone and Treatment Add-On Compared with Standard Outpatient Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1991-2000.	2.4	62

#	ARTICLE	IF	CITATIONS
775	The monoamine stabilizer (α)-OSU6162 counteracts downregulated dopamine output in the nucleus accumbens of long-term drinking Wistar rats. <i>Addiction Biology</i> , 2016, 21, 438-449.	2.6	26
776	Reduced Social Network Drinking is Associated with Improved Response Inhibition in Women During Early Recovery from Alcohol Use Disorders: A Pilot Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 170-177.	2.4	7
777	Involvement of delta opioid receptors in alcohol withdrawal-induced mechanical allodynia in male C57BL/6 mice. <i>Drug and Alcohol Dependence</i> , 2016, 167, 190-198.	3.2	17
778	Injectable formulations of poly(lactic acid) and its copolymers in clinical use. <i>Advanced Drug Delivery Reviews</i> , 2016, 107, 213-227.	13.7	122
779	Efficacy of Combination of Motivational Interviewing and Cognitive Behavior Intervention with Substance Abuse Street Adolescents in India: A Randomized Control Study. <i>Journal of Social Work Practice in the Addictions</i> , 2016, 16, 337-357.	0.7	2
780	Finding success in failure: using latent profile analysis to examine heterogeneity in psychosocial functioning among heavy drinkers following treatment. <i>Addiction</i> , 2016, 111, 2145-2154.	3.3	44
781	Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. <i>European Neuropsychopharmacology</i> , 2016, 26, 1950-1959.	0.7	118
782	Therapist empathy, combined behavioral intervention, and alcohol outcomes in the COMBINE research project.. <i>Journal of Consulting and Clinical Psychology</i> , 2016, 84, 221-229.	2.0	39
783	Alcohol use disorders in Australia. <i>Internal Medicine Journal</i> , 2016, 46, 1259-1268.	0.8	16
784	An evidence-based approach to screening and providing appropriate interventions for unhealthy alcohol use in primary care settings. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 521-524.	1.4	1
785	Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1961-1970.	2.4	14
786	Examining multi-session brief intervention for substance use in primary care: research methods of a randomized controlled trial. <i>Addiction Science &amp; Clinical Practice</i> , 2016, 11, 8.	2.6	13
787	Possibilities for Change. , 2016, , 143-164.		0
788	Client Evaluation of Treatment for Alcohol Use Disorder in COMBINE. <i>Journal of Substance Abuse Treatment</i> , 2016, 67, 38-43.	2.8	4
789	Implementation of integrated stepped care for unhealthy alcohol use in HIV clinics. <i>Addiction Science &amp; Clinical Practice</i> , 2016, 11, 1.	2.6	38
790	Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone. <i>Journal of Addictive Diseases</i> , 2016, 35, 305-314.	1.3	32
791	Alcohol-induced dysregulation of stress-related circuitry: The search for novel targets and implications for interventions across the sexes. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 252-259.	4.8	21
792	Efficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive Review. <i>European Addiction Research</i> , 2016, 22, 1-16.	2.4	35

#	ARTICLE	IF	CITATIONS
793	Sacred Cows and Greener Pastures: Reflections from 40 Years in Addiction Research. <i>Alcoholism Treatment Quarterly</i> , 2016, 34, 92-115.	0.8	12
794	Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 70, 148-161.	4.8	33
795	Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 269-287.	4.8	33
796	"The Age of Feeling in-Between": Addressing Challenges in the Treatment of Emerging Adults With Substance Use Disorders. <i>Cognitive and Behavioral Practice</i> , 2016, 23, 270-288.	1.5	30
797	An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder. <i>Alcohol</i> , 2016, 53, 45-50.	1.7	12
798	Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series. <i>Journal of Psychopharmacology</i> , 2016, 30, 402-409.	4.0	7
799	A Prospective 5-Year Re-examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder. <i>Biological Psychiatry</i> , 2016, 79, 489-498.	1.3	105
800	Ablation of $\frac{1}{4}$ opioid receptor-expressing GABA neurons in rostromedial tegmental nucleus increases ethanol consumption and regulates ethanol-related behaviors. <i>Neuropharmacology</i> , 2016, 107, 58-67.	4.1	29
802	Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 191-202.e4.	4.4	126
803	Personality Predictors of Drinking Outcomes in Depressed Alcohol-Dependent Patients. <i>Alcohol and Alcoholism</i> , 2016, 51, 296-301.	1.6	14
804	Alcohol use disorders. <i>Lancet, The</i> , 2016, 387, 988-998.	13.7	277
805	Zero-inflated count models for longitudinal measurements with heterogeneous random effects. <i>Statistical Methods in Medical Research</i> , 2017, 26, 1774-1786.	1.5	25
806	Men Who Have Sex With Men in Peru: Acceptability of Medication-Assisted Therapy for Treating Alcohol Use Disorders. <i>American Journal of Men's Health</i> , 2017, 11, 1269-1278.	1.6	18
807	The antihypertensive drug pindolol attenuates long-term but not short-term binge-like ethanol consumption in mice. <i>Addiction Biology</i> , 2017, 22, 679-691.	2.6	21
808	Inhibiting subthalamic nucleus decreases cocaine demand and relapse: therapeutic potential. <i>Addiction Biology</i> , 2017, 22, 946-957.	2.6	11
809	Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. <i>Addiction Biology</i> , 2017, 22, 581-615.	2.6	50
810	The Starting Treatment for Ethanol in Primary care Trials (STEP Trials): Protocol for Three Parallel Multi-Site Stepped Care Effectiveness Studies for Unhealthy Alcohol Use in HIV-Positive Patients. <i>Contemporary Clinical Trials</i> , 2017, 52, 80-90.	1.8	25
811	Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence. <i>Addiction</i> , 2017, 112, 1077-1085.	3.3	20

#	ARTICLE	IF	CITATIONS
812	Review article: pharmacotherapy for alcohol dependence – the why, the what and the wherefore. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 865-882.	3.7	68
813	Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 77, 14-31.	6.1	70
814	Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1054-1062.	2.4	25
815	Predicting drinking outcomes: Evidence from the United Kingdom Alcohol Treatment Trial (UKATT). <i>Addictive Behaviors</i> , 2017, 71, 61-67.	3.0	7
816	Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. <i>Drug and Alcohol Dependence</i> , 2017, 174, 158-170.	3.2	28
817	Toward Rational, Evidence-Based, and Clinically Relevant Measures to Determine Improvement Following Treatment for Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 703-707.	2.4	5
818	Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008–2013. <i>Clinical Toxicology</i> , 2017, 55, 275-284.	1.9	39
819	Epigenetics: a link between addiction and social environment. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2735-2747.	5.4	50
820	A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 466-472.	2.4	16
821	Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter?. <i>American Journal of Drug and Alcohol Abuse</i> , 2017, 43, 703-710.	2.1	58
822	Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. <i>Lancet Psychiatry</i> , 2017, 4, 469-476.	7.4	108
823	The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial. <i>Journal of Substance Abuse Treatment</i> , 2017, 77, 72-78.	2.8	3
824	A Qualitative Assessment of Alcohol Consumption and Sexual Risk Behaviors Among Men Who Have Sex With Men and Transgender Women in Peru. <i>Substance Use and Misuse</i> , 2017, 52, 831-839.	1.4	12
825	Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1510-1517.	2.4	12
826	Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 211-224.	2.7	12
827	Screening and Counseling for Unhealthy Alcohol Use in Primary Care Settings. <i>Medical Clinics of North America</i> , 2017, 101, 823-837.	2.5	9
829	Personality disorder and alcohol treatment outcome: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2017, 211, 22-30.	2.8	30
830	Alcoholics Anonymous and other mutual help organizations: Impact of a 45-minute didactic for primary care and categorical internal medicine residents. <i>Substance Abuse</i> , 2017, 38, 183-190.	2.3	4

#	ARTICLE	IF	CITATIONS
832	Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 86-119.	2.6	55
833	Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 179-186.	2.4	123
834	Orbitofrontal cortex connectivity as a mechanism of adolescent behavior change. <i>NeuroImage</i> , 2017, 151, 14-23.	4.2	15
835	The search for an elusive cutoff remains: Problems of binary classification of heavy drinking as an endpoint for alcohol clinical trials. <i>Drug and Alcohol Dependence</i> , 2017, 171, 91-96.	3.2	15
836	Management of Alcohol Misuse in Patients with Liver Diseases. <i>Journal of Investigative Medicine</i> , 2017, 65, 673-680.	1.6	12
837	Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?. <i>European Addiction Research</i> , 2017, 23, 219-230.	2.4	67
838	Hostile interpretation training for individuals with alcohol use disorder and elevated trait anger: A controlled trial of a web-based intervention. <i>Behaviour Research and Therapy</i> , 2017, 99, 57-66.	3.1	38
839	Text message reminders for improving patient appointment adherence in an office-based buprenorphine program: A feasibility study. <i>American Journal on Addictions</i> , 2017, 26, 581-586.	1.4	14
840	Risk and resilience factors for substance use among street adolescents: Assessment and development of an integrative model. <i>Asian Social Work and Policy Review</i> , 2017, 11, 216-233.	1.4	6
841	Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study. <i>American Journal on Addictions</i> , 2017, 26, 795-801.	1.4	42
842	Viability of the World Health Organization quality of life measure to assess changes in quality of life following treatment for alcohol use disorder. <i>Quality of Life Research</i> , 2017, 26, 2987-2997.	3.1	37
843	Guidelines for the understanding and management of pain in chronic pancreatitis. <i>Pancreatology</i> , 2017, 17, 720-731.	1.1	214
844	Distinctions between seeking- and non-seeking-treatment research participants: implications for clinical trials effectiveness. <i>American Journal of Drug and Alcohol Abuse</i> , 2017, 43, 628-630.	2.1	1
845	Developing a Fitbit-supported lifestyle physical activity intervention for depressed alcohol dependent women. <i>Journal of Substance Abuse Treatment</i> , 2017, 80, 88-97.	2.8	59
846	Efficacy of Naltrexone for the Treatment of Alcohol Dependence in Latino Populations. <i>Journal of Studies on Alcohol and Drugs</i> , 2017, 78, 629-634.	1.0	4
847	Addictionâ€™25 Years Later. <i>Harvard Review of Psychiatry</i> , 2017, 25, 97-100.	2.1	1
848	Identifying â€œHitting Bottomâ€•Among Individuals with Alcohol Problems: Development and Evaluation of the Noteworthy Aspects of Drinking Important to Recovery (NADIR). <i>Substance Use and Misuse</i> , 2017, 52, 1602-1615.	1.4	9
849	Group Therapy for Substance Use Disorders: A Survey of Clinician Practices. <i>Journal of Groups in Addiction and Recovery</i> , 2017, 12, 243-259.	0.4	25



#	ARTICLE	IF	CITATIONS
850	Can 3,4-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder?. Journal of Psychedelic Studies, 2017, 1, 1-9.	1.2	2
851	Causal Spousal Health Spillover Effects and Implications for Program Evaluation. American Economic Journal: Economic Policy, 2017, 9, 144-166.	3.1	37
853	Task-shifting alcohol interventions for HIV+ persons in Kenya: a cost-benefit analysis. BMC Health Services Research, 2017, 17, 239.	2.2	16
854	Patient-centered primary care for adults at high risk for AUDs: the Choosing Healthier Drinking Options In primary CarE (CHOICE) trial. Addiction Science & Clinical Practice, 2017, 12, 15.	2.6	14
855	Pharmacotherapy of alcoholism – an update on approved and off-label medications. Expert Opinion on Pharmacotherapy, 2017, 18, 1187-1199.	1.8	81
856	Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. American Journal of Medicine, 2017, 130, 124-134.	1.5	107
857	Central administration of the anorexigenic peptide neuromedin U decreases alcohol intake and attenuates alcohol-induced reward in rodents. Addiction Biology, 2017, 22, 640-651.	2.6	20
858	Noninvasive brain stimulation treatments for addiction and major depression. Annals of the New York Academy of Sciences, 2017, 1394, 31-54.	3.8	114
859	Baseline health status and quality of life after alcohol treatment for women with alcohol dependence. Addictive Behaviors, 2017, 64, 35-41.	3.0	15
860	Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence. Alcohol and Alcoholism, 2017, 52, 72-79.	1.6	7
861	Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Expert Opinion on Drug Safety, 2017, 16, 27-39.	2.4	30
862	A randomized controlled trial of cognitive remediation and work therapy in the early phase of substance use disorder recovery for older veterans: Neurocognitive and substance use outcomes.. Psychiatric Rehabilitation Journal, 2017, 40, 94-102.	1.1	18
863	Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes. Addiction, 2017, 112, 685-694.	3.3	56
864	Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprostate and naltrexone. Addiction Biology, 2017, 22, 1528-1539.	2.6	40
865	Deep Brain Stimulation. , 2017, , 239-248.		2
866	Implementing the teen marijuana check-up in schools—a study protocol. Implementation Science, 2017, 12, 103.	6.9	5
867	A Comparative Study of Factors Associated with Relapse in Alcohol Dependence and Opioid Dependence. Indian Journal of Psychological Medicine, 2017, 39, 627-633.	1.5	39
868	Mechanical Stimulation of the HT7 Acupuncture Point to Reduce Ethanol Self-Administration in Rats. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-6.	1.2	8



#	ARTICLE	IF	CITATIONS
869	Alcohol: Treatment. , 2017, , 75-82.		0
870	Epidemiology of alcohol dependence in UK primary care: Results from a large observational study using the Clinical Practice Research Datalink. PLoS ONE, 2017, 12, e0174818.	2.5	10
871	Mice expressing a "hyper-sensitive" form of the CB1 cannabinoid receptor (CB1) show modestly enhanced alcohol preference and consumption. PLoS ONE, 2017, 12, e0174826.	2.5	15
872	Functional beliefs and risk minimizing beliefs among Thai healthcare workers in Maharaj Nakorn Chiang Mai hospital: its association with intention to quit tobacco and alcohol. Substance Abuse Treatment, Prevention, and Policy, 2017, 12, 34.	2.2	7
873	Efficacy of long-acting, injectable versus oral naltrexone for preventing admissions for alcohol use disorder. Mental Health Clinician, 2017, 7, 106-110.	1.0	4
874	Complexities with group therapy facilitation in substance use disorder specialty treatment settings. Journal of Substance Abuse Treatment, 2018, 88, 9-17.	2.8	10
875	Personality Disorder and Alcohol Use Disorder: An Overview. Psychopathology, 2018, 51, 130-136.	1.5	14
876	Nicotine Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2018, 42, 751-760.	2.4	26
877	Predictors of Treatment Referral After AUDIT-C Screening for Heavy Drinking. Addictive Disorders and Their Treatment, 2018, 17, 124-133.	0.5	1
878	Calcium chloride mimics the effects of acamprosate on cognitive deficits in chronic alcohol-exposed mice. Psychopharmacology, 2018, 235, 2027-2040.	3.1	13
879	A Randomized, Placebo-controlled, Clinical Trial of Prazosin for the Treatment of Alcohol Use Disorder. Journal of Addiction Medicine, 2018, 12, 339-345.	2.6	42
880	A Comparison of International Drunk-Driving Policies and the Role of Drinking Patterns. American Journal of Preventive Medicine, 2018, 55, 263-270.	3.0	4
881	EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. Journal of Hepatology, 2018, 69, 154-181.	3.7	591
882	Advancing Pharmacotherapy Development from Preclinical Animal Studies. Handbook of Experimental Pharmacology, 2018, 248, 537-578.	1.8	13
883	Defining Substance Use Disorders: The Need for Peripheral Biomarkers. Trends in Molecular Medicine, 2018, 24, 109-120.	6.7	16
884	A quantification of the alcohol use consequences association in college student and clinical populations: A large, multi-sample study. American Journal on Addictions, 2018, 27, 116-123.	1.4	39
885	Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions. CNS Drugs, 2018, 32, 13-31.	5.9	9
886	Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking. JAMA Psychiatry, 2018, 75, 129.	11.0	79

#	ARTICLE	IF	CITATIONS
887	Alcohol-related and mental health care for patients with unhealthy alcohol use and posttraumatic stress disorder in a National Veterans Affairs cohort. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 1-9.	2.8	17
888	Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 478-488.	2.4	163
889	Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. <i>Alcohol and Alcoholism</i> , 2018, 53, 268-276.	1.6	24
890	Duration of therapy “ Does it matter?. <i>Journal of Substance Abuse Treatment</i> , 2018, 84, 57-67.	2.8	17
891	Increasing Prevalence of Alcohol Use Disorders: Meeting the Challenge in Primary Care. <i>Journal of General Internal Medicine</i> , 2018, 33, 236-237.	2.6	1
892	Integration of a Clinical Pharmacy Specialist into a Substance use Disorder Intensive Outpatient Treatment Program to Improve Prescribing Rates of Alcohol use Disorder Pharmacotherapy. <i>Substance Abuse</i> , 2018, 39, 190-192.	2.3	15
893	Small molecule modulators of $\delta$ 2R/Tmem97 reduce alcohol withdrawal-induced behaviors. <i>Neuropsychopharmacology</i> , 2018, 43, 1867-1875.	5.4	35
894	Pharmacotherapy for Alcohol Use Disorder. <i>Medical Clinics of North America</i> , 2018, 102, 653-666.	2.5	9
895	Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 613-623.	2.4	17
896	Low dose naltrexone for induction of remission in Crohn's disease. <i>The Cochrane Library</i> , 2018, 4, CD010410.	2.8	14
897	Short- and Long-Term Effects of Within-Session Client Speech on Drinking Outcomes in the COMBINE Study. <i>Journal of Studies on Alcohol and Drugs</i> , 2018, 79, 217-222.	1.0	14
898	Alcohol-Related Nurse Care Management in Primary Care. <i>JAMA Internal Medicine</i> , 2018, 178, 613.	5.1	33
899	New steps for treating alcohol use disorder. <i>Psychopharmacology</i> , 2018, 235, 1759-1773.	3.1	37
900	Broad Coping Repertoire Mediates the Effect of the Combined Behavioral Intervention on Alcohol Outcomes in the COMBINE Study: An Application of Latent Class Mediation. <i>Journal of Studies on Alcohol and Drugs</i> , 2018, 79, 199-207.	1.0	30
901	Extended-release naltrexone and drug treatment courts: Policy and evidence for implementing an evidence-based treatment. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 101-104.	2.8	12
902	Personality disorder and treatment outcome in alcohol use disorder. <i>Current Opinion in Psychiatry</i> , 2018, 31, 50-56.	6.3	11
903	Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics. <i>Journal of General Internal Medicine</i> , 2018, 33, 258-267.	2.6	68
904	The cost-effectiveness of therapies to treat alcohol use disorders. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 43-49.	1.4	19

#	ARTICLE	IF	CITATIONS
905	Bayesian joint modelling of longitudinal data on abstinence, frequency and intensity of drinking in alcoholism trials. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2018, 181, 869-888.	1.1	3
906	Why MDMA therapy for alcohol use disorder? And why now?. <i>Neuropharmacology</i> , 2018, 142, 83-88.	4.1	47
907	Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes. <i>Neuropsychopharmacology</i> , 2018, 43, 891-899.	5.4	91
908	Alcohol addiction - the safety of available approved treatment options. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 169-177.	2.4	33
909	Effective Treatments for Older Adult Baby Boomers with Alcohol-Use Disorders: A Literature Review. <i>Journal of Social Work Practice in the Addictions</i> , 2018, 18, 389-410.	0.7	5
910	Linear-rank testing of a non-binary, responder-analysis, efficacy score to evaluate pharmacotherapies for substance use disorders. <i>Statistical Methods in Medical Research</i> , 2018, 27, 2154-2167.	1.5	0
911	Glass-Box Testing the Centre for Addiction and Mental Health Integrated Care Pathway for Major Depressive and Alcohol Use Disorders: Is It More Than a Sum of Its Components?. <i>Canadian Journal of Addiction</i> , 2018, 9, 7-17.	0.4	2
912	Alcohol Withdrawal Management and Relapse Prevention in Pregnancy. <i>Canadian Journal of Addiction</i> , 2018, 9, 32-41.	0.4	1
913	Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2453-2465.	2.4	82
914	Association between alcoholic interventions and abstinence rates for alcohol use disorders. <i>Medicine (United States)</i> , 2018, 97, e13566.	1.0	13
915	Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers. <i>Journal of Studies on Alcohol and Drugs</i> , 2018, 79, 918-928.	1.0	5
916	Alcohol misuse and outpatient follow-up after hospital discharge: a retrospective cohort study. <i>Addiction Science &amp; Clinical Practice</i> , 2018, 13, 24.	2.6	12
917	Reduction in Nonabstinent <sc>WHO</sc> Drinking Risk Levels and Change in Risk for Liver Disease and Positive <sc>AUDIT</sc>â€ Scores: Prospective 3â€Year Followâ€Up Results in the <sc>U.S.</sc> General Population. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2256-2265.	2.4	43
918	Ethical Guidelines for Genetic Research on Alcohol Addiction and Its Applications. <i>Kennedy Institute of Ethics Journal</i> , 2018, 28, 1-22.	0.5	1
919	Microscopes and Telescopes: the Societal Impact of Substance Use Disorder Treatment. <i>American Journal of Psychiatry</i> , 2018, 175, 925-926.	7.2	0
920	Cannabis use during alcohol treatment is associated with alcohol-related problems one-year post-treatment. <i>Drug and Alcohol Dependence</i> , 2018, 193, 29-34.	3.2	7
921	Les innovations thÃ©rapeutiques en alcoologie. <i>Annales Medico-Psychologiques</i> , 2018, 176, 750-757.	0.4	0
922	Acceptability of pharmacotherapy for hazardous alcohol use among men who have sex with men: Findings from a qualitative study. <i>Addictive Behaviors Reports</i> , 2018, 8, 122-127.	1.9	1

#	ARTICLE	IF	CITATIONS
923	Study protocol: a cluster-randomized trial implementing Sustained Patient-centered Alcohol-related Care (SPARC trial). <i>Implementation Science</i> , 2018, 13, 108.	6.9	41
924	Interactions between TLR4 methylation and alcohol consumption on subjective responses to an alcohol infusion. <i>Alcohol and Alcoholism</i> , 2018, 53, 650-658.	1.6	6
925	Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2011-2021.	2.4	13
926	Anticraving therapy for alcohol use disorder: A clinical review. <i>Neuropsychopharmacology Reports</i> , 2018, 38, 105-116.	2.3	39
927	Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder. <i>American Journal of Psychiatry</i> , 2018, 175, 1216-1224.	7.2	59
928	Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease. <i>Current Addiction Reports</i> , 2018, 5, 287-296.	3.4	7
929	The Role of Technology-Based Interventions for Substance Use Disorders in Primary Care. <i>Medical Clinics of North America</i> , 2018, 102, 715-731.	2.5	54
930	Office-Based Addiction Treatment in Primary Care. <i>Medical Clinics of North America</i> , 2018, 102, 635-652.	2.5	17
931	Addressing Unhealthy Substance Use in Primary Care. <i>Medical Clinics of North America</i> , 2018, 102, 567-586.	2.5	23
932	Treatment for Alcohol Use Disorder: Progress in Predicting Treatment Outcome and Validating Nonabstinent End Points. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1874-1879.	2.4	6
933	Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial. <i>BMJ Open</i> , 2018, 8, e019562.	1.9	22
934	Current and Promising Pharmacotherapies for Substance Use Disorders among Justice-Involved Populations. <i>European Journal on Criminal Policy and Research</i> , 2018, 24, 145-153.	1.9	5
935	Differences in Perceptions of and Practices Regarding Treatment of Alcohol Use Disorders Among VA Primary Care Providers in Urban and Rural Clinics. <i>Journal of Rural Health</i> , 2018, 34, 359-368.	2.9	13
936	Diagnosis and Pharmacotherapy of Alcohol Use Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 815.	7.4	382
937	Alcoholic liver disease. <i>Nature Reviews Disease Primers</i> , 2018, 4, 16.	30.5	660
938	Outcomes of an integrated care pathway for concurrent major depressive and alcohol use disorders: a multisite prospective cohort study. <i>BMC Psychiatry</i> , 2018, 18, 189.	2.6	10
939	The Unmet Challenges of Co-Occurring Alcohol and Opioid Use. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1406-1407.	2.4	5
940	Opioid Misuse as a Predictor of Alcohol Treatment Outcomes in the COMBINE Study: Mediation by Medication Adherence. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1249-1259.	2.4	13

#	ARTICLE	IF	CITATIONS
941	Measuring both primary and secondary outcomes when evaluating treatment effectiveness in alcohol and drug treatment programmes. <i>Clinical Psychologist</i> , 2019, 23, 152-164.	0.8	6
942	What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?. <i>Addiction</i> , 2019, 114, 9-15.	3.3	56
943	Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. <i>AIDS and Behavior</i> , 2019, 23, 211-221.	2.7	26
944	Why cognitive event-related potentials (ERPs) should have a role in the management of alcohol disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 106, 234-244.	6.1	27
945	Response to Dr. Mark Litt's Commentary. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 2255-2256.	2.4	0
946	Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes. <i>Addiction Science &amp; Clinical Practice</i> , 2019, 14, 24.	2.6	24
947	Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. <i>Journal of Substance Abuse Treatment</i> , 2019, 104, 34-41.	2.8	3
948	Nalmefene in alcoholâ€dependent patients with a high drinking risk: Randomized controlled trial. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 697-706.	1.8	37
949	Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. <i>Lancet HIV</i> , 2019, 6, e509-e517.	4.7	42
950	Pharmacogenetics of alcohol use disorder treatments: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 553-564.	3.3	23
951	Outcome Assessment in Trials of Pharmacological Treatments for Alcohol Use Disorders: Fair and Strict Testing. <i>CNS Drugs</i> , 2019, 33, 649-657.	5.9	5
952	Developing neuroscience-based treatments for alcohol addiction: A matter of choice?. <i>Translational Psychiatry</i> , 2019, 9, 255.	4.8	65
953	Opioid Use Disorder Treatment Decision Making And Care Navigation Upon Release From Prison: A Feasibility Study. <i>Substance Abuse and Rehabilitation</i> , 2019, Volume 10, 57-67.	4.8	6
954	Sleep and the Pharmacotherapy of Alcohol Use Disorder: Unfortunate Bedfellows. A Systematic Review With Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1164.	3.5	9
955	Prevention, screening, and treatment for heavy drinking and alcohol use disorder. <i>Lancet Psychiatry</i> , 2019, 6, 1054-1067.	7.4	82
956	Technologyâ€Delivered Cognitiveâ€Behavioral Interventions for Alcohol Use: A Metaâ€Analysis. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 2285-2295.	2.4	39
957	Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis. <i>BMC Medicine</i> , 2019, 17, 174.	5.5	34
958	Advances in the science and treatment of alcohol use disorder. <i>Science Advances</i> , 2019, 5, eaax4043.	10.3	265

#	ARTICLE	IF	CITATIONS
959	Estimating Long-Term Drinking Patterns for People with Lifetime Alcohol Use Disorder. <i>Medical Decision Making</i> , 2019, 39, 765-780.	2.4	7
960	Dose-Response Characteristics of the Alcohol Biomarker Phosphatidylethanol (PEth) in Outpatients in Treatment for Reduced Drinking. <i>Alcohol and Alcoholism</i> , 2019, 54, 567-573.	1.6	29
961	Mindfulness-based relapse prevention for alcohol dependence: Findings from a randomized controlled trial. <i>Journal of Substance Abuse Treatment</i> , 2019, 100, 8-17.	2.8	21
962	Predictive value of non-consumption outcome measures in alcohol use disorder treatment. <i>Addiction</i> , 2019, 114, 1086-1092.	3.3	14
963	Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans. <i>Journal of Substance Abuse Treatment</i> , 2019, 103, 23-32.	2.8	16
964	Treating Alcohol Use Disorder in U.S. Veterans: The Role of Traumatic Brain Injury. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 319-327.	1.8	4
965	Commentary on Kirouac & Witkiewitz (2019): A clinical perspective of non-consumption outcomes. <i>Addiction</i> , 2019, 114, 1093-1094.	3.3	1
966	Letter to the Editor: Training General Psychiatrists to Treat Patients with Substance Use Disorders: It is Time to Change the Training Requirements in Psychiatry Residency Training. <i>American Journal on Addictions</i> , 2019, 28, 150-152.	1.4	1
967	Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). <i>Contemporary Clinical Trials</i> , 2019, 81, 102-109.	1.8	9
968	Telehealth Treatment for Alcohol Misuse: Reviewing Telehealth Approaches to Increase Engagement and Reduce Risk of Alcohol-Related Hypertension. <i>Current Hypertension Reports</i> , 2019, 21, 59.	3.5	9
969	Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. <i>Drug and Alcohol Dependence</i> , 2019, 201, 16-22.	3.2	19
970	Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis. <i>Addiction Biology</i> , 2019, 24, 1138-1152.	2.6	38
971	What the World Needs Now: A Prescriptive Measure of Alcohol Outcomes Commentary on Witkiewitz et al., "Maintenance of World Health Organization Risk Drinking Level Reductions and Post-Treatment Functioning Following a Large Alcohol Use Disorder Clinical Trial". <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1643-1644.	2.4	2
972	Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 103, 384-398.	6.1	13
973	Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent. <i>Drug and Alcohol Dependence</i> , 2019, 200, 181-190.	3.2	10
974	Cessation and reduction in alcohol consumption and misuse after psychedelic use. <i>Journal of Psychopharmacology</i> , 2019, 33, 1088-1101.	4.0	145
975	The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. <i>Focus (American Psychiatric Publishing)</i> , 2019, 17, 158-162.	0.8	14
976	Crossed Eye/Hand Laterality and Left-Eyedness Predict a Positive 24-Month Outcome in Alcohol-Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1308-1317.	2.4	11



#	ARTICLE	IF	CITATIONS
977	Design of a randomized controlled trial examining the efficacy of oxytocin to enhance alcohol behavioral couple therapy. <i>Contemporary Clinical Trials</i> , 2019, 82, 1-8.	1.8	5
978	Measurement errors and misestimation: their effects on drinking outcomes. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 427-429.	2.1	0
979	Applications of <i>Pueraria lobata</i> in treating diabetics and reducing alcohol drinking. <i>Chinese Herbal Medicines</i> , 2019, 11, 141-149.	3.0	20
980	Ventral Pallidum and Alcohol Addiction. , 2019, , 163-170.		5
981	Dual Therapy for Alcohol Use Disorders: Combining Naltrexone With Other Medications. , 2019, , 653-660.		0
982	Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. <i>Drug and Alcohol Dependence</i> , 2019, 197, 228-235.	3.2	42
983	Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 937-944.	2.4	14
984	Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials. <i>JAMA Psychiatry</i> , 2019, 76, 374.	11.0	77
985	Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions. <i>Addiction Science &amp; Clinical Practice</i> , 2019, 14, 6.	2.6	25
986	Lessons learned from measuring fidelity with the Motivational Interviewing Treatment Integrity code (MITI 4). <i>Journal of Substance Abuse Treatment</i> , 2019, 97, 59-67.	2.8	68
987	Differences in Receipt of Alcohol-Related Care Across Rurality Among VA Patients Living With HIV With Unhealthy Alcohol Use. <i>Journal of Rural Health</i> , 2019, 35, 341-353.	2.9	14
988	Consumption outcomes in clinical trials of alcohol use disorder treatment: Consideration of standard drink misestimation. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 451-459.	2.1	8
989	Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 979-987.	2.4	41
990	Mindfulness-Based Relapse Prevention and Transcranial Direct Current Stimulation to Reduce Heavy Drinking: A Double-Blind Sham-Controlled Randomized Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1296-1307.	2.4	40
991	Is fidelity to motivational interviewing associated with alcohol outcomes in treatment-seeking 60+ year-old citizens?. <i>Journal of Substance Abuse Treatment</i> , 2019, 101, 1-11.	2.8	9
992	Withdrawal effects following repeated ethanol exposure are prevented by N-acetylcysteine in zebrafish. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 93, 161-170.	4.8	28
993	Hunting for What Works: Adolescents in Addiction Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 578-592.	2.4	39
994	Readiness to change and commitment as predictors of therapy compliance in adolescents with Delayed Sleep-Wake Phase Disorder. <i>Sleep Medicine</i> , 2019, 55, 48-55.	1.6	19



#	ARTICLE	IF	CITATIONS
995	Sex differences in stress-related alcohol use. <i>Neurobiology of Stress</i> , 2019, 10, 100149.	4.0	237
996	State-of-the-Art Treatment of Alcohol Use Disorder. , 2019, , 123-135.		0
997	Concurrent treatment of substance use disorders and PTSD using prolonged exposure: A randomized clinical trial in military veterans. <i>Addictive Behaviors</i> , 2019, 90, 369-377.	3.0	131
998	Ethanol and Naltrexone Have Distinct Effects on the Lateral Nano-organization of Mu and Kappa Opioid Receptors in the Plasma Membrane. <i>ACS Chemical Neuroscience</i> , 2019, 10, 667-676.	3.5	8
999	Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV. <i>Drug and Alcohol Dependence</i> , 2019, 194, 288-295.	3.2	8
1000	Neuroplastic and cognitive impairment in substance use disorders: a therapeutic potential of cognitive stimulation. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 106, 23-48.	6.1	44
1001	Medication Development: Reducing Casualties in the Valley of Death and Providing Support for Survivors. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 22-25.	2.4	1
1002	State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 124-140.	2.1	76
1003	Distribution-free models for latent mixed population responses in a longitudinal setting with missing data. <i>Statistical Methods in Medical Research</i> , 2019, 28, 3273-3285.	1.5	2
1004	Use of Prolonged Exposure and Sertraline in the Treatment of Posttraumatic Stress Disorder for Veterans. <i>JAMA Psychiatry</i> , 2019, 76, 109.	11.0	4
1005	Body mass index and craving predict 24-month hospital readmissions of alcohol-dependent in-patients following withdrawal. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 90, 300-307.	4.8	27
1006	Activation of amylin receptors attenuates alcohol-mediated behaviours in rodents. <i>Addiction Biology</i> , 2019, 24, 388-402.	2.6	29
1007	Formative work in the development of a physical activity smartphone app targeted for patients with alcohol use disorders. <i>Psychology of Sport and Exercise</i> , 2019, 41, 162-171.	2.1	8
1008	Item Responses in Quantity-Frequency Questionnaires: Implications for Data Generalizability. <i>Assessment</i> , 2020, 27, 1029-1044.	3.1	2
1009	Improving medical decision-making with a management science game theory approach to liver transplantation. <i>Omega</i> , 2020, 94, 102050.	5.9	9
1010	High-risk social drinkers and heavy drinkers display similar rates of alcohol consumption. <i>Addiction Biology</i> , 2020, 25, e12734.	2.6	17
1011	A sleeping giant: Suvorexant for the treatment of alcohol use disorder?. <i>Brain Research</i> , 2020, 1731, 145902.	2.2	40
1012	Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 843-851.	1.9	9

#	ARTICLE	IF	CITATIONS
1013	Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107700.	3.2	33
1014	Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows. <i>Neurotherapeutics</i> , 2020, 17, 127-141.	4.4	14
1015	Evaluation of adding the community reinforcement approach to motivational enhancement therapy for adults aged 60 years and older with DSM-5 alcohol use disorder: a randomized controlled trial. <i>Addiction</i> , 2020, 115, 69-81.	3.3	32
1016	Opioid Craving in Human Laboratory Settings: a Review of the Challenges and Limitations. <i>Neurotherapeutics</i> , 2020, 17, 100-104.	4.4	9
1017	The disengaging brain: Dynamic transitions from cognitive engagement and alcoholism risk. <i>NeuroImage</i> , 2020, 209, 116515.	4.2	16
1018	Alcohol Use Disorder Interventions Targeting Brain Sites for Both Conditioned Reward and Delayed Gratification. <i>Neurotherapeutics</i> , 2020, 17, 70-86.	4.4	8
1019	Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis. <i>Hepatology</i> , 2020, 71, 2080-2092.	7.3	106
1020	A Call to Action: A Systematic Review Examining the Failure to Include Females and Members of Minoritized Racial/Ethnic Groups in Clinical Trials of Pharmacological Treatments for Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1933-1951.	2.4	19
1021	Alcohol intake reduction for controlling hypertension. <i>The Cochrane Library</i> , 2020, 2020, CD010022.	2.8	9
1022	Molecular mechanisms of psychiatric diseases. <i>Neurobiology of Disease</i> , 2020, 146, 105136.	4.4	21
1023	Case Study: Naltrexone for the Treatment of Nitrous Oxide Use. <i>Journal of Addiction Medicine</i> , 2020, 14, e277-e279.	2.6	5
1024	Effect of holistic relapse prevention intervention among individuals with alcohol dependence: a prospective study at a mental health care setting in India. <i>Journal of Ethnicity in Substance Abuse</i> , 2022, 21, 687-707.	0.9	8
1025	The recognition and management of protracted alcohol withdrawal may improve and modulate the pharmacological treatment of alcohol use disorder. <i>Journal of Psychopharmacology</i> , 2020, 34, 1171-1175.	4.0	10
1026	Trauma-related cognitions predict treatment response in smokers with PTSD: Evidence from cross-lagged panel analyses. <i>Addictive Behaviors</i> , 2020, 108, 106376.	3.0	3
1027	The Mesolimbic Dopamine Activity Signatures of Relapse to Alcohol-Seeking. <i>Journal of Neuroscience</i> , 2020, 40, 6409-6427.	3.6	49
1028	Quality of life, caregiver burden and mental health disorders in primary caregivers of patients with Cirrhosis. <i>Liver International</i> , 2020, 40, 2939-2949.	3.9	17
1030	Managing alcohol use in primary care. <i>BMJ</i> , The, 2020, 371, m4129.	6.0	5
1031	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. <i>Journal of Clinical Medicine</i> , 2020, 9, 3817.	2.4	27

#	ARTICLE	IF	CITATIONS
1032	TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response. <i>Molecular Psychiatry</i> , 2021, 26, 3122-3133.	7.9	17
1033	Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2084-2096.	2.4	4
1034	Differences in the delivery of motivational interviewing across three countries. <i>Journal of Ethnicity in Substance Abuse</i> , 2020, , 1-22.	0.9	5
1035	Predictive factors of long-term follow-up in treatment of Korean alcoholics with naltrexone or acamprosate. <i>International Clinical Psychopharmacology</i> , 2020, 35, 345-350.	1.7	2
1036	Pharmacotherapies and personalized medicine for alcohol use disorder: a review. <i>Pharmacogenomics</i> , 2020, 21, 1117-1138.	1.3	11
1037	Can Alcohol Use Disorder Recovery Include Some Heavy Drinking? A Replication and Extension up to 9 Years Following Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1862-1874.	2.4	31
1038	Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders. <i>JAMA Network Open</i> , 2020, 3, e208279.	5.9	105
1039	A novel human laboratory model for screening medications for alcohol use disorder. <i>Trials</i> , 2020, 21, 947.	1.6	3
1040	The Feasibility, Tolerability, and Safety of Administering a Very High Alcohol Dose to Drinkers with Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2588-2597.	2.4	5
1041	Differences in Sociodemographic and Alcohol-Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study for Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2097-2108.	2.4	11
1042	Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1431-1443.	2.4	23
1043	The search for mechanisms of cognitive behavioral therapy for alcohol or other drug use disorders: A systematic review. <i>Behaviour Research and Therapy</i> , 2020, 131, 103648.	3.1	37
1044	Inpatient adoption of medications for alcohol use disorder: A mixed-methods formative evaluation involving key stakeholders. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108090.	3.2	8
1045	Alcohol and the Hospitalized Patient. <i>Medical Clinics of North America</i> , 2020, 104, 681-694.	2.5	4
1046	Latent Class Mediation: A Comparison of Six Approaches. <i>Multivariate Behavioral Research</i> , 2021, 56, 543-557.	3.1	6
1047	Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. <i>Molecular Psychiatry</i> , 2021, 26, 5053-5060.	7.9	17
1048	Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 24.	2.2	10
1049	Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy. <i>PLoS ONE</i> , 2020, 15, e0228433.	2.5	5

#	ARTICLE	IF	CITATIONS
1050	Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms. <i>JAMA Internal Medicine</i> , 2020, 180, 728.	5.1	114
1051	Pilot trial investigating a brief behavioral economic intervention as an adjunctive treatment for alcohol use disorder. <i>Journal of Substance Abuse Treatment</i> , 2020, 113, 108002.	2.8	28
1052	The ventral pallidum and relapse in alcohol seeking. <i>British Journal of Pharmacology</i> , 2020, 177, 3855-3864.	5.4	11
1053	A systematic review of gene-by-intervention studies of alcohol and other substance use. <i>Development and Psychopathology</i> , 2021, 33, 1410-1427.	2.3	6
1054	Reduction in World Health Organization Risk Drinking Levels and Cardiovascular Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1625-1635.	2.4	17
1056	Ethanol metabolism: The good, the bad, and the ugly. <i>Medical Hypotheses</i> , 2020, 140, 109638.	1.5	57
1057	Pharmacotherapeutic management of co-morbid alcohol and opioid use. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 823-839.	1.8	14
1058	Documented brief intervention associated with reduced linkage to specialty addictions treatment in a national sample of VA patients with unhealthy alcohol use with and without alcohol use disorders. <i>Addiction</i> , 2020, 115, 668-678.	3.3	24
1059	World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. <i>Addiction</i> , 2020, 115, 1668-1680.	3.3	44
1060	Drink goal difficulty effect on outcomes in moderation-based alcohol treatment for sexual minority men. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 1-9.	2.8	6
1061	Systematic review and meta-analysis of the moderating effect of rs1799971 in <i>OPRM1</i> , the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. <i>Addiction</i> , 2020, 115, 1426-1437.	3.3	27
1062	Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2020, 52, 374-391.	0.9	29
1063	Alcohol-Specific Computerized Interventions to Alter Cognitive Biases: A Systematic Review of Effects on Experimental Tasks, Drinking Behavior, and Neuronal Activation. <i>Frontiers in Psychiatry</i> , 2019, 10, 871.	2.6	24
1064	Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. <i>Addiction</i> , 2021, 116, 96-104.	3.3	65
1065	Effects of a selective long-acting amylin receptor agonist on alcohol consumption, food intake and body weight in male and female rats. <i>Addiction Biology</i> , 2021, 26, e12910.	2.6	12
1066	Effect of <i>Withania somnifera</i> (L.) Dunal aqueous root extract on reinstatement using conditioned place preference and brain GABA and dopamine levels in alcohol dependent animals. <i>Journal of Ethnopharmacology</i> , 2021, 274, 113304.	4.1	5
1068	Culturally tailored evidence-based substance use disorder treatments are efficacious with an American Indian Southwest tribe: an open-label pilot feasibility randomized controlled trial. <i>Addiction</i> , 2021, 116, 949-960.	3.3	26
1069	Cognitive behavioral therapy for insomnia among young adults who are actively drinking: a randomized pilot trial. <i>Sleep</i> , 2021, 44, .	1.1	17

#	ARTICLE	IF	CITATIONS
1070	Reconsidering alcohol treatment non-responders: psychosocial functioning among heavy drinkers 3 years following treatment. <i>Addiction</i> , 2021, 116, 1262-1269.	3.3	5
1071	Stability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder. <i>Journal of General Internal Medicine</i> , 2021, 36, 404-412.	2.6	12
1072	The Sigma-2 receptor / transmembrane protein 97 (σ2R/TMEM97) modulator JW-1034 reduces heavy alcohol drinking and associated pain states in male mice. <i>Neuropharmacology</i> , 2021, 184, 108409.	4.1	27
1073	Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1286-1294.	3.7	22
1074	Quetiapine treatment for cannabis use disorder. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108366.	3.2	16
1075	Community-based yoga for women undergoing substance use disorder treatment: A descriptive study. <i>International Journal of Yoga</i> , 2021, 14, 50.	1.0	3
1076	Cognitive-Behavioral Therapy. , 2021, , .		0
1077	Treatment of Alcohol-Related Disorders. , 2021, , .		0
1078	Treatment-Related Evidence that Food Addiction Is a Valid Construct. , 2021, , 143-151.		0
1079	Prospective Associations between Attitudes toward Sweet Foods, Sugar Consumption, and Cravings for Alcohol and Sweets in Early Recovery from Alcohol Use Disorders. <i>Alcoholism Treatment Quarterly</i> , 2021, 39, 269-281.	0.8	7
1080	The Role of the Family in Alcohol Use Disorder Recovery for Adults. <i>Alcohol Research: Current Reviews</i> , 2021, 41, 06.	3.6	26
1081	Multimodal multidisciplinary management of alcohol use disorder in liver transplant candidates and recipients. <i>Translational Gastroenterology and Hepatology</i> , 0, 7, 28-28.	3.0	4
1082	First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. <i>Journal of Psychopharmacology</i> , 2021, 35, 375-383.	4.0	66
1083	Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 959-970.	2.1	15
1084	Dopamine and relapse to drug seeking. <i>Journal of Neurochemistry</i> , 2021, 157, 1572-1584.	3.9	8
1086	Incidence and management patterns of alcohol-related liver disease in Korea: a nationwide standard cohort study. <i>Scientific Reports</i> , 2021, 11, 6648.	3.3	2
1087	An efficacy trial of adaptive interventions for alcohol use disorder. <i>Journal of Substance Abuse Treatment</i> , 2021, 123, 108264.	2.8	9
1088	A new approach to treating alcohol use disorder in people experiencing homelessness. <i>Lancet Psychiatry</i> , 2021, 8, 260-261.	7.4	1

#	ARTICLE	IF	CITATIONS
1089	Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial. <i>Lancet Psychiatry</i> , 2021, 8, 287-300.	7.4	29
1090	A cascade of care for alcohol use disorder: Using 2015–2019 National Survey on Drug Use and Health data to identify gaps in past 12-month care. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 1276-1286.	2.4	28
1091	Comparison of Treatments for Cocaine Use Disorder Among Adults. <i>JAMA Network Open</i> , 2021, 4, e218049.	5.9	58
1092	Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis. <i>Addiction</i> , 2022, 117, 271-281.	3.3	20
1093	Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. <i>Neuropsychopharmacology</i> , 2021, 46, 2250-2256.	5.4	40
1094	Current Interventions for People Living with HIV Who Use Alcohol: Why Gender Matters. <i>Current HIV/AIDS Reports</i> , 2021, 18, 351-364.	3.1	6
1095	Protocol for the Project SAVE randomised controlled trial examining CBT for insomnia among veterans in treatment for alcohol use disorder. <i>BMJ Open</i> , 2021, 11, e045667.	1.9	2
1097	<i>Psychopharmacology and Neurotherapeutics.</i> , 2021, , 342-388.		0
1098	<i>Disorders Related to Stress and Trauma.</i> , 2021, , 166-178.		0
1099	<i>Feeding and Eating Disorders.</i> , 2021, , 289-317.		0
1100	<i>Health Policy and Population Health in Behavioral Health Care in the United States.</i> , 2021, , 473-485.		0
1101	Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.. <i>Psychology of Addictive Behaviors</i> , 2022, 36, 505-514.	2.1	9
1102	<i>Psychosocial Interventions.</i> , 2021, , 389-414.		0
1103	Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl. <i>American Journal on Addictions</i> , 2021, 30, 470-476.	1.4	10
1104	<i>Neurocognitive Disorders.</i> , 2021, , 263-288.		0
1105	<i>Introduction to the Patient Interview.</i> , 2021, , 38-69.		0
1106	<i>Global Health and Mental Health Care Delivery in Low-Resource Settings.</i> , 2021, , 486-496.		0
1109	<i>Child Psychiatry and Neurodevelopmental Disorders.</i> , 2021, , 318-328.		0

#	ARTICLE	IF	CITATIONS
1111	Psychiatry of Gender and Sexuality. , 2021, , 448-472.		0
1112	Obsessive-Compulsive and Related Disorders. , 2021, , 146-165.		0
1117	Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology, 2021, 46, 2132-2139.	5.4	19
1119	Psychiatric Evaluation in the Medical Setting. , 2021, , 415-447.		0
1121	Schizophrenia Spectrum and Other Psychotic Disorders. , 2021, , 102-127.		0
1122	Clinical Neuroscience. , 2021, , 9-37.		0
1123	Implementation of Oral and Extended-Release Naltrexone for the Treatment of Emergency Department Patients With Moderate to Severe Alcohol Use Disorder: Feasibility and Initial Outcomes. Annals of Emergency Medicine, 2021, 78, 752-758.	0.6	12
1124	Non-abstinent treatment outcomes for cannabis use disorder. Drug and Alcohol Dependence, 2021, 225, 108765.	3.2	7
1125	Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers. Drug and Alcohol Dependence, 2021, 225, 108825.	3.2	3
1126	Daily associations between alcohol and sweets craving and consumption in early AUD recovery: Results from an ecological momentary assessment study. Journal of Substance Abuse Treatment, 2022, 132, 108614.	2.8	2
1127	Recovery and outcomes of patients denied early liver transplantation for severe alcohol-associated hepatitis. Hepatology, 2022, 75, 104-114.	7.3	25
1128	Developmental Considerations for the Use of Naltrexone in Children and Adolescents. Journal of Pediatric Pharmacology and Therapeutics, 2021, 26, 675-695.	0.5	5
1129	An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders. Drug and Alcohol Dependence, 2021, 226, 108886.	3.2	8
1130	Alcohol use disorders and ADHD. Neuroscience and Biobehavioral Reviews, 2021, 128, 648-660.	6.1	27
1131	An Application of Moderated Nonlinear Factor Analysis to Develop a Commensurate Measure of Alcohol Problems Across Four Alcohol Treatment Studies. Drug and Alcohol Dependence, 2021, 229, 109068.	3.2	0
1132	Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial. American Journal of Psychiatry, 2021, 178, 818-828.	7.2	18
1133	Commentary on Murphy et al .: What will it take to prescribe extended-release naltrexone to treat alcohol use disorder?. Addiction, 2021, , .	3.3	0
1134	Taurine modulates behavioral effects of intermittent ethanol exposure without changing brain monoamine oxidase activity in zebrafish: Attenuation of shoal- and anxiety-like responses, and abolishment of memory acquisition deficit. Pharmacology Biochemistry and Behavior, 2021, 209, 173256.	2.9	8



#	ARTICLE	IF	CITATIONS
1135	Within-AUD outpatient treatment heavy drinking transitions and associations with long-term outcomes. <i>Drug and Alcohol Dependence</i> , 2021, 228, 108968.	3.2	1
1136	Therapy of Withdrawal Syndromes, <i>Addiction Disorders, and Substitution Therapies.</i> , 2021, , 1-18.		0
1137	Traditional treatment strategies for alcoholism and the withdrawal symptoms. , 2021, , 213-280.		0
1138	Some Alcohol-Related Consequences for Women May Signal an Escape from Interpersonal Violence. <i>Advances in Applied Sociology</i> , 2021, 11, 177-184.	0.3	0
1140	Characterizing the Variation of Alcohol Cessation Pharmacotherapy in Primary Care. <i>Journal of General Internal Medicine</i> , 2021, 36, 1989-1996.	2.6	5
1142	New Pharmacological Treatment Strategies for Relapse Prevention. <i>Current Topics in Behavioral Neurosciences</i> , 2012, 13, 583-609.	1.7	49
1143	Adolescent Substance Abuse Treatment: A Review of Evidence-Based Research. , 2009, , 73-96.		13
1144	A Relapse Prevention Model for Older Alcohol Abusers. , 2008, , 61-75.		4
1145	Primary Care Is the De Facto Mental Health System. , 2008, , 9-21.		68
1146	How I Learned About Integrated Care by Failing Miserably: The Deadly Sins of Integration. , 2008, , 39-50.		3
1147	Pharmacotherapy for Alcoholism and Some Related Psychiatric and Addictive Disorders: Scientific Basis and Clinical Findings. , 2010, , 943-980.		1
1148	Physical Considerations for Treatment Complications of Alcohol and Drug Use and Misuse. , 2010, , 1115-1145.		1
1149	Role of the Human Laboratory in the Development of Medications for Alcohol and Drug Dependence. , 2010, , 129-157.		2
1150	Opportunities, Challenges, and Successes in the Development of Medicines for the Treatment of Addiction. , 2010, , 1525-1537.		2
1151	Pharmacotherapy. <i>Issues in Children's and Families' Lives</i> , 2011, , 259-277.	0.2	2
1152	Management of Patients with Alcohol Dependence in Recovery: Options for Maintenance and Anticipating and Managing Relapse in Primary Care. , 2013, , 85-92.		3
1154	The Multidisciplinary Approach to the Management of Substance Abuse. , 2015, , 193-207.		1
1155	The Development of ProNeura Technology for the Treatment of Addictions. , 2009, , 689-708.		2

#	ARTICLE	IF	CITATIONS
1157	Evidence-Based Practice: Toward Optimizing Clinical Outcomes. , 2010, , .		11
1158	Translational Approaches to Medication Development. Current Topics in Behavioral Neurosciences, 2011, , 543-582.	1.7	4
1159	A Translational Approach to Novel Medication Development for Protracted Abstinence. Current Topics in Behavioral Neurosciences, 2012, , 647-670.	1.7	9
1160	New Pharmacological Treatment Strategies for Relapse Prevention. Current Topics in Behavioral Neurosciences, 2012, , 583-609.	1.7	47
1161	Hypotheses Regarding Ayahuasca's Potential Mechanisms of Action in the Treatment of Addiction. , 2014, , 111-132.		10
1162	Pharmacotherapy of Alcohol Dependence: Improving Translation from the Bench to the Clinic. , 2008, , 91-178.		3
1163	The Clinical Course of Addiction Treatment. , 2009, , 21-45.		4
1164	Medication for Cravings in Substance Use Disorders. , 2013, , 527-542.		2
1165	Misuse of, and dependence on, alcohol and other drugs. , 2010, , 353-389.		2
1166	Advances in the treatment of craving for alcohol and tobacco. , 2007, , 211-237.		10
1167	Translational research involving adolescent substance abuse. , 2007, , 341-360.		2
1168	Alcohol screening and intervention in medical and surgical settings. , 2007, , 379-398.		1
1169	Relapse Prevention. , 2007, , 37-71.		6
1172	Suchterkrankungen. , 2012, , 291-346.		3
1173	Unterbringung im Maßregelvollzug gem. Â§64 StGB. , 2020, , 433-450.		1
1174	Suchterkrankungen. , 2009, , 345-409.		1
1175	Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder. NeuroImage: Clinical, 2020, 26, 102162.	2.7	5
1176	Outpatient management of alcohol-related liver disease. The Lancet Gastroenterology and Hepatology, 2020, 5, 485-493.	8.1	14

#	ARTICLE	IF	CITATIONS
1179	Alcoholism and the Loss of Willpower. <i>Journal of Psychophysiology</i> , 2010, 24, 240-248.	0.7	42
1180	Psychotherapies for addiction: Empirically supported interventions for the addiction syndrome.. , 2012, , 87-103.		3
1181	Functional neural changes following behavioral therapies and disulfiram for cocaine dependence.. <i>Psychology of Addictive Behaviors</i> , 2017, 31, 534-547.	2.1	20
1182	Cognitive behavioral interventions for alcohol and drug use disorders: Through the stage model and back again.. <i>Psychology of Addictive Behaviors</i> , 2017, 31, 847-861.	2.1	136
1183	Revisiting the Drinker Inventory of Consequences: An extensive evaluation of psychometric properties in two alcohol clinical trials.. <i>Psychology of Addictive Behaviors</i> , 2018, 32, 52-63.	2.1	11
1184	Adding tools to the toolbox: The role of coping repertoire in alcohol treatment.. <i>Journal of Consulting and Clinical Psychology</i> , 2016, 84, 599-611.	2.0	27
1185	Concurrent varenicline and prolonged exposure for patients with nicotine dependence and PTSD: A randomized controlled trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2017, 85, 862-872.	2.0	23
1186	Drinking goals and attainment in a naltrexone trial of young adult heavy drinkers.. <i>Journal of Consulting and Clinical Psychology</i> , 2018, 86, 765-774.	2.0	11
1187	Patterns of transitions between relapse to and remission from heavy drinking over the first year after outpatient alcohol treatment and their relation to long-term outcomes.. <i>Journal of Consulting and Clinical Psychology</i> , 2020, 88, 1119-1132.	2.0	12
1188	Adapting the CRAFT approach for use in group therapy.. <i>Journal of Behavior Analysis in Health, Sports, Fitness and Medicine</i> , 2009, 2, 109-120.	0.2	3
1189	Qualitative and quantitative feedback following workshop training in evidence-based practices: A dissemination study.. <i>Professional Psychology: Research and Practice</i> , 2016, 47, 413-417.	1.0	2
1190	The association between cognitive coping strategies and treatment outcomes in smokers with PTSD.. <i>Psychological Trauma: Theory, Research, Practice, and Policy</i> , 2020, 12, 92-100.	2.1	5
1191	Can Individuals With Alcohol Use Disorder Sustain Non-abstinent Recovery? Non-abstinent Outcomes 10 Years After Alcohol Use Disorder Treatment. <i>Journal of Addiction Medicine</i> , 2021, 15, 303-310.	2.6	18
1192	A Sample Size Calculator for SMART Pilot Studies. <i>SIAM Undergraduate Research Online</i> , 2016, 9, 229-250.	0.2	7
1193	The Relationship Between Substance Use Patterns and Economic and Health Outcomes Among Low-Income Caregivers and Children. <i>Psychiatric Services</i> , 2008, 59, 974-981.	2.0	3
1195	Glutamate plasticity woven through the progression to alcohol use disorder: a multi-circuit perspective. <i>F1000Research</i> , 2017, 6, 298.	1.6	34
1196	Chronic Ethanol Consumption in Rats Produces Opioid Antinociceptive Tolerance through Inhibition of Mu Opioid Receptor Endocytosis. <i>PLoS ONE</i> , 2011, 6, e19372.	2.5	20
1197	The Dual Orexin/Hypocretin Receptor Antagonist, Almorexant, in the Ventral Tegmental Area Attenuates Ethanol Self-Administration. <i>PLoS ONE</i> , 2012, 7, e44726.	2.5	59

#	ARTICLE	IF	CITATIONS
1198	Screening for Drug and Alcohol Use Disorders and Their Association with HIV-Related Sexual Risk Behaviors among Men Who Have Sex with Men in Peru. PLoS ONE, 2013, 8, e69966.	2.5	45
1199	Using Ecological Momentary Assessment in Testing the Effectiveness of an Alcohol Intervention: A Two-Arm Parallel Group Randomized Controlled Trial. PLoS ONE, 2013, 8, e78436.	2.5	22
1200	Randomized Controlled Trial of a Mobile Phone Intervention for Improving Adherence to Naltrexone for Alcohol Use Disorders. PLoS ONE, 2015, 10, e0124613.	2.5	30
1201	The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients. PLoS ONE, 2015, 10, e0129289.	2.5	24
1202	Substance Use Disorders in the U.S. Armed Forces. , 2013, , .		20
1203	Características de personalidad en pacientes alcohólicos mediante el cuestionario Temperament and Character Inventory (TCI). Diferencias según la existencia de abuso de benzodiazepinas (BZD) y trastornos de la personalidad. Revista De Psicología De La Salud, 2008, 20, 143.	0.5	4
1204	Alcohol Consumption among Men and Women with Tuberculosis in Tomsk, Russia. Central European Journal of Public Health, 2010, 18, 132-138.	1.1	17
1205	Opioid and Cannabinoid Systems as Therapeutic Targets for the Treatment of Alcohol Dependence: From Animal Models to Clinical Practice. The Open Neuropsychopharmacology Journal, 2009, 2, 53-63.	0.3	2
1206	Therapeutic options and challenges for substances of abuse. Dialogues in Clinical Neuroscience, 2007, 9, 431-445.	3.7	11
1207	Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT. Health Technology Assessment, 2019, 23, 1-72.	2.8	3
1208	Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT. Health Technology Assessment, 2019, 23, 1-144.	2.8	17
1209	Sex and Gender Effects in Recovery from Alcohol Use Disorder. Alcohol Research: Current Reviews, 2020, 40, 03.	3.6	64
1210	Naltrexone Pharmacogenetics in Alcohol-dependent Patients. Psychiatric Annals, 2008, 38, .	0.1	1
1211	Efficacy of Acamprosate for the Treatment of Alcohol Dependence Long After Recovery From Withdrawal Syndrome. Journal of Clinical Psychiatry, 2015, 76, 181-188.	2.2	22
1212	Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence. Journal of Clinical Psychiatry, 2019, 80, .	2.2	17
1213	Factors influencing adherence to anti-craving medications and drinking outcomes in patients with alcohol dependence: A hospital-based study. Journal of Pharmacology and Pharmacotherapeutics, 2016, 7, 72-79.	0.4	10
1214	Alcohol consumption in India— An epidemiological review. Journal of Family Medicine and Primary Care, 2020, 9, 49.	0.9	51
1215	Factors associated with relapse and remission of alcohol dependent persons after community based treatment. Open Journal of Psychiatry, 2013, 03, 264-272.	0.6	13

#	ARTICLE	IF	CITATIONS
1216	Treatment of the Alcohol Use Disorder at Outpatient Psychiatric Clinic. Journal of Korean Neuropsychiatric Association, 2019, 58, 159.	0.5	4
1217	A modified classification tree method for personalized medicine decisions. Statistics and Its Interface, 2016, 9, 239-253.	0.3	9
1218	Treating substance abuse in primary care: a demonstration project. International Journal of Integrated Care, 2007, 7, e36.	0.2	16
1219	Impulsivité et troubles liés à une substance: un mélange explosif!. Psychiatrie Et Violence, 2013, 12, .	0.0	4
1220	Brief Interventions for Problem Drinking: Another Piece of the Puzzle. Annals of Internal Medicine, 2007, 146, 223.	3.9	5
1221	Practical outpatient pharmacotherapy for alcohol use disorder. Drugs in Context, 2018, 7, 1-14.	2.2	20
1223	A review of the use of oral and injectable naltrexone for alcohol and opioid addiction treatment. Mental Health Practice, 2018, 21, 46-51.	0.2	2
1224	Adding Psychotherapy to the Naltrexone Treatment of Alcohol Use Disorder: Meta-analytic Review. Cureus, 2018, 10, e3107.	0.5	2
1225	Neurobiological research on addiction: What value has it added to the concept?. The International Journal of Alcohol and Drug Research, 2015, 4, 53-59.	0.9	7
1226	Alcohol Use Disorders and Psychiatric Comorbidities. Advances in Mental Health and Addiction, 2021, , 197-209.	0.2	0
1227	Is extended release naltrexone superior to buprenorphine/naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. Alcoholism: Clinical and Experimental Research, 2021, 45, 2569-2578.	2.4	3
1228	Relapse prevention for alcohol use disorders: combined acamprosate and cue exposure therapy as aftercare. Nordic Journal of Psychiatry, 2022, 76, 394-402.	1.3	3
1229	Pharmacotherapies for the Treatment of Alcohol Dependence. , 2007, , 123-143.		0
1230	Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study: A Randomized Controlled Trial. Yearbook of Psychiatry and Applied Mental Health, 2007, 2007, 95-96.	0.1	0
1231	Psychotherapie bei Alkoholismus. , 2008, , 501-522.		0
1232	Alcohol Treatment. , 2008, , 116-124.		0
1233	Abordagem terapêutica da dependência alcoólica. Revista Portuguesa De Clínica Geral, 2008, 24, 305-316.	0.0	0
1234	Rating Scales for Alcohol and Nicotine Addictions. , 2009, , 87-123.		1

#	ARTICLE	IF	CITATIONS
1235	Clinical Use of Opioid Antagonists in the Treatment of Alcohol Dependence. , 2009, , 371-386.		0
1236	Alkoholabh�ngigkeit (ICD-10 F1). , 2009, , 23-38.		0
1237	Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia. , 2009, , 473-483.		1
1238	Les m�dicaments d'aide au maintien de l'abstinence alcoolique. , 2009, , 307-314.		0
1239	Unterbringung im Ma�regelvollzug gem� § 64 StGB. , 2009, , 469-482.		1
1240	Treatment Of The Hospitalized Alcohol-Dependent Patient With Alcohol Withdrawal Syndrome. Internet Journal of Internal Medicine, 2009, 8, .	0.1	1
1241	Challenges of an Evidence-Based Approach to Addiction Treatment. , 2009, , 439-448.		1
1242	Unhealthy Alcohol and Drug Use in Primary Care. , 2010, , 847-874.		0
1243	Brief Interventions for the Treatment of Alcohol or Other Drug Addiction. , 2010, , 783-796.		0
1245	Evidence-Based Decision for Pharmacological Management of Alcoholic Liver Disease and Alcohol Dependence. , 2010, , 173-183.		0
1246	Alcohol-Related Disease. , 2010, , 2375-2392.		3
1247	Alcohol Abuse and Dependence. , 2010, , 1001-1005.		0
1254	Alcohol Use Disorders. , 2011, , 1091-1104.		0
1255	Evidence-Based Practices for Co-occurring Chemical Dependency and Mental Illness. , 2012, , 277-292.		0
1256	Cognitive Behavioral Therapy with Substance Use Disorders: Theory, Evidence, and Practice. , 2012, , 101-118.		0
1257	Medikamente zur Behandlung von Abh�ngigkeit und Entzugssymptomen. , 2012, , 733-749.		0
1258	Alcohol Abuse and Dependence. , 2012, , 146-153.		0
1259	Technical, Ethical and Social Issues in the Bioprediction of Addiction Liability and Treatment Response. , 2012, , 115-135.		0

#	ARTICLE	IF	CITATIONS
1261	Behandeling met medicatie. , 2012, , 261-282.		0
1262	Treatment of alcohol dependence. , 2012, , 447-459.		0
1263	Alcohol Pharmacotherapies. , 2013, , 49-61.		0
1264	Alkoholabh�ngigkeit (ICD-10 F1). , 2013, , 25-38.		0
1268	Alcohol Abuse and Dependence. , 2013, , 1-8.		0
1271	Medications Used in Smoking Cessation and Alcohol Use Disorders. , 2013, , 249-258.		0
1272	Psychology and Population Health Management. , 2014, , 3-18.		2
1273	New and Old Drugs to Treat Alcohol Use Disorders. Journal of Alcoholism and Drug Dependence, 2014, 02, .	0.2	0
1274	Drug Abuse and Alcohol Dependence Among Inmates. , 2014, , 1147-1159.		0
1275	Ghrelin Receptor Antagonism as a Potential Therapeutic Target for Alcohol Use Disorders: A Preclinical Perspective. Receptors, 2014, , 123-134.	0.2	0
1276	Dependent drinkers and recovery. , 2014, , 39-58.		0
1278	A Person-centered Approach to Diagnosis and Care for Bipolar Disorder and Alcoholism. International Journal of Person Centered Medicine, 2014, 3, 198-204.	0.2	2
1279	Cognitive Behavioural Therapies for Substance Use Problems. , 2015, , 793-809.		0
1280	Alcohol Use and Depression: Public Health and Clinical Implications.. International Journal of Clinical Psychiatry and Mental Health, 2014, 2, 156-160.	0.3	0
1282	Suchterkrankungen. , 2015, , 291-347.		1
1284	Unterbringung im Ma�regelvollzug gem�� � 64 StGB. , 2015, , 389-403.		0
1285	27. Il n�� existe aucun traitement efficace de l��alcoolisme�?. , 2015, , 129-141.		0
1287	Psychische St�rungen. , 2016, , 51-81.		0



#	ARTICLE	IF	CITATIONS
1288	Adulthood, Addiction, and Antisocial Behavior. , 2016, , 157-180.		1
1289	Counselor Training in Two Evidence-Based Practices: Motivational Interviewing and Cognitive Behavior Therapy. Journal of Counselor Preparation and Supervision, 2016, , .	0.2	1
1291	Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. Current Pharmaceutical Design, 2016, 22, 5837-5854.	1.9	11
1292	Risk/Benefit Discussion of Alcohol Use Disorder Medications: Behavioral Economic Considerations and General Recommendations. Journal of Addiction Research & Therapy, 2017, 08, .	0.2	0
1293	Alcohol Use Disorder. , 2017, , .		0
1294	La terapia farmacologia dell'alcolismo: il disulfiram e il naltrexone i primi due farmaci anti-alcol approvati dagli organismi regolatori per la pratica clinica. Parte II. Mission, 2017, , .	0.1	0
1295	La terapia farmacologica dell'alcolismo: l'acamprosato e il nalmefene gli ultimi due farmaci anti-alcol approvati dagli organismi regolatori per la pratica clinica. Parte IV. Mission, 2017, , .	0.1	0
1296	La terapia farmacologica dell'alcolismo: i farmaci anti-alcol non ancora autorizzati dagli organismi regolatori ma utilizzati nella pratica clinica o in fase di sperimentazione. I farmaci che modulano il sistema del glutammato: il topiramato e il gabapent. Mission, 2017, , .	0.1	0
1297	Important Individual Differences in Clinician/Client Interactions. , 2018, , 327-362.		2
1298	Non-Pharmacological Therapies for Substance Use Disorders (DRAFT). , 2018, , .		0
1299	Alcohol Pharmacotherapy. , 2019, , 157-168.		0
1300	Psychotherapieforschung bei Suchterkrankungen. , 2019, , 67-79.		0
1301	Suchterkrankungen. , 2019, , 247-299.e5.		1
1303	Treatment of Alcohol Use Disorder With Adjunctive Addiction-Focused EMDR: A Feasibility Study. Journal of EMDR Practice and Research, 2019, 13, 187-220.	0.6	3
1304	An Introduction to Integrating MI and CBT. , 2019, , 46-64.		0
1305	Ascertainment and Classification of Outcomes. , 2020, , 1-12.		0
1307	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. , 2020, , 1-56.		0
1308	Therapeutische Strategien bei Alkohol- und Tabakabh�ngigkeit. , 2020, , 189-270.		0

#	ARTICLE	IF	CITATIONS
1310	Alcohol and other substance use after liver transplant. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 46-47, 101685.	2.4	12
1311	Alcohol Use Disorders: Clinical Features and Treatment. , 2021, , 128-146.		0
1312	Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 45-59.	17.8	50
1313	A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 15-24.	2.4	3
1315	Drinking and Driving. , 2020, , 1-31.		0
1316	Therapeutic Strategies in Alcohol and Tobacco Addiction. , 2020, , 195-270.		0
1317	Literature Review: Cognitive Behavior Therapy for People with Alcohol Abuse. , 0, , .		0
1319	Using Ecological Momentary Assessments and Fitbit Data to Examine Daily Associations Between Physical Activity, Affect and Alcohol Cravings in Patients with Alcohol Use Disorder. <i>International Journal of Behavioral Medicine</i> , 2022, 29, 543-552.	1.7	3
1320	Individual and Community Social Determinants of Health and Recovery from Alcohol Use Disorder Three Years following Treatment. <i>Journal of Psychoactive Drugs</i> , 2021, 53, 394-403.	1.7	12
1322	Psychische Störungen und Verhaltensstörungen durch psychotrope Substanzen. , 2008, , 785-845.		2
1323	Nurse-Led Body-Mind-Spirit Based Relapse Prevention Intervention for People With Diagnosis of Alcohol Use Disorder at a Mental Health Care Setting, India. <i>Journal of Addictions Nursing</i> , 2020, 31, 276-286.	0.4	6
1325	Pharmacological Treatment of Alcohol Use Disorder. , 2021, , 123-139.		0
1326	Alcohol dependence patterns and their impact on New York City. <i>MedGenMed: Medscape General Medicine</i> , 2007, 9, 23.	0.2	0
1327	Short-term outcomes in patients attending a primary care-based addiction shared care program. <i>Canadian Family Physician</i> , 2009, 55, 1108-1109.e5.	0.4	8
1329	The COMBINE Study:- An Overview of the Largest Pharmacotherapy Study to Date for Treating Alcohol Dependence. <i>Psychiatry</i> , 2006, 3, 36-9.	0.3	7
1332	Outpatient Long-term Intensive Therapy for Alcoholics (OLITA): a successful biopsychosocial approach to the treatment of alcoholism. <i>Dialogues in Clinical Neuroscience</i> , 2007, 9, 399-412.	3.7	4
1334	Treating alcoholism as a chronic disease: approaches to long-term continuing care. <i>Alcohol Research</i> , 2011, 33, 356-70.	1.0	20
1335	Anxiety and alcohol use disorders: comorbidity and treatment considerations. , 2012, 34, 414-31.		74

#	ARTICLE	IF	CITATIONS
1336	Treatment of co-occurring alcohol and other drug use disorders. Alcohol Research, 2008, 31, 155-67.	1.0	14
1337	Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. Alcohol Research, 2008, 31, 400-7.	1.0	6
1338	Alcohol dependence, withdrawal, and relapse. Alcohol Research, 2008, 31, 348-61.	1.0	49
1339	Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver disease in HIV-infected patients. Alcohol Research, 2010, 33, 229-36.	1.0	39
1340	Interventions targeting HIV-infected risky drinkers: drops in the bottle. Alcohol Research, 2010, 33, 267-79.	1.0	28
1341	Advances in alcoholism treatment. Alcohol Research, 2011, 33, 295-9.	1.0	8
1342	Medications for unhealthy alcohol use: across the spectrum. Alcohol Research, 2011, 33, 300-12.	1.0	12
1343	Behavioral therapy across the spectrum. Alcohol Research, 2011, 33, 313-9.	1.0	13
1344	The past and future of research on treatment of alcohol dependence. Alcohol Research, 2010, 33, 55-63.	1.0	14
1346	Gaps in clinical prevention and treatment for alcohol use disorders: costs, consequences, and strategies. , 2013, 35, 238-43.		5
1347	How to design PET experiments to study neurochemistry: application to alcoholism. Yale Journal of Biology and Medicine, 2014, 87, 33-54.	0.2	8
1349	Comparison of healthcare utilization among patients treated with alcoholism medications. American Journal of Managed Care, 2010, 16, 879-88.	1.1	17
1350	Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders. Rhode Island Medical Journal (2013), 2014, 97, 20-4.	0.2	4
1351	Pharmacotherapy of alcohol use disorders: seventy-five years of progress. Journal of Studies on Alcohol and Drugs Supplement, 2014, 75 Suppl 17, 79-88.	3.7	46
1352	Paradigm shift: Moving the management of alcohol use disorders from specialized care to primary care. Canadian Family Physician, 2015, 61, 491-3, 495-7.	0.4	7
1353	Primary care management of alcohol use disorder and at-risk drinking: Part 2: counsel, prescribe, connect. Canadian Family Physician, 2015, 61, 515-21.	0.4	13
1354	Cognitive Neuroscience Approaches to Understanding Behavior Change in Alcohol Use Disorder Treatments. , 2015, 37, 29-38.		16
1355	Precision in Addiction Care: Does It Make a Difference?. Yale Journal of Biology and Medicine, 2015, 88, 415-22.	0.2	14

#	ARTICLE	IF	CITATIONS
1357	Test-Retest Reliability and descriptive analyses of the Modified Important People and Activities (MIPA) Interview. <i>Heroin Addiction and Related Clinical Problems</i> , 2016, 18, 41-48.	1.0	2
1358	An Overview of Pharmacotherapy Options for Alcohol Use Disorder. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2018, 35, 48-58.	0.6	0
1359	Pharmacotherapy for Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder: Targeting the Opioidergic, Noradrenergic, Serotonergic, and GABAergic/Glutamatergic Systems. <i>Alcohol Research: Current Reviews</i> , 2018, 39, 193-205.	3.6	3
1360	Behavioral Treatments for Alcohol Use Disorder and Post-Traumatic Stress Disorder. <i>Alcohol Research: Current Reviews</i> , 2018, 39, 181-192.	3.6	5
1361	Applying Geriatric Principles to Hazardous Drinking in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2022, 38, 145-158.	2.6	3
1362	Alcohol Use Disorder in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2022, 38, 1-22.	2.6	11
1363	Integrated Care Approach to the Prevention of Opioid Use Disorder. , 2021, , 267-292.		1
1364	Mechanisms of ketamine and its metabolites as antidepressants. <i>Biochemical Pharmacology</i> , 2022, 197, 114892.	4.4	66
1365	The transdiagnostic role of food craving: An application of substance use models. <i>Appetite</i> , 2022, 170, 105867.	3.7	4
1464	Post-treatment effects of topiramate on alcohol-related outcomes: A combined analysis of two placebo-controlled trials. <i>Addiction Biology</i> , 2022, 27, e13130.	2.6	4
1465	What Obstetrician-Gynecologists Should Know About Substance Use Disorders in the Perinatal Period. <i>Obstetrics and Gynecology</i> , 2022, 139, 317-337.	2.4	15
1466	Integration of addiction treatment and behavioral therapies in comprehensive liver transplantation care to augment adherence and reduce alcohol relapse. <i>Journal of Liver Transplantation</i> , 2022, 5, 100061.	0.4	4
1468	Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study. <i>British Journal of Pharmacology</i> , 2022, , .	5.4	4
1469	Within- and between-person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 477-491.	2.4	4
1470	Inpatient Addiction Medicine Consultation Service Impact on Post-discharge Patient Mortality: a Propensity-Matched Analysis. <i>Journal of General Internal Medicine</i> , 2022, 37, 2521-2525.	2.6	10
1471	Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. <i>American Journal of Psychiatry</i> , 2022, 179, 152-162.	7.2	46
1472	Alcohol use disorder: An analysis of the evidence underpinning clinical practice guidelines. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109287.	3.2	1
1473	The rates and measurement of adherence to acamprosate in randomised controlled clinical trials: A systematic review. <i>PLoS ONE</i> , 2022, 17, e0263350.	2.5	1

#	ARTICLE	IF	CITATIONS
1474	Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. <i>Drugs</i> , 2022, 82, 251-274.	10.9	56
1477	Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. <i>The Cochrane Library</i> , 2022, 2022, CD012857.	2.8	8
1478	Sex differences in stress-induced alcohol intake: a review of preclinical studies focused on amygdala and inflammatory pathways. <i>Psychopharmacology</i> , 2022, 239, 2041-2061.	3.1	12
1479	Review article: current and emerging therapies for the management of cirrhosis and its complications. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1099-1115.	3.7	20
1480	Using practice facilitation to improve alcohol-related care in primary care: a mixed-methods pilot study protocol. <i>Addiction Science &amp; Clinical Practice</i> , 2022, 17, 19.	2.6	0
1481	Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy. <i>Seminars in Liver Disease</i> , 2022, 42, 138-150.	3.6	9
1482	Viral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 462-471.	2.1	2
1483	Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 416-425.	8.1	60
1485	Biopsychosocial Process of Change in Alcohol Use Disorder Recovery. , 2021, , 25-40.		0
1486	Latent Variable Mixture Modeling Approaches to Investigating Longitudinal Recovery Processes. , 2021, , 137-156.		0
1487	The Relationship Between Reductions in WHO Risk Drinking Levels During Treatment and Subsequent Healthcare Costs for the ACTIVE Workgroup. <i>Journal of Addiction Medicine</i> , 2022, 16, 425-432.	2.6	4
1489	Blended Treatment for Alcohol Use Disorder (Blend-A): Explorative Mixed Methods Pilot and Feasibility Study. <i>JMIR Formative Research</i> , 2022, 6, e17761.	1.4	5
1490	27. Il nâ€™existe aucun traitement efficace de lâ€™alcoolismeÂ?. , 2020, , 127-137.		0
1492	To err is machine: Considerations on the clinical impact of machine learning models in patients with unhealthy alcohol use. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 912-914.	2.4	0
1493	Using machine learning to predict heavy drinking during outpatient alcohol treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 657-666.	2.4	3
1494	Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 137, 104674.	6.1	27
1495	The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamineâ€™s effects. <i>Behavioural Pharmacology</i> , 2022, Publish Ahead of Print, .	1.7	2
1499	Specialist treatment. , 0, , 197-217.		0

#	ARTICLE	IF	CITATIONS
1502	Alcohol use disorder pharmacotherapy and treatment in primary care (ADaPT-PC) trial: Impact on identified barriers to implementation. <i>Substance Abuse</i> , 2022, 43, 1043-1050.	2.3	0
1503	Assessing Naltrexone Prescribing and Barriers to Initiation for Alcohol Use Disorder: A Multidisciplinary, Multisite Survey. <i>Frontiers in Psychiatry</i> , 2022, 13, .	2.6	5
1504	Review article: current and emerging therapies for acute alcohol-associated hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 28-40.	3.7	11
1505	Outpatient Long-term Intensive Therapy for Alcoholics (OLITA): a successful biopsychosocial approach to the treatment of alcoholism. <i>Dialogues in Clinical Neuroscience</i> , 2007, 9, 399-412.	3.7	21
1508	Alcohol Treatment Research Contributing to Changes in Substance Use Behavior and Related Negative Consequences.. <i>Journal of Studies on Alcohol and Drugs</i> , 2022, 83, 364-373.	1.0	0
1509	Predictors of abstinence, no heavy drinking days, and a 2-level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 1331-1339.	2.4	1
1510	Differences in the association between kappa opioid receptors and pain among Black and White adults with alcohol use disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 1348-1357.	2.4	2
1511	Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?. <i>European Journal of Internal Medicine</i> , 2022, , .	2.2	4
1512	Alcohol Treatment Research Contributing to Changes in Substance Use Behavior and Related Negative Consequences. <i>Journal of Studies on Alcohol and Drugs</i> , 2022, 83, 364-373.	1.0	0
1515	Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	6
1516	Residual Structural Equation Models. <i>Structural Equation Modeling</i> , 2023, 30, 1-31.	3.8	17
1517	Consideration of sex and gender differences in addiction medication response. <i>Biology of Sex Differences</i> , 2022, 13, .	4.1	18
1518	PRACTICE TESTS ANSWER KEY (CHAPTER 14). , 2023, , 161-188.		0
1519	Alcohol Use Disorder. , 2023, , 31-46.		0
1526	Index by Drug Name. , 2020, , 895-910.		0
1530	Index by Class. , 2020, , 919-922.		0
1534	Index by Use. , 2020, , 911-918.		0
1577	Exploring the Role of DARPP-32 in Addiction: A Review of the Current Limitations of Addiction Treatment Pathways and the Role of DARPP-32 to Improve Them. <i>NeuroSci</i> , 2022, 3, 494-509.	1.2	2

#	ARTICLE	IF	CITATIONS
1578	Endoplasmic reticulum-targeted inhibition of CYP2E1 with vitamin E nanoemulsions alleviates hepatocyte oxidative stress and reverses alcoholic liver disease. <i>Biomaterials</i> , 2022, 288, 121720.	11.4	20
1579	Molecular Basis of Inhibitory Mechanism of Naltrexone and Its Metabolites through Structural and Energetic Analyses. <i>Molecules</i> , 2022, 27, 4919.	3.8	0
1580	Constructs derived from the addiction cycle predict alcohol use disorder treatment outcomes and recovery 3 years following treatment.. <i>Psychology of Addictive Behaviors</i> , 2023, 37, 376-389.	2.1	5
1581	An Alcohol Symptom Checklist identifies high rates of alcohol use disorder in primary care patients who screen positive for depression and high-risk drinking. <i>BMC Health Services Research</i> , 2022, 22, .	2.2	2
1582	The Added Value of Pharmacotherapy to Cognitive Behavior Therapy And Vice Versa in the Treatment of Alcohol Use Disorders: A Systematic Review. <i>Alcohol and Alcoholism</i> , 0, , .	1.6	2
1583	Ascertainment and Classification of Outcomes. , 2022, , 843-854.		0
1584	Mechanisms of quality-of-life improvement in treatment for alcohol use disorder.. <i>Journal of Consulting and Clinical Psychology</i> , 2022, 90, 601-612.	2.0	4
1587	Effects of chess-based cognitive remediation training as therapy add-on in alcohol and tobacco use disorders: protocol of a randomised, controlled clinical fMRI trial. <i>BMJ Open</i> , 2022, 12, e057707.	1.9	2
1588	Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. <i>JCI Insight</i> , 2022, 7, .	5.0	23
1589	Virtual reality intervention effects on future self-continuity and delayed reward preference in substance use disorder recovery: pilot study results. <i>Discover Mental Health</i> , 2022, 2, .	2.0	2
1590	Substance Use Disorders: Second Wave Approaches. , 2022, , 563-582.		0
1591	Evaluating Craving in Alcohol Use Disorder: Psychometric Characteristics of the Craving Typology Questionnaire-15 (CTQ-15). <i>Alcohol and Alcoholism</i> , 0, , .	1.6	1
1593	Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease. <i>Hepatology Communications</i> , 2022, 6, 3433-3442.	4.3	20
1594	A Smartphone Physical Activity App for Patients in Alcohol Treatment: Single-Arm Feasibility Trial. <i>JMIR Formative Research</i> , 2022, 6, e35926.	1.4	0
1595	Body mass index interacts with sex to predict readmission in inpatients with alcohol use disorder. <i>Addiction Biology</i> , 2023, 28, .	2.6	2
1596	Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review. <i>Journal of Substance Abuse Treatment</i> , 2023, 144, 108919.	2.8	0
1597	Topiramate, Naltrexone, and Acamprosate in the Treatment of Alcohol Use Disorders. , 2022, , 2535-2550.		0
1598	Therapy of Withdrawal Syndromes, Addiction Disorders, and Substitution Therapies. , 2022, , 4525-4542.		0



#	ARTICLE	IF	CITATIONS
1599	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. , 2022, , 305-359.		0
1600	Precision medicine in alcohol use disorder: Mapping etiologic and maintenance mechanisms to mechanisms of behavior change to improve patient outcomes.. Experimental and Clinical Psychopharmacology, 2023, 31, 769-779.	1.8	5
1601	Behandlung von riskantem, schädlichem und abhängigem Alkoholgebrauch. , 2022, , 51-356.		0
1602	Collective Motivational Interviewing for Individuals with Drug Use Problems: A Pre-Post Follow-Up, Uncontrolled Pilot Study. International Journal of Environmental Research and Public Health, 2022, 19, 16344.	2.6	0
1603	Hazardous drinking and alcohol use disorders. Nature Reviews Disease Primers, 2022, 8, .	30.5	24
1604	Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels. Alcoholism: Clinical and Experimental Research, 2022, 46, 2258-2266.	2.4	0
1605	Liver transplantation for alcohol-associated hepatitis. Current Opinion in Organ Transplantation, 2023, 28, 85-94.	1.6	1
1606	Preventing incubation of drug craving to treat drug relapse: from bench to bedside. Molecular Psychiatry, 2023, 28, 1415-1429.	7.9	6
1607	Short-term naltrexone use associated with delayed-onset fever and hepatotoxicity: A case report. Taiwanese Journal of Psychiatry, 2022, 36, 188.	0.2	0
1608	Understanding Ohio X-Waivered Advanced Practice Registered Nurses' Rate of Naltrexone Prescription for Alcohol Use Disordered Patients. Journal of the American Psychiatric Nurses Association, 0, , 107839032211510.	1.0	0
1609	Ethanol blocks a novel form of iLTD, but not iLTP of inhibitory inputs to VTA GABA neurons. Neuropsychopharmacology, 0, , .	5.4	0
1610	Time to Treat Alcohol Use Disorder in the Emergency Department. Annals of Emergency Medicine, 2023, 81, 450-452.	0.6	2
1611	Comparative effectiveness of psychosocial interventions in adults with harmful use of alcohol: a systematic review and network meta-analysis. Addiction, 2023, 118, 1414-1429.	3.3	4
1612	Trajectories of change in subclinical anxiety and alcohol use during alcohol treatment: A parallel process growth model. Drug and Alcohol Dependence, 2023, 246, 109838.	3.2	0
1613	A critical perspective on updating drug memories through the integration of memory editing and brain stimulation. Frontiers in Psychiatry, 0, 14, .	2.6	1
1614	Alcohol treatment discussions and clinical outcomes among patients with alcohol-related cirrhosis. BMC Gastroenterology, 2023, 23, .	2.0	4
1615	Efficacy of Cognitive Behavioral Therapy for Alcohol and Other Drug Use Disorders: Is a One-Size-Fits-All Approach Appropriate?. Substance Abuse and Rehabilitation, 0, Volume 14, 1-11.	4.8	7
1616	Medical and social implications of alcohol use among adult women in a rural area of Ranchi, Jharkhand: A cross-sectional study. Journal of Family Medicine and Primary Care, 2023, 12, 320.	0.9	0

#	ARTICLE	IF	CITATIONS
1617	Evidence-based Treatment for Substance Use Disorders in Community Mental Health Centers: the ACCESS Program. <i>Journal of Behavioral Health Services and Research</i> , 0, , .	1.4	0
1618	Influence of sex in alcohol-related liver disease: Pre-clinical and clinical settings. <i>United European Gastroenterology Journal</i> , 2023, 11, 218-227.	3.8	5
1619	Alcohol use as a mediator of the effect of two alcohol reduction interventions on mental health symptoms of ART clients in Vietnam. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2023, 35, 1691-1699.	1.2	0
1621	Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. <i>Hepatology Communications</i> , 2023, 7, .	4.3	12
1622	Pharmacotherapy options for alcohol use disorder in patients with alcohol-associated liver disease: a brief guide for clinicians. <i>Clinical Liver Disease</i> , 2023, 21, 125-129.	2.1	1
1623	Metabotropic glutamate group II receptor activation in the ventrolateral dorsal striatum suppresses incentive motivation for cocaine in rats. <i>Psychopharmacology</i> , 2023, 240, 1247-1260.	3.1	0
1624	Office-Based Management of Perinatal Substance Use and Substance Use Disorder for the General Obstetrician-Gynecologist. <i>Obstetrics and Gynecology Clinics of North America</i> , 2023, , .	1.9	0
1625	Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. <i>World Psychiatry</i> , 2023, 22, 203-229.	10.4	10
1626	Medications for Alcohol Use Disorder and Retention in Care in Medicaid-Enrolled Youth, 2014-2019. <i>Journal of Adolescent Health</i> , 2023, , .	2.5	0
1627	Alcohol use disorder: Recognition, testing, and initial management strategies. <i>Clinical Liver Disease</i> , 2023, 22, 18-22.	2.1	0
1628	Alcohol and Drug Use Disorders. , 2023, , 71-84.		0
1629	Management of alcohol use disorder in patients with chronic liver disease. <i>Hepatology Communications</i> , 2023, 7, .	4.3	5
1630	Intramuscular, extended-release naltrexone inadvertently administered in the deltoid muscle: A case report. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2023, 63, 1245-1248.	1.5	0
1631	Principles of care for pregnant and parenting people with substance use disorder: the obstetrician gynecologist perspective. <i>Frontiers in Pediatrics</i> , 0, 11, .	1.9	2
1632	Medications for treating alcohol use disorder: A narrative review. <i>Alcoholism: Clinical and Experimental Research</i> , 2023, 47, 1224-1237.	2.4	1
1633	Medication treatment for alcohol use disorder in special populations. <i>American Journal on Addictions</i> , 2023, 32, 433-441.	1.4	1
1634	Medications for alcohol use disorder promote abstinence in alcohol-associated cirrhosis: Results from a systematic review and meta-analysis. <i>Hepatology</i> , 2024, 79, 368-379.	7.3	3
1635	Pharmacological Treatment of Substance Use Disorders. , 2023, , 1-28.		0

#	ARTICLE	IF	CITATIONS
1636	Need to rethink tDCS protocols for the treatment of alcohol use disorder: Insights from a randomized sham-controlled clinical trial among detoxified inpatients. <i>Journal of Addictive Diseases</i> , 0, , 1-7.	1.3	0
1638	Overview of Alcohol Use Disorder. <i>American Journal of Psychiatry</i> , 2023, 180, 565-572.	7.2	3
1639	Opioid receptor antagonism and neural response to monetary rewards: Pilot studies in light and heavy alcohol users. <i>Journal of Psychopharmacology</i> , 2023, 37, 937-941.	4.0	0
1640	Substance Use Disorder. <i>Emergency Medicine Clinics of North America</i> , 2024, 42, 53-67.	1.2	1
1641	The Current State of Alcohol Screening and Management in Virginia Primary Care Practices. <i>Medical Clinics of North America</i> , 2023, , .	2.5	0
1642	Patterns of drinking behavior around a treatment episode for alcohol use disorder: Predictions from pre-treatment measures. , 2023, 47, 2138-2148.		0
1643	Epigenetic regulation of GABA catabolism in iPSC-derived neurons: The molecular links between FGF21 and histone methylation. <i>Molecular Metabolism</i> , 2023, 77, 101798.	6.5	0
1644	Frequency of Narcissistic Personality Disorder in Cannabis Consumer Engineering Students. <i>Revista Colombiana De Psiquiatría</i> , 2023, , .	0.3	0
1645	Multidisciplinary Care of Alcohol-related Liver Disease and Alcohol Use Disorder: A Narrative Review for Hepatology and Addiction Clinicians. <i>Clinical Therapeutics</i> , 2023, 45, 1177-1188.	2.5	2
1646	Does starting naltrexone in a patient with alcohol use disorder and elevated baseline liver transaminases cause further liver injury compared with acamprosate and gabapentin?. <i>Evidence-Based Practice</i> , 0, , .	0.0	0
1647	Acamprosate reduces ethanol intake in the rat by a combined action of different drug components. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
1648	Approved, Promising, and Experimental Medications for Treatment of Alcohol Use Disorder. , 2023, , 261-288.		0
1649	Evidence-Based Behavioral Treatments. , 2023, , 237-260.		0
1650	Modeling the impact of a long-term horizon and multiple treatment episodes on estimates of the cost-effectiveness of alcohol treatment in the United States. , 2023, 47, 2121-2137.		1
1651	Pharmacotherapy for Alcohol Use Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2023, 330, 1653.	7.4	6
1652	Neurobiology and the Treatment of Alcohol Use Disorder: A Review of the Evidence Base. <i>Substance Abuse and Rehabilitation</i> , 0, Volume 14, 157-166.	4.8	0
1653	Organic cation transporters in psychiatric and substance use disorders. , 2024, 253, 108574.		0
1654	Treatments for Substance Use Disorders. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
1655	Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT. <i>Health Technology Assessment</i> , 0, , 1-88.	2.8	0
1656	Evidence of subgroup differences from meta-analyses evaluating medications for alcohol use disorder: an umbrella review. , 0, , .		0
1657	Minimizing Metabolic and Cardiac Risk Factors to Maximize Outcomes After Liver Transplantation. <i>Transplantation</i> , 0, , .	1.0	0
1660	Subjective stress and any drinking during alcohol treatment: Disentangling within and between person autoregressive effects. <i>Neurobiology of Stress</i> , 2024, 29, 100602.	4.0	0
1662	Reductions in WHO risk drinking levels correlate with alcohol craving among individuals with alcohol use disorder. , 2024, 48, 420-429.		0
1663	Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial. <i>BMC Psychiatry</i> , 2024, 24, .	2.6	0
1664	Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: A systematic review and network meta-analysis. <i>Addiction</i> , 2024, 119, 815-832.	3.3	0
1666	A pilot, randomized clinical trial: Left dorsolateral prefrontal cortex intermittent theta burst stimulation improves treatment outcomes in veterans with alcohol use disorder. , 2024, 48, 164-177.		0
1667	Development and evaluation of objective trial performance metrics for multisite clinical studies: Experience from the AlcHep Network. <i>Contemporary Clinical Trials</i> , 2024, 138, 107437.	1.8	0
1668	Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease. <i>Hepatology Communications</i> , 2024, 8, .	4.3	1
1669	Pharmacist-Driven Alcohol Use Disorder Screening May Increase Inpatient Utilization of Extended-Release Naltrexone: A Single Center Pilot Study. <i>Pharmacy (Basel, Switzerland)</i> , 2024, 12, 26.	1.6	0
1671	Implementation and analysis of a multifaceted intervention for alcohol use disorder from a single academic urban emergency department. <i>Academic Emergency Medicine</i> , 0, , .	1.8	0
1672	Quadruple pharmacotherapy for alcohol use disorder tolerable yet insufficient: a case report. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2024, 19, .	2.2	0
1673	Psychische Störungen. , 2023, , 59-95.		0
1674	Designing and testing treatments for alcohol use disorder. <i>International Review of Neurobiology</i> , 2024, , 277-312.	2.0	0
1675	Longitudinal stability of reward and relief drinking phenotypes in community and treatment-seeking individuals who engage in heavy drinking. , 2024, 48, 567-579.		0
1676	How Does Telehealth Expansion Change Access to Healthcare for Patients With Different Types of Substance Use Disorders?. , 0, , .		0
1677	Disorders due to Substance Use: Alcohol Abuse and Addiction. , 2023, , 1-47.		0

#	ARTICLE	IF	CITATIONS
1678	Current treatments of alcohol use disorder. International Review of Neurobiology, 2024, , 127-152.	2.0	0
1679	Repurposing drugs for treatment of alcohol use disorder. International Review of Neurobiology, 2024, , 153-185.	2.0	0
1680	Silymarin (Milk Thistle) Treatment of Adults With Gambling Disorder: A Double-Blind, Placebo-Controlled Trial. Clinical Neuropharmacology, 2024, 47, 54-58.	0.7	0